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ABSTRACT

DEVELOPMENT OF TOPICAL OPHTHALMIC IN SITU GEL-FORMING
ESTRADIOL DELIVERY SYSTEM INTENDED FOR THE PREVENTION OF AGERELATED CATARACTS

By
Udaya K. Kotreka
August 2011

Dissertation supervised by Moji Christianah Adeyeye, Ph.D. and Vicki Davis, Ph.D.
The increased risk of cataracts in aging women versus men, the reduced risk in
women on hormone replacement therapy, and studies in animal models suggest that
estrogen may protect lens transparency. To use estrogen for cataract prevention, we
hypothesized that an ophthalmic estradiol in situ gel-forming formulation would be more
effective for inducing lenticular estrogen responses without undesired uterine stimulation
associated with systemic delivery. The following aims tested this hypothesis: 1) to
develop an ophthalmic in situ gel-forming estradiol (E2) delivery system that is stable and
safe; 2) to determine if ocular estrogen formulation was more effective than systemic
therapy in inducing cataracts and activating estrogen-regulated genes in ERΔ3 mice,
while minimizing systemic side effects in the estrogen-responsive uterus; 3) to determine
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ocular safety and to estimate ocular and systemic drug bioavailability of the formulation
in rabbits.
An in situ gel-forming estradiol solution eye drop containing gellan gum polymer
was developed as it offers a unique advantage of solution for easy handling which then
undergoes a sol-gel transition in the presence of tear fluid in the eye to prolong drug
contact time and enhance ocular bioavailability. Pre-formulation studies identified
excipients that provided acceptable characteristics of clarity, isotonicity, and sterility to
the ocular formulation. Using design of experiments approach, an optimized formulation
with desirable viscoelastic and drug release characteristics was identified. In ERΔ3 mice,
estrogen-dependent cataracts occurred earlier at lower doses for ophthalmic versus
systemic delivery. Further, gene expression and uterotrophic studies demonstrated that
ocular estrogen therapy was more effective than systemic delivery in stimulating an
estrogen-regulated gene in the ER3 lens and in minimizing systemic absorption as
evidenced by little to no rodent uterine stimulation. Additionally, the in vivo studies in
rabbits demonstrated that the optimized estradiol formulation was practically nonirritating to the eyes with maximal ocular drug absorption and minimal systemic drug
bioavailability. Accelerated stability study indicated that the formulation was stable with
a tentative shelf-life of 2 years assigned to the product.
In summary, the developed ophthalmic estradiol formulation has the desired
safety profile, stability, and ocular bioavailability required for future testing in animals
and humans for cataract prevention.
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CHAPTER I
INTRODUCTION

I.A.

Statement of the Problem
Cataracts are a leading cause of blindness affecting millions of people across the

globe (Rucker CW, 1965; Taylor et al., 2001). Recently, the protective effect of estrogen
in reducing cataracts risk has been demonstrated in various epidemiological and preclinical studies (Bigsby et al., 1999; Davis et al., 2002; Chen et al., 2004; Benitez del
Castillo et al., 1997; Cumming RG and Mitchell P, 1997; Worzala et al., 2001; Fletcher,
2010). 17β-estradiol (E2) is the most potent estrogen that occurs naturally in the human
body. Epidemiological studies carried out to investigate the role of age and gender on the
prevalence of cataracts indicated the possible role of estradiol in retarding cataract
formation in women receiving hormone replacement therapy (Benitez del Castillo et al.,
1997; Cumming RG and Mitchell P, 1997; Worzala et al., 2001; Lindblad et al., 2010).
Prevalence of cataracts in postmenopausal women was higher relative to men of similar
age due to the low levels of estrogen after menopause (Livingston et al., 1994; Klein et
al., 1998). Therefore, the reduced risk observed in post menopausal women receiving
hormone replacement therapy suggests a possible role of the female hormone, estrogen,
in retarding cataract formation.
Studies done in various rodent models to investigate the relationship between
estrogen deficiency and cataract formation have provided further evidence towards the
protective effect of estrogen against loss of lens transparency (reviewed in Worzala et al.,
2001). Despite current availability of estrogen supplements in the form of oral (Lokind et
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al., 1996; Haiharan et al., 2006), buccal (Kitano et al., 1998), vaginal (Bachman G, 1998),
nasal (Al-Ghananeem et al., 2002), and transdermal formulations (Loftsson T and Bodor
N, 1989; Variankaval et al., 2002), many women are hesitant to take them due to high
risk of breast and endometrial cancers associated with high systemic levels of estrogen
and its metabolic product estrone (Colditz et al., 1995; Kerdelhué and Jolette, 2002;
Haiharan et al., 2006; Longcope et al., 1985; Lokind et al., 1996). Therefore a non-oral
and non-systemic route of estrogen delivery that will limit the amount of drug that is
systemically available will be advantageous in reducing the side effects.

The recent discovery of estrogen receptor (ER) in rat, bovine, and human retina
and rat, canine, and human lens suggests that eye can respond directly to estrogen
(Johansson and Oehman, 1985; Zhang et al., 2003; Colitz et al., 2009). Estradiol (E 2) is
the most potent form of estrogen which acts by regulating the transcription of estrogenresponsive genes. It is a lipophilic drug with poor aqueous solubility (0.03mg/L at 25C)
and high permeability (logP of 3.94) (Loftsson et al., 2002). Given the evidence
supporting the protective role of estrogen in cataracts reduction, E 2 delivered by
ophthalmic route will be able to permeate cornea and interact with the estrogen receptors
(ER) locally in the eye and delay or prevent the onset of cataracts at much lower doses
compared to systemic delivery. Ocular estrogen therapy would also offer an attractive
alternative to surgery which, so far, is the only available treatment for cataracts.

Drug delivery to ocular mucosa for local treatment is associated with great
possibilities, but often also with many obstacles. The physiological constraints imposed
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by the protective mechanisms of the eye lead to low absorption of drugs (Davies NM,
2000). The most common way to deliver drugs to the eye is to instill an aqueous solution
of the drug into the eye. The bioavailability of a drug introduced in this way is often very
low, typically <5%, depending on its physicochemical properties (Nanjawade et al.,
2007). Such low bioavailability is attributed to extensive precorneal drug loss by
nasolachrymal drainage. The rapid elimination of the instilled drug often results in a short
duration of therapeutic effect and, consequently, the need for a frequent dosing regimen
(Bourlais et al., 1998). Also, systemic absorption of E 2 solution drained through the
nasolachrymal duct may increase the risk for undesirable side effects (e.g., breast cancer,
endometrial cancer, etc.). Ocular therapy would be significantly improved if the
precorneal residence time of E2 could be increased. The best way of doing so is by
designing in situ gel-forming drug delivery systems that are conveniently administered
into the eye as a liquid; whereafter, they undergo a transition into a gel brought about by
the presence of stimuli-responsive polymers.
An in situ gel-forming solution delivery system combines the advantages of a
solution, being patient convenient, with the favorable residence time of a gel. Due to their
viscoelastic properties, these gels resist ocular drainage leading to longer contact times
and duration of action. Parameters that can change and trigger this sol-gel phase
transition include pH or temperature or ionic strength of the tear fluid. Numerous types of
stimuli-responsive polymers used in ocular drug delivery systems have been reviewed
previously (Mundada and Avari, 2009). Of all these systems, gellan gum-based in situ gel
systems have been shown to significantly prolong the ocular contact time of the drug in
animal and human studies (Carlfors et al., 1998; Schenker et al., 2000). The gellan
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systems form clear gels in the presence of mono (Na+, K+) and divalent (Ca2+) cations of
the tear fluids with good in situ gelling characteristics at as low as 0.1%(w/v) polymer
concentration (Paulsson et al., 1999). A key challenge in the development of a sterile
ophthalmic in situ gel-forming solution lies in the ability to ensure that the formulation
has acceptable characteristics of sterility, clarity, tonicity, drug release, viscoelasticity,
and stability. E2 being a biopharmaceutical classification system (BCS) class-II drug, its
delivery by ocular route as an in situ gel-forming solution is also limited by its poor
aqueous solubility.
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I.B. Hypothesis and Objectives
The project is based on the central hypothesis that a safe and stable in situ gelforming topical ophthalmic 17-estradiol (E2) drug delivery system, with appreciable
ocular absorption in order to stimulate estrogen responses but less systemic absorption,
can be developed for future testing for its efficacy in the prevention of age-related
cataracts.

Given the central hypothesis, the objectives were to:
1) Perform pre-formulation and formulation development of ion-activated in situ
gel- forming E2 eye drops
2) Identify the optimum formulation with desirable product performance
characteristics using statistical design of experiments
3) Establish pre-clinical in vivo safety of the developed E2 ophthalmic formulation
and capacity to induce known estrogen response in ER∆3 transgenic mouse
4) Evaluate in vivo ocular safety and estimate ocular and systemic drug
bioavailability from the optimized formulation in rabbits
5) Evaluate stability of the optimized in situ gel-forming E2 ophthalmic formulation
according to ICH Q1A (R2) guidelines
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I.C. Literature Review
I.C.1. Cataracts: What is it?
A cataract is defined as a clouding of the eye's natural lens. In normal eyes, the
lens focuses the incident light on the retina to activate photoreceptors and cause vision. In
cataractous eyes, due to the clouding of lens the incident light is scattered causing blurred
vision. It is the leading cause of blindness in the world and affects nearly 20 million
people at or above age 40 year in US alone (Rucker CW, 1965; Taylor et al., 2001). The
factors that lead to cataract formation include aging, diabetes mellitus, cigarette smoking,
elevated body mass index, UV light, and alcohol use (Ellwein and Urato, 2002; Worzala
et al., 2001). Since age is the single greatest factor, every one is at risk of developing
cataract. The age-related cataracts are classified as cortical, nuclear, and posterior subcapsular based on their anatomical location in the lens of the eye.

I.C.2. Cataracts: Treatment Options and Impact on Society
I.C.2.1. Surgery for the treatment of cataracts
Surgical treatment to replace the cataractous lens with a synthetic lens is the only
means currently available to treat cataracts. The surgery is a cure; however, implantation
of a synthetic lens may only temporarily restore vision as residual cells associated with
the lens capsule often grow to form new opacities called secondary cataracts, a risk often
associated with elderly patients. In these patients, the loss of sight that occurs is
physically and psychologically disabling due to the loss of independence. The World
Health Organization (WHO) estimates that in 2020, approximately 75 million individuals
will suffer from vision problems related to cataracts with a projected economical cost of
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$110 billion dollars in the United States (Ellwein and Urato, 2002). Despite such a huge
burden on economy there are currently no available treatments that delay or prevent
incidence of cataracts. It was also reported that a modest delay of only 14% in the rate of
cataract development would delay the onset of cataract by a decade and reduce the
number of surgeries by 50% (Javitt et al., 1996).

I.C.2.2. Alternative treatment for cataracts: Role of estrogens
Numerous epidemiological studies carried out to investigate the role of age and
gender in the incidence of cataracts suggests protective role of estrogen against cataracts.
These studies associated the higher prevalence of cataracts in women after menopause
relative to men of similar age to the low levels of estrogen after menopause (Livingston
et al., 1994; Leske et al., 2004; Fletcher, 2010). Cataracts are observed as a common side
effect in women on the anti-estrogen cancer therapy, tamoxifen (Greaves et al., 1993;
Gail et al., 1999; Reeder et al., 2007; Li et al., 2008), which suggests that inhibition of
estrogen action may result in the loss of lens transparency. Blue Mountain Eye Study
(BMES) and Beaver Dam Eye Study (BDES) established a correlation between cataract
incidence and the age at puberty and menopause in women. It was observed that women
with late age of puberty and/or earlier onset of menopause had greater risk for cataracts
and vice versa; these findings suggest that a shorter lifetime exposure to endogenous
estrogens might increase the risk of age-related cataracts (Cumming and Mitchell, 1997;
Klein et al., 2000).

Also, the evidence that postmenopausal women on hormone

replacement therapy (HRT) experienced lower risk for cortical cataracts suggested a
possible role of the female hormone, estrogen, in retarding cataract formation.
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In conjunction with epidemiological evidence, the protective effect of estrogen
against loss of lens transparency in cataracts is also seen in animal models (Bigsby et al.,
1999; Hales et al., 1997; Davis et al., 2002). In an in vivo rodent model, ovariectomized
rats were treated with a cataractogenic compound, methylnitrosourea (MNU) to induce
cataracts that simulate morphological changes associated with age-related cataracts in
humans. Estrogen treatment significantly lowered the incidence of methylnitrosourea
(MNU)-induced cortical cataracts compared to untreated ovariectomized rats (Bigsby et
al., 1999; Roy et al., 1989). In addition, the type of estrogen used also influenced the
efficacy in inhibiting lens opacities, with the weaker estrogen, estrone, being less
effective in reducing the incidence of cataracts than the more potent estrogen, 17estradiol (E2). In another rodent model, transforming growth factor (TGF)--induced
sub-capsular cataracts in cultured rat lenses were reduced when the potent form of
estrogen, 17-estradiol, was administered to the rat before lens culture (Hales et al.,
1997; Chen et al., 2004). Based on the evidence of epidemiological studies and laboratory
tests in rodent models, it is suggested that estrogen is protective; however, little is known
on how estrogen exerts protection against cataract development.
Classical mechanism of estrogen action involves binding to estrogen receptors
(ER) in the cell nucleus to form dimers that bind to an estrogen response element (ERE)
and regulating the transcription of estrogen-responsive genes. Accordingly, if estrogen
provides protection in the lens against the development of age-related cataracts, more
than likely its actions will be mediated through its receptors. The two subtypes of ER that
are known to exist currently are ER and ER. ERα was the first estrogen receptor
identified and cloned in 1986 (Green et al., 1986). The second ER, ERβ, was identified in
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1996 (Kuiper et al., 1996). Nuclear estrogen receptors have been identified in ocular
tissues (Ogueta, 1999; Bigsby, 1999; Wickham 2000; Cammarata, 2004). ER receptor
transcripts were detected for ERα in lenses from rat and rabbits (Bigsby, 1999; Wickham,
2004) and for ERβ in rat lenses (Bigsby, 1999). Further, ERα and ERβ messages were
detected in human lens epithelial cells (Cammarata, 2004) and ERα protein was detected
in the human lens (Ogueta, 1999). Expression of ER receptors in the lens of rodent
animals and humans suggest the potential of estrogen to act directly via estrogen
receptors expressed in the lens.
To test if lack of estrogen receptor or inhibition of estrogen signaling mechanism
could lead to cataract development, Davis and colleagues developed an ERΔ3 mouse
model to investigate estrogen inhibition (Davis et al., 2002). ERΔ3 mice express the
ERΔ3 receptor, a dominant negative variant of ERα, resulting from the in-frame deletion
of exon3 by alternative splicing. The region of the ERα receptor translated from exon 3
is part of the DNA-binding domain. Deletion of this region results in the receptor lacking
the second zinc finger while all other domains of ERα such as ligand-dependent
dimerization domain remain intact. In this transgenic model, morphological changes
associated with cortical cataracts are spontaneously developed in adult female, but not
male, ERΔ3 mice due to inhibition of estrogen action via estrogen activation of the
dominant negative estrogen receptor. But, cataracts were not observed in adult female
mice if they are ovariectomized before, but not after the onset of puberty. In addition,
spontaneous cortical cataracts were observed in male and ovariectomized female ERΔ3
mice treated with exogenous estrogen, 17β-estradiol (E2), but not in ovariectomized mice
treated with vehicle; which suggest that eliminating exposure to estrogens can prevent
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cataracts in ERΔ3 mice (Kirker and Davis, unpublished). These results also indicate that
estrogen is required to activate ERΔ3 repressor to dimerize and, thus, inhibit the activity
of the wild-type ER. The major mechanism for dominant negative activity occurs through
the formation of heterodimers; that is, the ERΔ3 dominant negative variant could bind to
and form a complex with wild1994; Bollig and Miksicek, 2000). Based on in vitro studies, these specific ERΔ3:ERα
heterodimers do not possess the ability to bind to an ERE and/or transactivate an estrogen
responsive gene (Wang and Miksicek, 1991; Yen and Chin, 1994). These data agree with
studies in women showing estrogen is protective, since women would not have the ER3
inhibitor present in their eyes to inhibit estrogen action in the lens. In addition to estrogen
receptor-dependent mechanisms, the actions of estrogens in the eye may also occur by
estrogen receptor-independent mechanisms, where estradiol acts as an anti-oxidant
(Wang et al., 2003). For example, estrogen has been shown to provide neuroprotection
and protection against macular degeneration by acting as a free-radical scavenger, which
does not require an estrogen receptor (Prokai et al., 2003).
Kirker and Davis (unpublished data) also observed E 2 binding sites in the nuclear,
cytosolic, and membrane fractions of both the wild-type mouse and human lens, which
suggests that estrogen can bind directly to receptors present in the lens. If it binds to these
high affinity receptors, estrogen has the potential to regulate its downstream signaling
mechanism critical for the maintenance of lens transparency. In addition, E 2 was capable
of stimulating the expression of several genes (pax6, six3, sox2, tcfap2a, and pdgfa)
known to influence development, proliferation, and differentiation in the lenses of the
ERΔ3 mice, which further substantiates the evidence that estrogen possess actions in
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lens. Since ERΔ3 receptors are also expressed in the retina, a known ocular tissue that
influences lens cell proliferation, the protective nature of E2 in the lens may be a result of
E2 action in the neighboring cells at the retina which in turn induces changes that are
observed in the cells of the lens.
Since E2 can bind to its receptors in the lens and is protective against cataracts, the
current work attempts to develop a topical ophthalmic E 2 delivery system and evaluate its
capacity to induce known estrogen responses in ERΔ3 mouse relative to systemic E2
therapy. ERΔ3 cataract model will be used to evaluate different estrogen therapies for
cataract development after estrogen exposure and also to investigate the regulation of
estrogen-induced genes in the lens. If topical estrogen therapy remains safe and
efficacious, it will pave the way for testing the potential of estrogen for cataract
prevention.
I.C.3. 17β-estradiol (E2): Drug Profile
I.C.3.1. Chemical structure
17β-estradiol or estradiol (Figure I.1.) is a white crystalline powder, chemically
described as estra-1, 3, 5(10)-triene-3, 17β-diol. It has an empirical formula of C18H24O2
and molecular weight of 272.39.

Figure I.1: Chemical structure of 17β-estradiol (E2)
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I.C.3.2. Clinical pharmacology
The main actions of estrogen drug products are to regulate the transcription of
estrogen-responsive genes. Estrogens diffuse through cell membranes, distribute
themselves throughout the cell, bind to and activate the nuclear estrogen receptor, a
DNA-binding protein which is found in estrogen-responsive tissues. The activated
estrogen receptor binds to specific DNA sequence called estrogen response elements
(ERE) and modifies the transcription of estrogen-regulated genes (Figure I.2). Estrogen
receptors have been identified in tissues of the reproductive tract, breast, pituitary,
hypothalamus, liver, and bone of women and also in human lens and retina (Couse and
Korach 1999; Gustafsson, 1999; Ogueta, 1999; Cammarata, 2004; Zhang et al., 2003).

Figure I.2: Estradiol (E2) mechanism of action (Reproduced with permission from
Elsevier)

12

Estrogens are important in the development and maintenance of the female
reproductive system and secondary sex characteristics. By a direct action, they cause
growth and development of the uterus, fallopian tubes, and vagina. With other hormones,
such as pituitary hormones and progesterone, they cause enlargement of the breasts
through promotion of ductal growth, stromal development, and the accretion of fat.
Estrogens are intricately involved with other hormones, especially progesterone, in the
processes of the ovulatory menstrual cycle and pregnancy, and affect the release of
pituitary gonadotropins. They also contribute to the shaping of the skeleton, maintenance
of tone and elasticity of urogenital structures, changes in the epiphyses of the long bones
that allow for the pubertal growth spurt and its termination, and pigmentation of the
nipples and genitals (Couse and Korach, 1999).
Estrogens occur naturally in several forms. The primary source of estrogen in a
normally cycling adult woman is the ovarian follicle, which secretes 70 to 500
micrograms of estradiol daily, depending on the phase of the menstrual cycle. This is
converted primarily to estrone, which circulates in roughly equal proportion to estradiol,
and to small amounts of estriol. After menopause, most endogenous estrogen is produced
by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral
tissues. Thus, estrone, especially in its sulfate ester form, is the most abundant circulating
estrogen in postmenopausal women. Although circulating estrogens exist in a dynamic
equilibrium of metabolic interconversions, estradiol is the principal intracellular human
estrogen and is substantially more potent than estrone or estriol at its receptors.
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I.C.3.3. Clinical pharmacokinetics
Absorption
Estrogens used in therapy are well absorbed through the skin, mucous
membranes, and gastrointestinal tract. When applied for a local action, absorption is
usually sufficient to cause systemic effects. Circulating estrogens modulate the pituitary
secretion of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating
hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce
elevated levels of these hormones seen in postmenopausal women.
Distribution
The distribution of exogenous estrogens is similar to that of endogenous
estrogens. Estrogens are widely distributed in the body and are generally found in higher
concentrations in the sex hormone target organs. Estrogens circulate in the blood largely
bound to sex hormone binding globulin (SHBG) and albumin.
Metabolism
Exogenous estrogens are metabolized in the same manner as endogenous
estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic
interconversions. These transformations take place mainly in the liver. Estradiol is
converted reversibly to estrone, and both can be converted to estriol, which is the major
urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and
glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and
hydrolysis in the gut followed by re-absorption. In postmenopausal women, a significant
proportion of the circulating estrogens exist as sulfate conjugates, especially estrone
sulfate, which serves as a circulating reservoir for the formation of more active estrogens.
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Excretion
Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and
sulfate conjugates.

I.C.4. Estradiol (E2) Topical Ocular Drug Delivery System
As discussed in I.C.2.2, estrogens (with E2 being the most potent endogenous
estrogen) are shown to be protective in preventing cataracts. However, many women are
concerned about estrogen treatments due to the potential risk with breast cancer,
endometrial cancer, etc., associated with drug delivery systems that lead to high systemic
levels of estrogen, such as through the oral (Lokind et al., 1996; Haiharan et al., 2006),
buccal (Kitano et al., 1998), vaginal (Bachman G, 1998), nasal (Al-Ghananeem et al.,
2002), and transdermal formulations (Loftsson T and Bodor N, 1989; Variankaval et al.,
2002) routes. In addition, since the lens is an avascular tissue, delivery via systemic
routes would be expected to be less efficient. Hence, a topical ocular delivery of estrogen
that will allow localized interactions with ER receptors in the lens to elicit known
estrogen responses would be a more efficient way to treat cataracts. Such a localized
delivery will reduce drug dose and frequency of administration leading to lower systemic
drug levels and incidence of side effects associated with it. However, before an ocular
formulation can be developed, it is important to understand the anatomy of the eye.

I.C.4.1. Anatomy of the eye
A schematic representation of the human eye is depicted in Figure 1.3. In ocular
delivery, the physiological constraints imposed by the protective mechanisms of the eye,
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like short pre-corneal residence time of the solutions due to constant lachrymal drainage
usually results in low absorption of drugs and, consequently, a short duration of the
therapeutic effect. The faster washing by tear fluid in response to body‘s reflex defense
mechanism also results in frequent administration. Moreover, systemic absorption of the
drug drained through the nasolachrymal duct may result in some undesirable side effects
particularly in the case of estradiol formulations. Among the factors that limit ocular
absorption is the relatively impermeable nature of the corneal barrier. Nevertheless, the
barrier also serves to reduce undesired systemic absorption and side effects associated
with many drugs.

Figure I.3: Schematic representation of the human eye (Ludwig et al., 2005)
(Reproduced with permission from Elsevier).
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The cornea consists of three membranes, the epithelium, the endothelium, and
inner stroma which are the main absorptive barriers. The epithelium composed of
lipophilic cellular layers acts as barrier to ion transport. The tight junctions of epithelium
serve as a selective barrier for small molecules and prevent diffusion of macromolecules
via the paracellular route. The stroma beneath the epithelium is a highly hydrophilic layer
making up 90% of the cornea. The more lipophilic the drug is, the more resistance there
is to cross the stroma and the more hydrophilic a drug, the more resistant the transport
across the epithelium. Hence, physicochemical drug properties, such as lipophilicity
(Rojanasakul et al., 1992), solubility (Schoenwald and Huang, 1983), molecular size and
shape (Liaw and Robinson, 1992), and charge and degree of ionization (Maren and
Jankowska, 1985) affect the route and rate of permeation in cornea.

1.C.4.2. Ocular drug transport and pharmacokinetics
Corneal route
Drug absorption from the surface of the eye can be either corneal or non-corneal
(Fig. I.3). For most ocular drugs, passive diffusion is the main transport process across
the cornea. Passive diffusion is influenced by molecular weight, partition coefficient, and
degree of ionization of the drug. The corneal epithelium is the main limiting barrier for
hydrophilic drugs that penetrate through the paracellular pathway. The corneal surface
epithelial intercellular pore size has been estimated to range between 20 Å (Hämäläinen
et al., 1997b) and 30 Å (Tonjum 1974; Lee et al., 1986) and only very small ionic and
hydrophilic molecules penetrate corneal epithelium paracellularly. The corneal
epithelium is negatively charged and because the isoelectric point is 3.2, the paracellular
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space is more permeable to cations than to anions at physiological pH (Rojanasakul and
Robinson 1989; Liaw et al., 1992). Most drugs that are used clinically are sufficiently
lipophilic to permeate across the cornea via transcellular route (Sasaki et al., 1999). Drug
lipophilicity is one of the most important factors and it has been reported that the log
(partition coefficient) of 2-3 is optimal for corneal penetration (Schoenwald and Ward
1978; Huang et al., 1983; Schoenwald and Huang 1983). In general, adjusting pH so that
drug is mostly in the unionized form increases its lipophilicity and, thus, its transcellular
permeability and ocular absorption (Burstein and Anderson 1985; Mitra and Mikkelson
1988). The hydrophilic stroma represents a limiting barrier for penetration by highly
lipophilic compounds. The corneal endothelium is lipophilic in nature (Huang et al.,
1983). It is a 'leaky' barrier, which allows both paracellular and transcellular permeability
of many drugs (Prausnitz and Noonan 1998).

Non-corneal route
The non-corneal route involves penetration across the conjunctiva and sclera into
the intraocular tissues (Fig. I.3). The conjunctiva is a relative leaky membrane with rich
blood flow and a large surface area (Watsky et al., 1988). Despite these properties, this
pathway does not appear to be important in drug absorption for most ocular drugs, but the
route has been shown to be particularly important for hydrophilic compounds with large
molecular weights (Ahmed and Patton 1985 and 1987; Chien et al., 1990; Hämäläinen et
al., 1997a and b). Drug absorption through conjunctiva is influenced less by the
molecular size and lipophilicity than in the cornea. In general, sclera shows higher
permeability than the cornea and conjunctiva. Conjunctival uptake via its blood vessels
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and solution drainage via the nasolacrimal duct may lead to systemic absorption. In
addition, drainage of tears and instilled solutions away from the front of the eye increase
the precorneal loss of the drug (Patton and Robinson 1976).

I.C.4.3. Challenges with conventional ophthalmic formulations
As reported in literature the primitive ophthalmic solutions, suspensions, and
ointment dosage forms accounted for about 90% of available ophthalmic formulations in
U.S, and a similar percentage is still presumably valid for the current global market.
Solution dosage forms accounts for a majority (65%) of the commercially available
dosage forms. The practical reasons for selecting solutions are the generally favorable
cost advantage, the greater simplicity of formulation development and production, and
the good acceptance by patients despite a little burning. But, the bioavailability of a drug
introduced in this way is often very low, typically <5%, depending on its
physicochemical properties (Figure I.4) (Nanjawade et al., 2007). Such low
bioavailability is attributed to extensive precorneal drug loss by nasolachrymal drainage.
The rapid elimination of the instilled drug often results in a short duration of therapeutic
effect and, consequently, the need for a frequent dosing regimen. Also, systemic
absorption (i.e., ~50-100% of instilled dose) of drug drained through the nasolachrymal
duct may increase the risk for undesirable side effects (Nanjawade et al., 2007; MartensLobenhoffer and Banditt, 2002). For example, topical administration of beta-blockers for
treatment of wide angle glaucoma causes systemic side effects on the heart (Meseguer et
al., 1994; Qian et al., 2010).
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An optimum ocular drug delivery system would be one which can be delivered in
eye-drop solution form with no creation of blurred vision or irritancy and which would
need no more than one to two instillations each day for it to sustain its therapeutic effect.
The reportedly low ocular bioavailability (<5%) of many drugs as discussed earlier was
due to poor contact time of the instilled dose with the ocular tissues and faster elimination
due to tear drainage (Bourlais et al., 1998; Davies NM, 2000). Various ocular tear and
solute balance mathematical models have been developed to relate the characteristics of
the instilled preparations such as viscosity and surface tension to the factors that affect
ocular bioavailability such as pre-corneal tear volume and drainage rate (Zignani et al.,
1995; Zhu and Chauhan, 2005).

Figure I.4: Schematic diagram of ocular absorption (Nanjawade et al., 2007)

Ocular drug absorption by corneal route is a much slower process than its
elimination. A simplified ocular pharmacokinetic model describing the movement of a
topically applied drug to the eye is shown in Figure I.5. For many drugs Kloss is
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approximately 0.5–0.7/min and Kabs is about 0.001/min (Kaur and Kanwar, 2002). The
sum of these two rate constants controls the fraction of the applied dose absorbed into the
eye (Lee and Robinson, 1986). Thus, the ocular bioavailability can be increased
significantly by decreasing Kloss or by increasing Kabs. The former can be achieved by
modifying the ocular dosage forms and the latter by formulating ocular dosage forms
containing lipophilic pro-drugs or by adding penetration enhancers. Studies carried out
using viscous preparations resulted in a higher ocular bioavailability due to higher contact
time with the ocular tissues and reduced systemic absorption due to relatively lower tear
drainage rate (Guryny et al., 1981; Desai et al., 1998; Bonacucina et al., 2006). Hence,
most of the current formulation efforts in ocular delivery have focused on maximizing
ocular drug absorption through prolongation of the drug contact (residence) time in the
cornea and conjunctival sac, as well as to slow drug release from the delivery system and
minimize precorneal drug loss.

Figure I.5: Ocular drug pharmacokinetics in the eye (Kaur and Kanwar, 2002).

To overcome the challenges associated with conventional solution dosage forms,
alternative dosage forms such as suspensions, ointments, inserts, and aqueous gels, have
been investigated in attempts to extend the ocular residence time of the medications for
topical application to the eye (Lee and Robinson, 1986; Bourlais et al., 1998; Kuno and
Fujii, 2011). These alternative ocular drug delivery systems offer some improvement

21

over a conventional liquid dosage form, but are not devoid of problems of their own
typically, blurred vision (e.g. ointments) or lack of patient compliance (e.g. inserts). Their
problems have resulted in their poor acceptance. Therefore, good ocular bioavailability
following topical delivery of a drug to the eye remains a challenge yet to be satisfactorily
resolved.

I.C.4.4. In situ gel-forming systems for ocular drug delivery
From the point of view of patient acceptability, a liquid dosage form that can
sustain drug release and remain in contact with the cornea of the eye for extended periods
of time is ideal. If the precorneal residence time of a drug could be improved only
modestly, then improved local bioavailability, reduced dose concentrations, less total
drug dose, improved patient acceptability, and reduced dosing frequency may result.
Therefore, delivery systems based on in situ gel-formation offer an attractive alternative.
Such systems involve a phase transition in which the instilled liquid form gels upon
reaching the cul-de-sac of the eye. Therefore, these systems offer the dual advantage of
an easy to administer liquid formulation along with the increased residence time of a gel.
Parameters that can change and trigger the phase transition of in situ gels include
pH, temperature, and ionic strength (Shulin Ding, 1998; Mundada and Avari, 2009).
Literature examples of some of the polymers used in in situ gel systems that employed
one or more of these phase change mechanisms include the following:


Gelling triggered by a change in pH - CAP (cellulose acetate phthalate) latex, cross
linked polycarbophil acid and its derivatives such as carbomers and polycarbophil
(Desai and Blanchard, 1995; Le Bourlais et al., 1998).
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Gelling triggered by temperature change - poloxamers, methyl cellulose, and Smart
HydrogelTM (Gurny R, et al. 1987; Rozier et al., 1989; Cohen et al., 1997).



Gelling triggered by change in ionic strength - Gelrite (gellan gum) and alginate
(Rozier et al., 1997; Carlfors et al., 1998; Paulsson et al., 1999; Yuguchi et al., 2002)



Combination system with a thermally-induced gelling material (methyl cellulose) and
pH-induced gelling material (carbomer) was also used to achieve in situ gelling
property with less total polymer content (Bonacucina et al., 2006).
In all of the above systems, a polymer is used as the ―gelling‖ system. Many high

molecular weight polymers (Figure I.6) with different functional groups (such as
carboxyl, hydroxyl, amino, and sulfate) capable of forming hydrogen bonds, yet not
crossing biological membranes, have been screened as possible excipients for in situ gelforming ocular delivery systems (Ludwig, 2005; Mundada and Avari, 2009).

I.C.4.5. Polymers for in situ gel-forming drug delivery systems
Cellulose derivatives
A number of substituted cellulose-ethers have been employed for artificial tear
solutions and as viscosity-enhancing ophthalmic vehicles (see Figure I.6) (Calonge, 2001;
Lin and Boehnke, 1999). Methylcellulose also possesses wound-healing properties and is
a suitable tear substitute for dry eyes, especially for those with punctate lesions (Toda et
al., 1996). All cellulose-ethers impart viscosity to the solution and they have wetting
properties and increase the contact time by virtue of their film forming properties. Some
cellulose-ethers (e.g. hydroxypropylmethylcellulose and hydroxypropylcellulose) also
exhibit surface active properties, interact with components of the tear film, and alter the
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physicochemical parameters governing the tear film stability (Benedetto et al., 1975).
Surface active viscosifying agents can influence the blinking rate, which in turn
influences the elimination of the drug instilled. They cause irritation and extensive
lachrymation, provoking a rapid wash out of the ophthalmic solution and, consequently, a
poor bioavailability. Generally, less surface active hydroxyethylcellulose is better
tolerated, but the mucoadhesive properties of non-ionic cellulose-ethers are rather poor
(Meseguer et al., 1993; Sechoy et al., 2000). However, sodium carboxymethylcellulose
(NaCMC) exhibits a mucoadhesive capacity comparable to that of poly (acrylic acid)
(PAA) (Bourlais et al., 1995).

Acrylates
The mucoadhesive properties of poly (acrylic acid) are due mainly to hydrogen
bonding, while hydrophobic interaction with mucin is not significant (Leung and
Robinson, 1988). When anionic polymers interact with mucin, the maximum interactive
adhesive force occurs at an acidic pH, suggesting that the mucoadhesive polymer in its
protonated form is responsible for the mucoadhesion. The swollen polymer entangles
with mucin on the eye surface, stabilizing a thick hydrogel structure (Degim and
Kellaway, 1998).

Polyanionic polymers, such as polyacrylates or carbomers, were

proposed as long-lasting artificial tears for the relief of dry eye syndrome and traumatic
injury. The use of these high molecular weight polymers is based on inherent mucus-like
and lubricating properties, shear thinning behaviour, and good retention on the ocular
surface (Oescher and Keipert, 1999; Bron et al., 1998). To enable the controlled release
of drugs with low solubility, Setiawan and colleagues synthesized poly(acrylic acid)–
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cyclodextrin conjugates (Carbopol 934P:hydroxypropyl-beta-cyclodextrin) (Setiawan et
al., 1998). When administrated to the eye, an increase in the bioavailability of the drug
complexed with cyclodextrin can be obtained. Moreover, after instillation, the
preparation forms a gel. In rabbits, the aqueous humor bioavailability (as determined by
the area under the concentration time profile over the first 3 h) of hydrocortisone 0.3%
(w/v) in the new delivery system was 6-fold higher than for the suspension. A similar
increase was observed for the cornea and the iris/ciliary body bioavailability (Setiawan et
al., 1998).
Hyaluronan
Besides synthetic polymers, natural macromolecules such as hyaluronan (HA),
present in the vitreous body of the eye, were proposed as viscosifying agents. Sodium
hyaluronate molecules have physical properties and a composition comparable to tear
glycoproteins and easily coat the corneal epithelium. Polymers adsorbed at the
mucin/aqueous interface extend into the adjacent aqueous phase, thereby stabilizing a
thick layer of water. The non-Newtonian behaviour of sodium hyaluronate combines the
advantage of high viscosity at rest between blinks with those of lower viscosity during
blinking (Lauren, 1987; Wysenbeek et al., 1988).
Diluted solutions of sodium hyaluronate have been employed successfully as tear
substitutes in severe dry eye disorders. The beneficial effects are attributed to the
viscoelasticity, biophysical properties similar to mucins, which provide a long-lasting
hydration and retention. Moreover, good lubrication of the ocular surface is obtained
(Simmura et al., 1995; Solomon and Merin, 1998). Hyaluronic acid is an important
constituent of the extracellular matrix and may play a role in inflammation and wound
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healing and may promote corneal epithelial cell proliferation (Aragona et al., 2002).
Gurny and colleagues confirmed the positive influence of hyaluronate vehicles on the
bioavailability of pilocarpine. High molecular weight of the polymer is an essential
requirement for the prolonged precorneal residence time of the preparation (Gurny et al.,
1987).
Chitosan
The chitosan polymer is biodegradable, biocompatible and non-toxic. It possesses
antimicrobial and wound-healing properties. Moreover, chitosan exhibits a pseudoplastic
and viscoelastic behaviour (Hassan and Gallo, 1990; Greaves and Wilson, 1993; Felt et
al., 1998)). The mucoadhesive properties of chitosan are determined by the formation of
either secondary chemical bonds such as hydrogen bonds or ionic interactions between
the positively charged amino groups of chitosan and the negatively charged sialic acid
residues of mucins, depending on environmental pH (Alonso and Sanchez, 2003). The
mucoadhesive performance of chitosan is significantly higher at neutral or slightly
alkaline pH as in the tear film. Only in the presence of an excess of mucin, does a
strengthening of the mucoadhesive interface occur (Rossi et al., 2001). A 3-fold increase
of the precorneal residence time of tobramycin was achieved when adding chitosan to the
formulations, compared to the commercial solution of the drug. Only a minimal influence
was observed from the concentration and molecular weight of chitosans employed,
indicating a saturable bioadhesive mechanism based on ionic interactions of the cationic
polymer with the negative charges of the ocular mucus (Felt et al., 1999).
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Thiomers
Thiolated polymers, or so-called thiomers, are capable of forming covalent bonds
with cysteine-rich sub-domains of mucins. The extensive cross-linking process of the
thiomers with mucins resulted in a tremendous increase in viscosity and mucoadhesion
independent of pH or ionic strength of the medium. The mucoadhesive properties of a
chitosan thioglycolic acid conjugate and a poly (acrylic acid)–cysteine conjugate
improved 10-fold and even 100-fold, respectively, compare to the native polymers (Kast
and Bernkop-Schnuerch, 2001; Marschutz and Bernkop-Schnuerch, 2002).
Polysaccharides
Besides chitosan, numerous polysaccharides were evaluated as mucoadhesive
ophthalmic vehicles: polygalacturonic acid, xyloglucan, xanthan gum, pullulan,
scleroglucan, and carrageenan (Saettone et al., 1994; Albasini and Ludwig, 1995; Sintzel
et al., 1996; Madsen et al., 1998). Also, in the case of polysaccharides, the formation of
macromolecular ionic complexes with drugs improved the bioavailability and lengthened
the therapeutic effect when compared to drug solutions. Toxicological studies indicate
that xyloglucan is very well tolerated by conjunctival cells, has cell protective properties,
and is able to reduce drug-related toxicity (e.g. fluoroquinolones, timolol, merthiolate)
probably due to its mucin-like structure. Xyloglucan might promote wound healing
depending on its influence on the integrin recognition system (Burgalassi et al., 2000;
Raimondi et al., 2000). Timolol, in association with xyloglucan, has a prolonged duration
of action and is suitable for ocular administration in cases of elevated intraocular
pressure. In rabbits, high timolol concentrations in the ocular tissues were measured, but
with low systemic absorption (Burgalassi et al., 2000).
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Figure I.6: Polymers utilized in ocular drug delivery systems (Ludwig, 2005)
(Reproduced with permission from Elsevier)
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Gellan gum
Among all in situ gel-forming systems, systems that function upon activation by
change in ionic strength using gellan gum are most effective. These systems overcome
the draw backs associated with other systems where phase transition is mediated by pH
and temperature. In the former case, a highly acidic pH could result in ocular irritation
and temperature fluctuations during storage could affect gelation and the inevitable need
of high polymer contents.
Gellan gum is an exocellular microbial hetero polysaccharide that is secreted by
the strain Pseudomonas elodea and is of interest to the food and pharmaceutical
industries. Chemically, it is an anionic polymer with a high molecular weight (approx.
5105 daltons, deacetylated). The polymer is stable to both heat and pH (pH 3.5-10.0)
(Singh et al., 2004). Native gellan gum (Figure I.7a) consists of a backbone of repeating
unit of -1,3-D-glucose, -1,4-D-glucuronic acid, -1,3-D-glucose, -1,4-L-rhamnose,
and the two acyl groups, acetate and glycerate, bound to a glucose residue adjacent to
glucuronic acid. The acetyl groups in native gellan gum are removed by alkaline
treatment to produce deacetylated gellan gum (Figure I.7b).
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Figure I.7: Chemical structure of gellan gum; a) native grade, and b) deacetylated grade
(Bajaj et al., 2007).

Gellan gum has a characteristic property of temperature-dependent and cationinduced gelation. Gellan gum in solutions forms a coaxial triangular 3-fold double helix
from two left-handed chains coiled around each other with the acetate residues on the
periphery and glyceryl groups stabilizing the inter-chain associations. Hydrogen-bonds
are formed between the hydroxymethyl of 4-linked glucosyl units of one chain and the
carboxylate group of other. There are ion-binding sites by carboxylate oxygen atoms and
a hydroxyl group in one chain and two hydroxyl groups in the other, plus one stronglybound water molecule (Crescenzi et al., 1990). Hence, the mechanism of gelation
involves formation of double-helical junction zones followed by aggregation of the
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double-helical segments to form a three-dimensional network by complexation with
cations and hydrogen bonding with water (Grasdalen H, et al 1987).
Acetyl content is the most important factor affecting the gel strength of the gellan
gum based in situ gel formulations. There are two types of deacetylated gellan gum
which are differentiated on the basis of degree of deacetylation: high acyl gellan gum
(partially deacetylated) (e.g., Kelcogel® CG-HA) and low acyl gellan gum (highly
deacetylated) (e.g., Kelcogel® CG-LA). Gellan gum with different acetyl content gives
gels with different properties. Native gellan gum provides soft, elastic, thermoreversible
gels, is very weak because of bulky acetyl and glyceryl groups that prevent close
association between gellan polymer chains in bulk-helix formation, and hinders compact
packing of the cross-linked double helix. Deacetylated gellan gum forms a firm, brittle,
and thermoreversible gel because of the absence of acetyl and glyceryl groups (Bajaj et
al., 2007).
Gellan gum based systems are the only systems that offer clear gels with good in
situ gelling characteristics in the presence of mono (Na+, K+) and divalent (Ca2+) cations
present in physiological fluids even at as low as 0.1%(w/v) polymer concentrations.
Reflex tearing upon ocular administration in eye further enhances the viscosity of the
formulation by increasing the cation concentration in the tear fluid. The viscoelastic
nature of the gellan gum preparations offers further advantages of low viscosity during
blinking and stability of tear film during fixation. Gelrite ® (gellan gum) has also been
used in the formulation of a prescription ophthalmic product that has been approved by
the US FDA. Timoptic-XE®, timolol in Gelrite®, was developed as an extension of the
Timoptic® ophthalmic solution product line. Through formulation into an in situ gel, the
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dosing frequency of Timoptic® was reduced from twice-a-day to once-a-day and without
loss of ease of instillation (Schenker et al., 2000).

I.C.4.6. Kinetics of drug release from in situ gel-forming delivery systems
As discussed in the earlier section (I.C.4.4), in situ gel-forming systems have a
unique combination of characteristics that make them useful in drug delivery
applications. Due to their hydrophilicity, hydrogels can imbibe large amounts of water
(>90 wt.%). Therefore, the molecule release mechanisms from hydrogels are very
different from hydrophobic polymers. Both simple and sophisticated models have been
previously developed to predict the release of an active agent from a hydrogel device as a
function of time (Boldhane SP, Kuchekar BS, 2009; Nagarwal et al., 2009; Singh et al.,
2010). These models are based on the rate limiting step for controlled release, and
therefore are categorized as diffusion controlled and swelling controlled systems. Drug
diffusion time and polymer chain relaxation time are two key parameters determining
drug delivery from polymeric matrices. In diffusion-controlled delivery systems, the
time-scale of drug diffusion, t, is the rate-limiting step; while in swelling-controlled
delivery systems, the time-scale for polymer relaxation is the rate limiting step.

Diffusion-controlled systems
Diffusion-controlled is the most widely applicable mechanism for describing drug
release from in situ gel-forming systems. Fick's law of diffusion with either constant or
variable diffusion coefficients is commonly used in modeling diffusion-controlled
release. Drug diffusivities are generally determined empirically or estimated a priori
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using free volume, hydrodynamic, or obstruction-based theories (Amsden, 1998). In
diffusion-controlled delivery systems, Fickian diffusion dominates the molecule release
process and diffusion equation proposed by Peppas et al. (shown in Equation I.1) which
assumes a time-dependent power law function and can be used to predict molecule
release (Peppas et al., 2000; Siepmann and Peppas, 2001 ).

Mt
 K tn
M

Equation I.1

Here, K is a structural/geometric constant for a particular system and n is designated as
release exponent representing the geometry of the device as well as the physical
mechanism for release. The n values for delivery matrices with different geometries and
release mechanisms are summarized in Figure I.8 (Siepmann and Peppas, 2001). It is
noteworthy that in a purely swelling-controlled, slab-based delivery system, the drug
fractional release (Mt/M∞) appears to be zero-order as the release exponent equals unity.
The power law is easy to use and can be applied to most diffusion-controlled release
systems. However, it is too simple to offer a robust prediction for complicated release
phenomena. For example, in diffusion-controlled systems, where n=0.5, the power law is
only valid for the first 60% of the release profile. These empirical models can only
predict the release profile after certain release experiments are conducted and have
limited capability to predict how the release profiles will change as the chemical or
network properties of the system are varied.
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Figure I.8: Release exponent values (n) in the empirical power law model (Siepmann
and Peppas, 2001).

Swelling-controlled systems
Another mechanism for drug delivery from in situ gel-forming systems is
swelling controlled delivery. In situ forming hydrogels may undergo a swelling-driven
phase transition from a glassy state where entrapped molecules remain immobile to a
rubbery state where molecules rapidly diffuse. In these systems, the rate of molecule
release depends on the swelling rate of polymer networks. Swelling-controlled release
occurs when diffusion of drug is faster than hydrogel swelling. The modeling of this
mechanism usually involves moving boundary conditions where molecules are released
at the interface of rubbery and glassy phases of swollen hydrogels (Siepmann and Peppas,
2001). The empirical power law (Eq. I.1) used to describe diffusion-controlled drug
release from hydrogel matrices can also be used comprehensively in swelling controlled
delivery systems. A modification of Eq.I.1 takes into account both the drug diffusion and
polymer relaxation.

Mt
 K1 t m  K 2 t 2m
M

Equation I.2

where K1, K2, and m are constants characteristic of drug polymer system. This expression
describes the release rates in terms of relaxation-controlled transport process, K2t2m, and
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the diffusion-controlled process, K1tm (Lin and Metters, 2006; Ganji and VasheganiFarahani, 2009).

I.C.5. Estradiol (E2) Aqueous Solubility Enhancement
I.C.5.1. Use of cyclodextrins (CD)
One of the major limitations in ocular delivery of drugs is poor aqueous solubility
and/or poor permeability. Estradiol is a BCS class-II drug with low aqueous solubility
(0.03mg/L at RT) and high permeability (logp-3.94). Hence ocular absorption of estradiol
from the formulation is solubility limited. Aqueous solubility enhancement of several
steroidal drugs such as progesterone, cortisone, testosterone, hydrocortisone, 17estradiol, and other drugs for ophthalmic delivery, using cyclodextrins has been widely
reported in the literature (Liu et al., 1990; Zia et al., 2000). CD complexation generally
results in improved wettability, dissolution, solubility, and stability in solutions and with
reduced side-effects (Bourlais et al., 1998).
Cyclodextrins (CDs) are a family of cyclic ( -1,4)-linked oligosaccharides
containing 6, 7 or 8 D-glucopyranosyl units and are referred to as alpha (), beta () and
gamma () CD respectively (Figure 1.9) (Rajewski et al., 1995; Loftsson and Brewster,
1996; Thompson, 1997).
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Figure I.9: Structure of -cyclodextrin (Loftsson and Brewster, 1996)
CDs are toroid-shaped due to lack of free rotation about the bonds connecting the
glucopyranose units with all the secondary hydroxyl groups OH-2 and OH-3, located on
the wider rim and all primary hydroxyl groups, OH-6, on the narrower rim. The glucose
units are in the 4C1 chair conformation. The central cavity of the cyclodextrin molecule is
lined with skeletal carbons and ethereal oxygens of the glucose residues making it
lipophilic. The polarity of the cavity has been estimated to be similar to that of aqueous
ethanolic solution (Coleman et al., 1995). The secondary -OH groups at the wider rim of
the CD cavity form intra-molecular H-bonds in which OH-3 group of one glucose unit
interacts with the OH-2 group of the neighboring glucose unit. This interaction leads to a
belt of hydrogen bonds around the secondary CD cavity side that gives the whole
molecule a rather rigid structure, especially in the case of -CD. This rigidity is probably
why -CD has the lowest water solubility (1.85 g/100ml) of all the CDs. Moreover,
aggregation of these rigid -CD molecules may also contribute to the low aqueous
solubility (Coleman et al., 1995). The H-bond belt is incomplete in -CD molecule
(solubility of 14.5 g/100ml) because one glucopyranose unit is in a distorted position,
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leading to only four H-bonds instead of six possible H-bonds. The -CD is a noncoplanar, more flexible structure; therefore, it has better solubility (23.2 g/100ml) of the
three CDs. The primary OH-6 groups placed at the smaller rim‘s torus are not
participating in intramolecular hydrogen bonds and, therefore, can rotate so as to partially
block the cavity of CDs (Schneider et al., 1998). Parent cyclodextrins are readily soluble
in strongly polar aprotic solvents like dimethyl sulfoxide (DMSO), dimethyl formamide
(DMF), N,N-dimethylacetamide, and pyridine and mixtures of these.
The most critical draw back of the parent CDs is their relative insolubility and
toxic effects on the kidneys, which is the main organ for the removal of CDs. Hence,
modified

β-cyclodextrins,

like

hydroxypropyl-β-cyclodextrin

(HP-β-CD)

and

sulfobutylether-β-cyclodextrin (SBE- β-CD), are being used more extensively.

I.C.5.1.1. Sulfobutylether 7-cyclodextrins (SBE 7)
Stella and Rajewski described the preparation of sulfonate and sulfoalkylether
derivatives with different degree of substitution (Rajeswski et al., 1992; Rajeswski et al.,
1995). The reaction of butane sulfone and -CD generates a mixture of sulfobutylether 
cyclodextrin derivative. These derivatives were isolated as sodium salts, and
demonstrated solubilities independent of degree of substitution. Sulfobutylether -CD
(Figure 1.10) has a different binding behavior compared to parent CDs because
substitution at the 2, 3 or 6 hydroxy groups of the CD causes additional interactions.
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R= [-CH2-CH2-CH2-CH2-SO3-Na+]7
Figure I.10: Structure of Sulfobutylether 7-cyclodextrin

The sulfobutylether -CDs do not show pH-dependent solubility behavior since
they are expected to be ionized (pKa <1) between the pH of 3-10, that is typically
employed in pharmaceutical preparations. The anionic charge at the end of the butyl
chain in SBE -CD is expected to repel adjacent substituents, effectively maintaining an
opening to the CD cavity. Although the substituents are long enough to bend into the
cavity, they are not expected to do so because of the hydrophilic character of the ionic
sulfate, which prefers to interact with the aqueous solvent. One major difference in the
complexation performance of ionic (SBE--CD and CM--CD) versus neutral CDs such
as -CD and HP -CD is the inability of the former to participate in 1:2 or 1:3
complexations. The charged CDs do not effectively form higher order complexes
probably because of electrostatic repulsions between the first CD that has sequestered the
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drug and the incoming CD (Thompson, 1997). In addition to the charge on the CD torus,
the ionic state of the guest molecule is important in determining complexation
characteristics. The anionic SBEs often exhibit a 1:1 binding constant with neutral form
of drug, such as indomethacin and naproxen, that are comparable to or higher than those
observed for the neutral HP -CD (Okimoto et al., 1996). This better binding may be due
to the butyl micellar arms that extend the depth of the hydrophobic cavity of the CD.
As the degree of substitution increases in the case of SBE--CD, the CD torus
may be distorted in such a way as to result in decreased hydrophobic interaction between
some guest molecule and the interior of the CD cavity, thereby decreasing the driving
force for inclusion complexation. Additionally, steric interference may also play a role in
observed decreased binding capacity of modified CDs. The cavity opening may be
capped by substituents alone or by the formation of an aqueous solvation shell near the
entrance of the cavity associated with charged substituents (SBE--CD and CM--CD).
The presence of bulky highly charged and hydrated sulfonate groups near the cavity may
also inhibit the approach of a hydrophobic molecule, thus reducing complex formation.
On the other hand derivatization of the CD torus may provide additional sites of
interaction for stabilization of some complexes. For example, the alkyl chains may
provide additional hydrophobic binding sites or the sulfonate moieties may induce
specific interactions with the guest molecule (Zia et al., 1997).
Sulfobutylether 7 -CD has an average of seven negative charges and seven
sodium ions and, hence, it would be expected to also possess significant osmotic
properties. Okimoto and colleagues developed a controlled porosity osmotic pump system
for poorly water-soluble drug (testosterone) in which SBE 7 -CD acts as a solubilizing
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as well as an osmotic agent. The effect of anionic SBE 7 -CD was compared to a neutral
cyclodextrin, HP -CD (i.e., solubilizing agent and osmotic agent), and a sugar mixture
(i.e., osmotic agent). It was found that testosterone release was significantly faster with
SBE 7 -CD compared to HP--CD and sugar mixture due to a great extent to osmotic
pumping mechanism; whereas, for HP--CD, the major mechanism was by diffusion
(Okimoto et al., 1996) .

I.C.5.1.2. Mechanism of complexation
For the association of guest molecules with cyclodextrins, several intermolecular
interactions have been proposed such as the driving/binding forces for complexation.
These comprise non-bonded attractive forces, such as van der Waals interaction,
electrostatic attraction/repulsions and steric effects, and hydrogen bond interaction (a
primarily electrostatic phenomenon). Hydrogen bond interaction that is especially
significant to cyclodextrins because of many oxygen atoms that serve as Lewis base sites
and hydroxyl groups acting as Lewis acid contributor. Complex formation comprises of
the following steps: First, escape of water molecules from the CD cavity to an energy
level corresponding to that of the 'gaseous state', a state in which the molecules are
independent from each other with no intermolecular interaction. Second, conformation
energy of the cyclodextrin ring decreases on relaxation due to the escape of water
molecules from the cavity. Third, shedding of the hydrate shell by the guest molecule
takes place that assumes a state of an ideal gas. Fourth, the entry of the guest molecule
into the CD cavity results in stabilization of the complex by a non-bonded interaction,
such as van der Waals interaction and hydrogen bonding. The guest molecule retains one-
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dimensional rotational freedom. The fifth step is the condensation of displaced water
molecules, or transformation from the "gaseous state" to the liquid state. The last step
involves the restoration of water structure around the exposed part of the guest molecule
and integration with the cyclodextrin ring hydrate shell (Lipkowitz, 1998).
The complexation constant (K1:1, also known as stability or binding constant) and
the free energy of interaction between the guest molecule and the -cyclodextrin are
dependent on the enthalpy and entropy of complexation. Therefore, the evaluation of
these thermodynamic parameters, i.e., the enthalpy and entropy of interaction may
provide better insight into the various forces involved in complexation. In all
complexation processes, the enthalpy of complexation is negative; indicating that
complex formation is an exothermic process, i.e., there is release of high energy,
enthalpy-rich water molecules from the CD cavity. Traditionally, hydrophobic
interactions between two apolar molecules at room temperature have been known as an
entropy-driven process, where the enthalpy of the process is small and entropy of
interaction is large and positive. However, cyclodextrin inclusion complexation processes
at room temperature are usually enthalpy driven processes with minor favorable or
unfavorable entropies of interaction due to features specific to cyclodextrin cavity
(Westphal, 1986; Inoue et al., 1993; Rekhsarky, 1998). Several attempts have been made
to separate the contributions of the hydrophobic effect and the hydrogen bond interaction
from the other terms that contribute to the overall thermodynamics of complexation. The
thermodynamic contribution from the hydrophobic effect may be estimated from
increments in the measured values induced by the extension of the methylene chain,
while the hydrogen bonding may be estimated by adding hydroxyl groups to the guest
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molecule. Zia and colleagues found that complexation of substrates to sulfobutylether cyclodextrin to be more entropically favored as the number of sulfobutylether groups
increased (Zia et al., 1997). This favorable entropy of interaction was compensated by a
less favorable enthalpy of interaction. The systematic increase in the entropy of
interaction was explained in terms of additional hydrophobic interactions with the alkyl
chains. Moreover, derivatization of cyclodextrins may also distort the cavity interior
inducing interaction with the alkyl chains around the torus.

I.C.5.1.3. Characterization of inclusion complexation
Drug-cyclodextrin interactions may be studied by a variety of techniques in both
the solution and solid state, most of which examine the behavior of mixtures of the
cyclodextrin (host) and drug species (guest) in solution. One such technique in frequent
use is determination of the phase solubility diagram, which can be used to obtain
approximate stability constant for the complex. Isothermal titration calorimetry (ITC) is a
highly sensitive technique particularly useful for characterizing host-guest interactions
involving low heats of binding or in which the energetic changes are quite small. It is
used to establish the mechanism of interaction between the drug and cyclodextrin and to
obtain information about the thermodynamic parameters, the binding constants, and the
stoichiometry (Eli et al., 1999; Illapakurthy et al., 2005; Mic et al., 2009; Singh et al.,
2010). More direct evidence of complexation can also be obtained from proton nuclear
magnetic resonance (1H NMR) spectra of the host-guest mixture in solution, which
allows determination of the guest molecule orientation in the cyclodextrin cavity
(Anguiano-Igea et al., 1997; De Paula et al., 2007).
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Generally, the prepared CD inclusion complexes are used and stored mainly in
solid state, so characterization of the inclusion complexes in the solid state is critical. For
their analytical investigation, thermoanalytical technique, such as differential scanning
calorimetry (DSC), is predominantly used (Badawy et al., 1996; Mura et al., 2003; Yap et
al., 2005). Thermal analysis offers a simple, fast, and reliable approach of investigating
these compounds, since inclusion complex formation remarkably changes the original
thermal properties of the complexed guest(s), such as absence of melting or DSC peaks
or shift in decomposition towards higher temperature, etc. Powder X-ray diffraction
(PXRD) also provides useful evidence of complexation when the guest compound is a
solid crystalline substance, such as E2, where formation of amorphous complexes with
SBE 7 leads to the disappearance of certain peaks or the peaks become less sharp than
those of the pure compounds or physical mixture (Variankaval, 2001; Jain and Adeyeye,
2001). The application of FTIR is usually limited to the guests having some characteristic
bands, such as carbonyl or sulfonyl groups. Although this technique is not generally
suitable to detect the inclusion complexes and is less clarifying than the other methods, it
can still provide information about the involvement of hydrogen in various functional
groups (Koontz et al., 2009). The complexation generally shifts the absorbance bands to
the lower or higher frequencies and/or increases their intensity, etc. Also, though the use
of scanning electron microscopy (SEM) may not affirm inclusion complexation, it can
indicate the differences in crystallization state of the raw materials and the resultant
product obtained by co-precipitation/evaporation (Jun et al., 2007).
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I.C.5.1.4. Cyclodextrins in ocular drug delivery
Cyclodextrins may increase the ophthalmic delivery of drugs through multiple
mechanisms, such as increased solubility of poorly soluble drugs and/or alteration in
corneal permeability. If the corneal permeability is increased, the change may be
reversible or irreversible (permanent corneal damage) (Rajewski and Stella, 1996;
Okimoto et al., 1999). Hence, only non-damaging (i.e., safe) CDs have been used in
ocular drug delivery. Both parent and modified cyclodextrins have been used for the
ophthalmic delivery of a number of drugs, such as pilocarpine (Jarvinenet al., 1995;
Suhonen et al., 1995; Jarho et al., 1996), hydrocortisone (Davies et al., 1997),
dexamethasone acetate (Usayapant et al., 1991), anandamides (Pate et al., 1996; Pate et
al., 1996), acetazolamide (Maren et al., 1986), dipivefrine (Jarho et al., 1007), etc. For
example, co-administration of pilocarpine prodrug with either HP -CD or SBE 4 -CD
or SBE 7 -CD significantly reduced the ocular irritation at low levels and the coadministration of the CDs did not affect the mitotic response of the pilocarpine prodrug
solution (Jarvinen et al., 1995). At similar concentrations (9.2 mM), the negatively
charged SBE -CD increased the aqueous stability of positively charged dipivefrine (pKa
9.0) 15-30 times (at pH 5), and 20-300 times (at pH 7.4), while neutral HP -CD
increased the stability only 4-5 times at either pH values. However, in vitro interfacial
transfer and in vitro corneal uptake experiments suggested that the complexation of
dipivefrine with CDs, especially SBE7-CD may adversely affect the ocular
bioavailability of the drug due to the stronger complexation and greater intrinsic stability
of dipivefrine in the SBE7-CD complex compared to HP--CD complex.
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In general, only the free drug and not the drug/CD complex can penetrate
lipophilic biological barriers, and therefore, for ophthalmic absorption, the drug must be
released from the complex before absorption. In contrast to oral and parenteral
administration, ophthalmic preparations do not exhibit significant increase in the fraction
of available free drug after ocular administration due to the lack of drug/CD complex
dilution by the small tear fluid volume (approximately 7 l). In addition, aqueous eye
drops are removed from the pre-corneal area within a few minutes (Lipkowitz, 1998), so
that drug/CD complex may not have enough time to release the drug before its clearance
from the pre-corneal area. Thus, in ophthalmic preparation, complexation of a watersoluble drugs or excess complexation of a poorly water-soluble drug may decrease
bioavailability or control the release of the applied drug.

I.C.5.2. Use of surfactants for E2 solubility enhancement:
The ability of surfactants to enhance the solubility of poorly water-soluble
compounds in an aqueous solution is widely known and used in many aspects of drug
formulation development (Florence, 1981; Sweetana and Akers, 1996). For example,
surfactants are used as wetting agents to improve tablet dissolution (Chen and Zheng,
1993; Ruddy et al., 1999) and are commonly used in the media for dissolution testing to
maintain sink conditions for the drug (Rao et al., 1997).
Enhancement of the aqueous solubility by surfactants occurs as a result of the
dual nature of the surfactant molecule. Surfactants are amphiphilic molecules composed
of a hydrophilic or polar moiety known as head and a hydrophobic or nonpolar moiety
known as tail. The surfactant head can be charged (anionic or cationic), dipolar
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(zwitterionic),

or

non-charged

dodecyltrimethylammonium

(nonionic).

bromide

(DTAB),

Sodium

dodecyl

polysorbate

80,

sulfate
and

(SDS),

dioctanoyl

phosphatidylcholine are typical examples of anionic, cationic, nonionic and zwitterionic
surfactants, respectively. The surfactant tail is usually a long chain hydrocarbon residue
and less often a halogenated or oxygenated hydrocarbon or siloxane chain (Rosen, 1989;
Jones and Chapman, 1995).
When surfactant molecules are dissolved in water at concentrations above the
critical micelle concentration (cmc), they form aggregates known as micelles. In a
micelle, the hydrophobic tails flock to the interior in order to minimize their contact with
water, and the hydrophilic heads remain on the outer surface in order to maximize their
contact with water (see Figure I.11) (Tanford, 1980; Chevalier and Zemb, 1990). This
creates a discrete hydrophobic environment suitable for solubilization of many
hydrophobic compounds like E2. The micellization process in water results from a
delicate balance of intermolecular forces such as hydrophobic, steric, electrostatic,
hydrogen bonding, and van der Waals interactions. The main attractive force results from
the hydrophobic effect associated with the non-polar surfactant tails and the main
opposing repulsive force results from steric interactions and electrostatic interactions
between the surfactant polar heads (Israelachvili, 1991).
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Figure

I.11:

Schematic

illustration

of

the

reversible

monomer-micelle

thermodynamic equilibrium (Rangel-Yagui et al., 2005). The black circles represent
the surfactant heads (hydrophilic moieties) and the black curved lines represent the
surfactant tails (hydrophobic moieties).

I.C.5.3. Use of Surfactants in Ophthalmic Formulations
The use of surfactants is greatly restricted in formulating ophthalmic solutions.
Nonionic surfactants are most frequently used in pharmaceutical systems because of their
compatibility with other formulation excipients, stability, and low toxicity. The order of
surfactant toxicity is anionic> cationic >> nonionic (Liu et al., 2007). The nonionic
surfactants can be divided into those that are water soluble and those that are water
insoluble. Among the most widely used water-soluble surfactants are sorbitan ether esters
of oleic acid (Polysorbate or Tween 20 and 80), which are commonly used in oral,
parenteral, and topical pharmaceutical formulations (Alvarez-Nunez et al., 2000). The
head groups of these surfactant molecules contain no charged moieties, with their
hydrophilic properties due to the presence of hydroxyl groups.
Being a non-ionic surfactant, polysorbate 80, provides low toxicity and minimizes
possible interactions with other ionic excipients in the formulation. Besides, its low

47

critical micellar concentration (CMC) (i.e., 0.012 mM) (Zhang et al., 2003; Chakraborty
et al., 2009) allows achieving high aqueous solubility of sparingly water soluble drug
such as E2, at much lower surfactant concentrations. Also, polysorbate 80 as a non-ionic
drug solubilizing agent is widely used in ocular preparations to aid in dispersing drugs in
suspensions [e.g., fluorometholone (Morshima and Shiotani, 2008; Cagle GD et al.,
1992), tobramycin (Cagle GD et al., 1992), prednisolone acetate (Akram et al., 2010))
and emulsions (e.g., cyclosporine (Napoli, 2001), difluprednate (Yamaguchi et al., 2005)]
or to solubilize drugs to improve solution clarity and drug bioavailability [e.g.,
hydrocortisone (Zimmer et al., 1994), cyclosporine (Zhang, 2008), prostaglandin (Pilotaz,
2010), diclofenac (Berganimi et al., 1997), ketotifen (Chapin et al., 2010), loratidine
(Chang et al., 2003)]. Some of the commercial ophthalmic products that contain
polysorbate 80 are Restasis®, XibromTM, Rohto® V Ice, etc.

Micellar solubilization can be defined as the spontaneous dissolving of a
substance by reversible interaction with the micelles of a surfactant in water to form a
thermodynamically stable isotropic solution with reduced thermodynamic activity of the
solubilized material (Rosen, 1989). In the plot of drug solubility vs. surfactant
concentration (Figure I.12) solubility is very low until the surfactant concentration
reaches the cmc. At surfactant concentrations above the cmc the solubility increases
linearly with the concentration of surfactant, indicating that solubilization is related to
micellization.
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Figure I.12: Schematic plot of the concentration of a poorly soluble compound as a
function of the surfactant concentration in aqueous solution (Liu et al., 2007).

There are a number of possible loci of solubilization for a drug in a micelle
(Figure I.13). Accordingly, hydrophilic drugs are adsorbed on to the surface of the
micelle, drugs with intermediate solubility are located in intermediate positions within the
micelle and completely insoluble hydrophobic drugs may be located in the inner core of
the micelle (Torchilin, 2001). The existence of different sites of solubilization in the
micelle results from the fact that the physical properties, such as microviscosity, polarity
and hydration degree, are not uniform along the micelle (Dutt, 2003). The drug release
characteristics and transport/ pharmacokinetics of ocular preparations are addressed in
sections I.C.4.6 (pp. 32) and I.C.4.2 (pp.17), respectively.
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Figure I.13: Possible loci of solubilization of drugs in surfactant micelles, depending
on the drug hydrophobicity (Rangel-Yagui et al., 2005). The black bold lines represent
the drug at different sites in the micelle. The black circles represent the surfactant heads,
the black bold curved lines represent surfactant heads and the light black curved lines
represent the surfactant tails.

I.C.6. Safety of Ocular Formulations and Preclinical Testing
The success of a topical therapy intended for human administration is relied on its
safety. Hence the test‘s that evaluate the potential of the developed ocular formulation to
cause irritation or damaging effects to the eye forms a critical part of any ophthalmic
drug product approval process by regulatory authorities. Traditionally, Draize test in
rabbits has been used as a model for human drug exposure to test the ocular toxicity of
ophthalmic formulations (Darize, 1944; Wilhelmus, 2001).
Rabbits are used due to their availability, low cost, ease of handling and
maintenance, large eyes with conjunctival and corneal tissues that are easily observed,
and non-pigmented conjunctiva and iris facilitating observation of a response to irritation.
However, it is important to note that the rabbit eyes differ from the human eye by having
less tearing, a decreased blinking rate, looser eye lids, a nictitating membrane, a poorly
defined corneal Bowman‘s membrane, a slower rate of corneal re-epithelialization, and a
very labile blood-aqueous barrier (Nanjawade et al., 2007).
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In vitro or ex vivo alternatives to Draize eye test in rabbits such as isolated
chicken eye (ICE) test, the bovine corneal opacity and permeability (BCOP) assay, the
hens egg chorioallantoic membrane (HET-CAM) assay are also available for testing the
toxicity of the ocular formulations (Chan, 1985; Luepke and Kemper, 1986; Bruner et al.,
1991; Wilcox, 1992; Spielmann et al., 1993; Wilhelmus, 2001). But, these test tube
methods do not represent the effect of preparation on tear film and other ocular tissues
except corneal membrane.
Toxicity studies performed using these methods found that none of the alternative
tests, taken alone, proved to be a reliable replacement for the Draize animal test and
combinations of two or more tests are required to achieve reliable data. It is particularly
important to test the irritation potential of the in situ gel-forming ophthalmic drug
delivery systems in rabbits as the functionality of this novel formulation depends upon its
ability to form an in situ gel in the presence of either pH, ionic strength of the tear fluid,
or temperature of the eye. Potential for irritation upon ocular administration of a drug
formulation is typically a function of the length of time it stays in the eye and its effect on
tear film and other ocular tissues such as iris and conjunctiva. Further, blinking frequency
of the eye will impact the residence time of the drug in the eye and its potential for any
irritation. Hence, in this current research, rabbits will be used to evaluate the ocular
irritation potential of the developed topical ophthalmic in situ gel-forming estradiol (E2)
drug delivery system.
Considering all the characteristics of the drug, potential excipients that could be
used in the formulation of ophthalmic estradiol (E 2) delivery system and formulation
peculiarities including stability and ocular toxicity, the focus of the project is to develop a
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statistically designed stable in situ gel-forming E2 ophthalmic solution that is safe and to
evaluate the pharmacokinetic disposition and toxicity. The role of topically delivered
estrogen and its ability to induce known estrogen-dependent responses in the eye will
also be explored in order to understand the drug‘s treatment modality. These
investigations will serve as a prelude to potential future use of the delivery system to
prevent or delay cataract formation.
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CHAPTER II
MATERIALS AND EQUIPMENT
Table II.1. List of Materials
Material

Manufacturer

Sulfobutylether 7 -cyclodextrin

Cydex Pharmaceuticals, Inc.

(CaptisolTM)

Overland Park, KS

Deacetyalted gellan gum

CP Kelco,

(Kelcogel® CG-LA)

Atlanta, Georgia

Polysorbate 80, NF

Spectrum Chemicals

YG0196

Mannitol powder, USP

Spectrum Chemicals

YS1139

Potassium sorbate, NF

Spectrum Chemicals

ZQ1232

Edetate disodium dihydrate, USP

Spectrum Chemicals

YM0468

Estradiol, Micronized, USP

Spectrum Chemicals

XT3070

Estriol, USP

Sigma Aldrich

067K14851

Estrone, USP

Sigma Aldrich

080K1683

Benzalkonium chloride

Spectrum Chemicals

XB1013

Sigma Aldrich

076K2632

Sodium chloride, USP

Fisher Scientific

034671

Potassium chloride, USP

Spectrum Chemicals

ZQ3026

Calcium choride, USP

Spectrum Chemicals

VU0231

Sodium bicarbonate

Spectrum Chemicals

YX0581

Trypticase soy agar

BD & Company

9076809

Tryptic soy broth

EMD

VM766059

Reagent Alcohol, HLC grade

Spectrum Chemicals

ZP0825

Acetonitrile, HPLC grade

Spectrum Chemicals

ZS0505

Millipore

R7BN30772

3M

125

Benzyldodecyl dimethyl
ammonium bromide

Millex –HN 0.45 μm syringe
filter
CoTranTM 9711 microporous
polyethylene membrane
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Lot number
CY-04A-05006.2F
9G6158A

FiltrareTM 0.22 μm sterile

US Medical,, Inc.

hydrophilic filter

Hingham, MA

Opti-MoleTM

A048

Wescor, Inc

osmolality standards
Blue-T® buffer standards

Spectrum Chemicals

9041-15

DSC hermetic pans

TA

T092007

DSC hermetic lids

TA

T111007

Steri-Dropper®

The Medi-dose® group

T208100

Table II.2. List of Equipment
Equipment

Manufacturer

Model

HPLC separation module

Waters

2690

Chromatography column

Phenomenex,

(C18(2), 250 x 4.6 mm, 5 m)

Torrance, CA

HPLC PDA detector

Waters

996

Waters

2475

Guard cartridge system

Phenomenex, Torrance, CA

0575-56914

X-Ray Diffractometer

Phillips

PW 3710

DuPont DSC analyzer

TA Instrument

2910

Scanning electron microscopy

Phillips

XL 30 FEG

FTIR Spectrometer

Perkin Elmer, Norwalk, CT

1605

NMR Spectrometer

Bruker Instrument, Billerica, MA

Dissolution Apparatus

Vankel Industries Inc.

drx-500
VK6010

UV-Vis Spectrometer

Perkin-Elmer

Lambda 35

Vapor pressure osmometer

Wescor, Inc

VAPRO 5520

Water purifier

Millipore

Milli-Q®

Lab incubator

Fisher Scientific

Isotemp

Freezer

Fischer Scientific

Isotemp

Incubator shaker

New Brunswick Scientific Co.

Series 25

Mechanical convection oven

Thermo Scientific

Precision

HPLC Multi wavelength
fluorescence detector
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Luna

Stability chamber

Associated environmental systems

NA

Stability chanber

VMR

9000L

Sonicator

Branson

2510

pH meter

VWR Scientific products

9100

Magnetic stirrer and heater

Fisher Scientific

Isotemp

Autoclave

TOMY

ES-215

Vortexer

VWR Scientific

Genie-2

Precision microbalance

Denver Instruments

NA

Microbalance

Denver Instruments

XE-400

Micro centrifuge

Fisher Scientific

MicroV

Centrifuge

Fisher Scientific

Marathon 16KM

MicroCal, Inc.

ITC-200

Isothermal titration
calorimeter
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CHAPTER III
AQUEOUS SOLUBILITY ENHANCEMENT AND DEVELOPMENT OF AN IN
SITU GEL-FORMING OPHTHALMIC ESTRADIOL SOLUTION
III. A. INTRODUCTION
The aqueous solubility of E2 is around 2-3 μg/mL at 25C and its therapeutic dose
by ocular delivery ranges between 10 to 25 μg (Johansson and Ohman, 1987). This dose
results in a dose (D):solubility (S) ratio of 5-10. Due to the limitations associated with the
maximum volume of a solution that a eye can hold upon administration (~20-30 μL), and
the volume of tear fluid available for drug dissolution in the eye (~7-10 μL), E2 delivery
by ocular route require the D:S ratio to be ≤0.01. Sulfobutylether 7β-cyclodextrin (SBE
7), as discussed in Chapter I, is less toxic due to its anionic nature and provides greater
solubility and stability constants for complexation with hydrophobic drugs compared to
other cyclodextrin derivatives due to its high degree of substitution (i.e., seven). Hence,
aqueous solubility enhancement of E2 via inclusion complexation with SBE 7 was
investigated. The development of an ophthalmic in situ gel forming system with desirable
properties such as sterility, isotonicity, clarity, and viscoelasticity requires use of other
functional excipients in the formulation; therefore, their compatibility with the SBE 7,
and influence on product performance characteristics were further investigated.
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III. B. EXPERIMENTAL AND METHODS
III.B.1. Solution-state Characterization of E2 and SBE 7 Inclusion Complexation
III.B.1.1. HPLC Assay Method Development & Validation
HPLC based fluorescence method was developed to measure E 2 concentrations in the
binary mixtures with SBE 7 as it is relatively more sensitive and specific in E 2 estimation.
The developed method was further validated for specificity, linearity, accuracy and
precision, limit of detection (LOD) and quantitation (LOQ) according to ICH Q2 (R1)
guidelines as described below.
Instrumentation
The HPLC system consisted of a Waters Alliance (Waters Corporation, Milford,
MA, USA) equipped with a Waters 2690 separation module and Waters 2475
fluorescence detector. Data acquisition was performed by the Empower TM 2 Pro software.
Analysis was carried out at excitation and emission wavelengths of 280 and 298 nm,
respectively, with a Luna C18(2) reversed-phase column of 250 mm  4.6mm i.d., 5m
dimensions (Phenomenex, Torrance, CA, USA) at ambient temperature. The mobile
phase consisted of acetonitrile and water (50:50, v/v) set at a flow rate of 1 mL/min
Preparation of Solutions
Standard stock solution of 200μg/mL of 17β-estradiol (E2) was prepared by
dissolving accurately weighed amount in reagent alcohol. Calibration standards were then
prepared at concentrations of 60, 70, 80, 90, 100 and 120 ng/mL from the standard
solution by appropriate dilution with ethanol.
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Linearity and Range
The calibration curves were constructed with 6 concentrations ranging from 60 to
120 ng/ml. The fluorescence emission units of the drug solution were considered for
plotting the linearity graph. The linearity was evaluated by linear regression analysis,
which was calculated by least square regression method.
Specificity
Specificity of the developed method to accurately measure E 2 in the presence of
SBE 7 in the solution was evaluated by analyzing 6 replicates of a test sample containing
E2-SBE 7 binary mixture that corresponds to theoretical E 2 concentration of 90 ng/ml.
Specificity was demonstrated by comparing the estradiol retention times in the test
sample with the reference E2 standard chromatograms and reported as the mean peak
retention times along with standard deviation.

Accuracy and Precision
Accuracy and precision of the assay method was evaluated for both intra-day and
inter-day variations at three different concentrations (i.e., 60, 90 and 120 ng/mL) for three
consecutive days. Accuracy and precision were expressed in terms of percent mean
recovery and percent relative standard deviation (% RSD or %CV), respectively.
Repeatability or intra-assay precision refers to the variations in the recovery values
obtained upon analyzing the above samples within the laboratory over a short period of
time during the same day. Whereas, intermediate precision represents inter-assay
variations measured across different days (i.e., 3 days). Analysis of variance (ANOVA)
was used to identify statistical differences in the intra- and inter-day recovery values.
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Limit of Detection and Quantitation
LOD and LOQ were calculated based on the standard deviation of the response
(σ) and slope (S) of the calibration curve obtained from multiple calibration curves. LOD
being given by the 3.3σ/S and LOQ given by 10σ/S: Where σ is the standard deviation of
the intercept of the calibration curves and S is the mean slope of the calibration curves.

III.B.1.2. Phase Solubility Analysis
Phase solubility studies of E2 in the presence of SBE 7 were performed at 22 ±
1ºC and 37 ± 1ºC according to previously published method (Higuchi and Connors,
1965). In these studies, excess of E 2 was added to the glass vials containing aqueous
solutions of SBE 7 in the concentration range of 0.46-2.31mM. The vials were agitated in
an incubator shaker operated at 250 rpm and fixed temperature for 3 days until
equilibrium was reached. The vials were then centrifuged and the supernatant was filtered
through 0.45 µm nylon syringe filter and analyzed for E 2 concentration using a validated
reverse phase HPLC method described earlier.
Using the phase solubility data obtained at two different temperatures,
thermodynamic parameters, such as apparent stability constant of the complex (K1:1),
change in enthalpy (∆H°), change in Gibbs free energy (∆F°), and change in entropy
(∆S°) upon complexation were calculated using Eq(s). III.1 – III.4. In addition, the
solubilizing efficiency of the SBE 7 in the aqueous vehicle was determined by either the
slope of the phase solubility profile or the complex to free cyclodextrin ratio, which is
referred to as the complexation efficiency (CE) according to Eq(s). III.5 and III.6.

K 1:1 

slope
     (III.1)
S0 (1  slope)

ln(
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K2
T  T1
)  H o 2
     (III.2)
K1
RT1T2

S° =

Fo  RT ln K        (III.3)

CE  So K 1:1 

[D / CD]
slope

 (III.5)
[CD]
(1  slope)

(H° - F°)
     (III.4)
T

1 

D : CD  1 : 1 
    (III.6)
 CE 

So is the intrinsic aqueous solubility of the drug determined experimentally at a fixed
temperature, [D/CD] is the concentration of the dissolved complex, [CD] is the
concentration of the dissolved free SBE 7 and slope is obtained from the linear regression
analysis of the phase solubility data.

III.B.1.3. Isothermal Titration Calorimetry (ITC)
Isothermal calorimetric titration was performed using an isothermal titration
calorimeter (ITC) (MicroCal, Inc., NJ, USA) in an attempt to relate the complexation or
binding of E2 and SBE7 to the heat of reaction between the two entities. The isothermal
calorimetric unit consists of a reference cell and a sample cell enclosed in an adiabatic
environment. The calorimetric titration reactions were performed at 25°C. The E 2
solution prepared in 90% (v/v) methanol/water was placed in the sample cell and the
reference cell was filled with water. The solution in the sample cell was titrated with SBE
7 solution using a Hamilton injection syringe placed over the sample cell. All the
experiments were performed with constant stirring speed of 400 rpm, which produces
complete mixing in the cell within few seconds after an injection. This baseline, with
stirring, was used as the resting baseline so that no corrections for heat of stirring were
necessary. The sample cell volume was fixed at 1.345 mL in all the experiments.
Binding experiments were performed by injecting 3 L aliquots of SBE 7 solution into
the sample cell containing E2 solution. In the control experiments, 3 L aliquots of E2
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solution were injected into the sample cell containing 90% (v/v) methanol/water without
SBE 7. The concentrations of the E2 and SBE 7 solutions were 0.5 mM and 40 mM,
respectively. The concentrations were chosen such that saturation of all the binding sites
could be obtained. The calorimetric data was analyzed using Origin 5 MicroCal
software to obtain different thermodynamic parameters.

III.B.1.4. 1H NMR Measurements
1

H-NMR spectra of pure drug and the inclusion complex were recorded on a

Bruker drx-500 spectrometer (Bruker AXS Inc., Madison, WI) operating at 500 MHz.
Due to the limited solubility of E2 in D2O, the NMR spectra of E2 and their complexes
were measured by dissolving in the mixture of CD3OD/D2O (3:1). Briefly, 1 mg (7.34
mM) of E2 or the equivalent amount of the E 2: SBE 7 complex was weighed and diluted
with 0.5 mL of CD3OD:D2O (3:1) solvent mixture to determine proton chemical shifts
using NMR. The chemical shifts were measured as parts per million (ppm) downfield
with reference to the CD3OD signal at 3.31 ppm.
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III.B.2. Solid-state Characterization of E2 and SBE 7 Inclusion Complexation
III.B.2.1. Preparation of E2-SBE 7 Binary Mixtures
The inclusion complexes of E2 and SBE 7 in different molar ratios of 1:1 and 1:2
were prepared by solvent evaporation method. The solutions containing required amounts
of E2 and SBE 7 were prepared separately in 90% (v/v) methanol/water. These solutions
were then mixed, stirred at ambient temperature (20-25C) and evaporated to dryness
under fume hood. The dry mass obtained was scraped from the beaker, screened through
a sieve #60 and stored in a desiccator until analyzed. The corresponding physical
mixtures were prepared by admixing E2 with SBE 7 in a jar mill for 15 min. Drug content
uniformity in the physical mixtures was confirmed using the validated HPLC method
prior to further characterization.

III.B.2.2. Differential Scanning Calorimetry (DSC)
Differential scanning calorimetric measurements of pure components and their
binary mixtures were performed on DuPont 2910 DSC (TA Instruments, New Castle,
DE). 5-10 mg of the test samples were accurately weighed in aluminum pans and
crimped. All samples were heated under nitrogen flow at a scanning rate of 10C/min
from 25C to 195C. The upper limit was determined by the expected melting point of
estradiol hemihydrate which is in the range of 176-182C. An empty aluminum pan was
used as a reference. The thermodynamic data was obtained using Thermal Analyst data
acquisition software. The relative degree of crystallinity of the drug (RDC %) in physical
mixture and complexes was estimated according to the following equation (Mura et al.,
2003) :
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drug RDC% 

H sample
H pure drug

 100        (III.7)

where ΔHsample and ΔHpure drug are the heats of fusion of the drug calculated in the physical
mixtures or complexes and in the pure drug, respectively. Heat of fusion measurements
were carried out in triplicate.
III.B.2.3. Powder X-ray Diffraction (PXRD)
Powder XRD patterns of pure components and their binary mixtures were
recorded using a Philips X-ray diffractometer (Philips, Almelo, Holland) with PW 3710
scanner/PW 1830 generator and a Cu k anode operated at a voltage of 40 kV and a
current of 30 mA. All the samples were analyzed in the 2 angle range of 10 to 40
III.B.2.4. Fourier Transform Infrared (FTIR) Spectroscopy
The infra red spectra of pure components and their binary mixtures were recorded
on a Nicolet 360 FT-IR Analyzer (Thermo Scientific, Madison, WI) in the scan region of
4000-400 cm-1. The data were averaged over 16 scans at a sensitivity of 50 and resolution
of 4 cm-1.
III.B.2.5. Scanning Electron Microscopy (SEM)
The images of pure components and their binary mixtures were recorded using
Phillips XL 30 FEG scanning electron microscope (Philips, Almelo, Holland) at an
acceleration voltage of 2kV. The SBE 7 and E 2 pure components were used ‗as received‘
from the company.

Prior to analysis, all the samples were palladium-coated using

cresington sputter coater to neutralize any surface charge.
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III.B.3. Development and Characterization of a Prototype In situ Gel-forming E2
Ophthalmic Solution
III.B.3.1. Formulation of in situ gel-forming E2 ophthalmic solution
Having obtained considerable enhancement of E2 solubility in SBE 7, an in situ
gel-forming ophthalmic solution was prepared as described next. Fixed amounts of
tonicity adjusting agent (mannitol-4.75%w/v) and preservative (benzalkonium chloride
(0.015%w/v) or benzododecinium bromide (0.015%w/v)) were accurately weighed and
transferred to pre-weighed amount of Millipore water (~ 90 ml), while stirring in a 300
mL glass beaker. After the solution was clear, required amount (i.e., on dried basis) of
gellan gum polymer (Kelcogel® CG-LA) was added and allowed to hydrate in the beaker
for 15 min. The preparation was then heated to 80°C and maintained for 1 min or until it
turned clear. The clear solution obtained was then filtered through a Whatman filter
No.1 (42.5mm Ø) and cooled to room temperature. After weight adjustment of the water
loss due to evaporation, the preparation was sterilized by autoclave at 121°C and 15 psi
pressure for 15 min. E2 stock solution containing aliquot of the drug in SBE 7 was
prepared and added to the rest of the sterile preparation by filtering aseptically through
0.22 μm sterilizing filter in a laminar flow hood. The resultant mixture was then stirred
for 30 minutes to obtain a homogenous sterile in situ gel-forming estradiol ophthalmic
solution. The composition of the formulations prepared with different preservatives is
listed in Table III.1 shown below.

64

Table III.1: Composition of in situ gel-forming estradiol ophthalmic formulation
Ingredients

Functionality

Estradiol (E2)

Active ingredient

Concentration
(%w/v)
0.01

SBE 7 cyclodextrin

Drug solubilizing agent

0.5

Kelcogel® CG-LA

In situ gel-forming polymer

0.1 – 0.5

Mannitol

Tonicity agent

4.75

Benzalkonium Chloride (BKC) or
Benzododecinium Bromide (BDDR)

Preservative

0.015

III.B.3.2. Characterization of in situ gel-forming E2 ophthalmic solution
Pharmaceutical in situ gel-forming preparations intended for ocular administration
should exhibit certain desirable characteristics to be suitable for human use and meet
regulatory standards. These characteristics include clarity, pH, isotonicity, sterility
(single-unit dosage form), or anti-microbial efficacy (multi-unit dosage form). In
addition, the efficacy of an ophthalmic delivery system is dependent on prolonged drug
contact time in the ocular tissues and its ability to resist elimination by the protective eye
reflex mechanisms. Hence, the viscosity, shear thinning behavior, or viscoelasticity of the
formulation become very critical for the obvious reason earlier stated and for ease in
manufacturing, handling and administration and for improving overall patient
compliance.
In the subsequent sections, various methods used to test these characteristics are
briefly addressed. Table III.2, shown below lists the acceptable values of the primary
characteristics of the in situ gel-forming ophthalmic solutions considered in this study.
The methodology of testing these characteristics was described in the subsequent
sections.
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Table III.2: List of desirable characteristics of an ophthalmic formulation
Formulation Characteristic Acceptable Value
pH

6-7

Osmolality

275-325 mOsm/kg

Clarity
E2 Potency
Anti-microbial efficacy

Visually clear (or) light transmittance
>85% at 490 nm using water as reference
90-110% assay
Compliance with USP for Class-I
products


Viscoelastic or shear thinning nature
(i.e., G‘‘>G‘ and 0<δ<90°)

Rheology



Gel formation in the presence of
simulated tear fluid i.e. G‘>>G‖,
δ<45°, and G‘α ωn where n<0.7

Osmolality Testing
Osmolality of the formulations was tested using Wescor Vapor Pressure
Osmometer Model-5520. Prior to use, the instrument was calibrated using standard
solutions of 290, 1000, and, 100 mOsm/kg and clean test was performed to check the
level of contamination of the thermocouple sensor from previous measurements.
According to the manufacturer instructions, if the level of contamination was less than
10, test samples can be loaded and measured for osmolality. Measurements were done in
triplicate and mean value for each formulation was calculated.
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Clarity Measurement
Qualitative measure of the formulation‘s clarity was first performed by visual
observation against the light-dark background. Only those formulations that demonstrated
clarity on visual observation were then quantified for their % light transmission. Using
Perkin-Elmer UV-Vis spectrometer (Lambda 35 Model), formulations were initially
scanned using water as a reference standard in the visible region of 400-700 nm to
identify a wavelength where absorption due to drug (usually at 280 nm) was absent.
Further, based on the observed scan, and, also the evidence from the literature, 490 nm
was chosen as the wavelength for measurement of clarity. All formulations were scanned
for % light transmission at 490 nm against water reference as a measure of their clarity.

Formulation pH
The pH of the formulations was tested using VWR-9100 pH meter. Prior to
testing, the pH meter was calibrated using pH standards of 4, 7, and 10 ± 0.01 at 25°C.
All formulations were tested for pH in triplicate and the mean value was calculated.

E2 Potency
Drug (E2) content in the formulations was measured using the validated
fluorescence based HPLC method described earlier. Reagent alcohol was used as a
solvent for E2 and non-solvent for the polymer. For the extraction process, 50 μL of the
formulation was sampled and diluted to 1 mL with the solvent in a 1.2 mL centrifuge
tube. This mixture was then vortexed for a minute and sonicated for 15 min in a water
bath maintained at 35°C. Further, the tubes were vortexed for another minute and
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centrifuged in a MicroV micro centrifuge for 5 min at 8000 rpm. The supernatant was
then diluted and analyzed for E2 concentration.

Preservative Content in the Formulation and Assay Conditions
Antimicrobial effectiveness of any preservative is dependent on its concentration
in the formulation. Since, the procedure for formulation preparation as indicated earlier,
involves filtration, loss in preservative upon adsorption to the filter membrane was
probable. Hence, an HPLC assay method specific for the estimation of preservatives in
the presence of drug & other excipients in the formulation was developed. The
chromatographic conditions used for the estimation of preservative benzododecinium
bromide (BDDR) in the presence of drug (E 2) were as follows: a mobile phase of
acetonitrile (ACN) and pH 3.0 phosphate buffer (62: 38), flow rate of 1mL/min, and, UV
wavelength of estimation at 210 nm. Similarly, the chromatographic conditions for
estimation of another preservative, benzalkonium Chloride (BKC), in the presence of
drug were: a mobile phase of acetonitrile (ACN) and pH 3.0 phosphate buffer gradient of
85% ACN to 75% ACN in 4 min and continue further for 6 minutes, flow rate of 1
mL/min and UV wavelength of estimation at 210 nm.

USP Anti-microbial Efficacy
Formulations containing preservative (BDDR or BKC) along with their
appropriate positive (i.e., preservative solution) and negative controls (i.e., formulation
without preservative) were prepared and tested according to USP 31 <51> Antimicrobial
effectiveness testing procedure for USP Class-I products (i.e., ophthalmic and otic
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preparations). In this test, aliquots of each formulation were inoculated with 10 5-106
cfu/mL concentration of Pseudomonas aeruginosa, Escherichia coli, and, Staphylococcus
aureus and incubated for 28 days at 22.5 ± 2.5°C. The efficacy of preservatives in
inhibiting the growth of microorganisms was tested during storage at 7, 14, and 28 days.
According to USP 31 <51>, the preservative in the formulations are considered to be
anti-microbially effective only if there was a ―1log‖ decrease in the concentration of the
microorganisms at day 7, ―3log‖ decrease in the concentration of the microorganisms at
day 14 and no significant change in the concentration of microorganisms from day 14 to
day 28.

Rheological Characterization
To establish in situ gel formation, simulation of in situ gelling upon contact with
tear fluid and subsequent stability of the formulation upon storage, viscoelastic
characterization of the developed formulations was conducted with AR 1000 rheometer
(TA Instruments, New Castle, Delaware, USA) using double-concentric cylinder
geometry and dynamic small amplitude oscillatory rheometry (SAOR). The instrument
was operated according to the standard operating procedure. To evaluate viscoelasticity
or shear thinning behavior of the formulations alone, 6.5 mL of the formulation was
poured into the double-concentric cylinder geometry and measurements were taken.
Whereas, to characterize for in situ gel formation and viscoelastic behavior and also to
simulate the in vivo situation wherein the administered in situ gel-forming eye drops
interact with the tear fluid in the conjunctiva, formulation and the simulated tear fluid
(STF) are pre-mixed in 30:7 (v/v) ratios and 6.5 mL of the resulting mixture was
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transferred to the double-concentric cylinder geometry and analyzed for viscoelastic
parameters.. The STF was composed of 6.8 g NaCl, 2.2 g NaHCO 3, 0.084 g
CaCL2.2H2O, 1.4 g KCL in 1l of ultra pure water. These amounts results in the mono and
divalent ion concentrations of 142 mM of Na+, 19 mM of K+, and 0.6 mM of Ca2+ that
are comparable with ionic contents of the tears. The pH of the STF was then adjusted to
7.4 using 1N HCl. Prior to testing; the double-concentric cylinder geometry was
preheated to 35C, to make measurements at the physiological eye temperature.
In SAOR, the oscillatory ―stress sweep‖ and ―frequency sweep‖ examines the
micro structural properties of the material such as elastic modulus (G‘), viscous modulus
(G‖), and phase angle (δ) under increasing stress and frequency, respectively. These
properties are used to define the rheological characteristics of samples and to verify if
their structure corresponds to the rheological definition of gel. A gel state is defined in
rheological terms as where G‘ >> G‘‘ with low to moderate dependency on the angular
frequency and phase angle () is low, preferably <45°. In this study, the oscillatory
stress sweep measurements are carried out first to determine the linear viscoelastic (LVE)
region of the sample and, therefore, the consequent choice of the stress value to use in the
oscillatory frequency sweep test.
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III. C. RESULTS AND DISCUSSION
III.C.1. Solution-state Characterization of E2 and SBE 7 Complexation
III.C.1.1. HPLC Assay Method Development & Validation
The fluorescence based HPLC assay method was found to be suitable for the
estimation of drug in the binary mixtures with SBE 7. The least squared regression
analysis of the calibration curve data of E 2 in the range of 60-120 ng/mL was shown in
Figure III.1. The observed high correlation coefficient of 0.9989 indicated good
agreement and linearity between increasing drug levels and the observed fluorescence
emission units. The developed analytical method was further validated in compliance
with ICH Q2 (R1) guidelines as explained in Section III.B.1.1. The results of validation
studies are shown in Table III.3. It was observed that the developed method was accurate
(% mean recovery: 100.3 ± 3.1), precise (CV-3.1%) and highly reproducible with low
intra-day (CV<2%) and inter-day variation (CV<3%). Two-way ANOVA analysis
indicated no significant differences between the intra- and inter-day recoveries at
different E2 concentrations (p>0.05). The limit of detection and quantitation calculated
using the slope and intercept of the calibration curves were 10 and 33 ng/mL,
respectively.
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Figure III.1. Regression plot of E2 calibration standards
Table III.3. Validation parameters of fluorescence based E 2 HPLC assay method.
Validation
Parameters
Linearity and range
Specificity

Values
60 – 120 ng/mL (r2= 0.99)
90 ng/mL solution of E2 has retention time (RT) of 7.72 ± 0.02 min
E2 Conc.
(ng/mL)

Accuracy and
Precision

Intra-day

Inter-day

60

% Recovery
± SD
97.45 ± 1.93

Precision
(% RSD)
1.98

% Recovery
± SD
97.92 ± 2.99

Precision
(% RSD)
3.05

90

100.30 ± 2.01

2.00

99.10 ± 1.90

1.92

120

99.29 ± 1.21

1.22

100.78 ± 2.40

2.38

Limit of Detection
(LOD)
Limit of
Quantification
(LOQ)

10 ng/mL
33 ng/mL
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III.C.1.2. Phase Solubility Analysis
There was linearity in the phase solubility diagrams plotted as aqueous solubility
of E2 as a function of SBE 7 concentration at two different temperatures, 22C and 37C
(Fig. III.2). The observed linearity in the plots (r 2 >0.98) indicates formation of soluble
complexes of E2 and SBE 7 in the concentration range studied and also represents ALtype of behavior according to the classification proposed by Higuchi and Connors (1965).
The slope values obtained upon linear regression of the solubility data at 22C and 37C
were 0.427 and 0.434, respectively. The slope values of <1 reflect existence of 1:1
stoichiometry between E2 and SBE 7 in the complex. The 1:1 stability constants (K1:1)
and other thermodynamic parameters calculated using the solubility data are listed in
Table III.4. The observed differences in the thermodynamic parameters at two different
temperatures were a result of changes in non-bonded interactions, such as hydrogen
bonding, van der Waals, and hydrophobic forces between E2 and cyclodextrin due to
complexation. The observed negative change in enthalpy of association of E 2 and SBE 7
indicated that the complexation was an exothermic process, where E 2 inclusion into the
SBE 7 cavity displaced the enthalpy-rich water causing the release of energy that favored
the formation of inclusion complex. The apparent stability constant (K1:1), indicative of
the stability of the complex, decreased with increase in temperature from 25 to 37C due
to decrease in the non-bonded interactions, such as hydrogen bonding, van der Waals and
hydrophobic forces. At both investigated temperatures, the entropy change was negative,
indicating that the complexation was thermodynamically favored and caused an increase
in the order of the system. Further, using Eq(s). III.5 and III.6, CE values of 0.75 (22C)
and 0.77 (37C) along with the [D]/[CD] ratio of 1:2.3 were obtained. From these values
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it can be inferred that, on average, only about three out of every seven SBE 7 molecules
in solution are forming a water-soluble complex with E2, assuming 1:1 molar E2-SBE 7
complex formation. Furthermore, the similarity in the CE values at the two different
experimental temperatures is indicative of little or no effect of temperature on the
complexation efficiency of E2 with SBE 7.
Table III.4. Thermodynamic parameters of E2 complexation with SBE 7
Temperature
22°C (295°K)
37°C (310°K)

K1:1
ΔHo
ΔFo
ΔSo
-1
(M )
(KJ/mole) (KJ/mole) (J/mole/oK)
93.26 × 103
-28.07
-88.9
-54.3
31.97 × 103
-26.73
-88.9

CE

[D]/[CD]

0.75

1:2.3

0.77

1:2.3

Figure III.2. Phase solubility diagram of E2 with SBE 7 in water at 22 and 37°C
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III.C.1.3. Isothermal Titration Calorimetry (ITC)
The binding isotherm and the corresponding thermodynamic parameters obtained
at 25°C were K (1660  258 M-1), N (0.96  0.17), H (-63.84  13.48 KJ/mole) and S
(-6.67 J/mole/K) as shown in Fig(s). III.3a and 3b. The complexation process was
exothermic and enthalpy driven, as change in enthalpy obtained was negative. This
negative change in enthalpy was a result of partitioning of the hydrophobic E 2 molecule
into the SBE 7 cavity and release of enthalpy-rich water from cyclodextrin cavity. The
negative change in entropy also suggests that the binding was thermodynamically favored
and caused an increase in the order of the system. The ―N‖ values close to 1 (i.e., 0.96 
0.17) suggest that the stoichiometry of binding between E2 and SBE 7 is mainly 1:1.
Based on the assumption of 1:1 molecular complexation, the close agreement of the heat
of enthalpy value obtained in this experiment (H = -63.84  13.48 KJ/mole) to the
enthalpy value (-54.3 KJ/mole) calculated from the phase solubility data using the
empirical equation (Eq. III.2) further confirmed the validity of the equation.
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Figure III.3. a) Representative ITC plot of SBE 7 titration into E 2 solution at 25C, b)
binding isotherm of SBE 7 titration into E 2 solution at 25C

III.C.1.4. 1H NMR Measurements
Proton nuclear magnetic resonance (1H NMR) spectra of the host-guest mixture in
solution was used to confirm possible interaction (within the cavity or at the surface)
between estradiol and SBE 7 as implied from the DSC and PXRD measurements. In
addition, 1H-NMR experiments were performed to confirm that the increase in the
estradiol (E2) aqueous solubility occurred due to inclusion complexation with SBE 7
(Fig. III.4). The chemical shifts of the protons of E 2 were assigned according to the
published report (Variankaval et al., 2000). The induced shift, Δδ, is defined as the
difference in chemical shifts of E2 protons in the presence and absence of SBE 7. In the

76

present study, the induced shifts were calculated by the following equation: Δδ = Δδ
(complex)

– Δδ

(free).

In this convention, positive and negative signs show a downfield and

upfield shifts, respectively. The 1H chemical shifts of E2 in the absence and presence of
SBE 7 are shown in Table III.5. Aromatic protons of the phenyl group of E 2 showed
considerable

1

H-chemical shifts compared to E2 available freely in the solution,

indicating that the environment of the aromatic or phenyl group of E 2 is considerably
different due to complexation with SBE 7. Also, all the aromatic hydrogens were
deshielded due to decrease in the electron density around E2 molecules, probably due to
van der Waals forces, dipole-dipole interactions, and/or hydrogen bonds between the
drug and SBE 7 molecules. These results suggested that the possible orientation in which
E2 binds to the SBE 7 is with its A-ring into the cyclodextrin cavity (Fig. III.5). However,
the effect of E2 binding on the 1H chemical shifts of SBE 7 could not be measured as they
were overlapped by those of E2 in the NMR graphs.
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Figure III.4. One-dimensional 1H-NMR of a) SBE 7, b) E2, and c) complex of E2 with
SBE 7 in CD3OD:D2O (3:1) solvent mixture.

Table III.5. Chemical shifts (ppm) for the protons of E 2 due to complexation with SBE 7.
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Figure III.5. The model structure complex of E 2 and SBE 7 in 1:1 stoichiometry.

III.C.2. Solid-state Characterization of E2 and SBE 7 Complexation
III.C.2.1. Differential Scanning Calorimetry (DSC)
Thermal analysis using DSC offers a simple, fast, and reliable approach of
investigating these binary systems. Inclusion complex formation remarkably changes the
original thermal properties of the complexed guest(s), such as absence of melting peak or
shift in decomposition towards higher temperature, etc. The DSC curve of E 2 (Fig. III.6)
indicated the crystalline hemihydrate state of E 2 with the dehydration endotherm around
110C and the melting endotherm at a T onset= 177.49C, Tpeak= 179.22C, and enthalpy of
melting (Hf) of 102.7 J/g. SBE 7 did not exhibit a melting point, indicative of an
amorphous material. The DSC thermogram of SBE 7 (shown in Fig. III.6) showed a
broad endotherm in the range of 40 - 150C, consistent with dehydration of the sample.
In both the 1:1 equimolar physical mixtures (178.45C) and complexes (178.29C) of
drug with SBE 7, the characteristic, well identifiable peak of the drug appeared at the
temperature corresponding to its melting point. But, the intensity (i.e., change in
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enthalpy) was strongly reduced along with the relative degree of crystallinity (shown in
Table III.6) in the complex (∆Hf =1.45 J/g and RDC (%) = 16) compared to the physical
mixture (∆Hf =8.01 J/g and RDC (%) = 3). However, complete amorphization was only
obtained in the case of the 1:2 complexes of E 2 and SBE 7, where the characteristic E 2
melt peak completely disappeared while, it still remained distinct in the corresponding
physical mixture (Tmelt = 178.42C, ∆Hf =7.26 J/g and RDC (%) = 22). This observation
may be attributed to amorphization of the drug and/or the formation of an inclusion
complex between E2 and SBE 7.

Figure III.6. Differential scanning thermograms of E 2, SBE 7, and their corresponding
1:1 and 1:2 molar physical mixtures and complexes.
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Table III.6. DSC thermodynamic data and relative degree of crystallinity (RDC %) of E 2
in physical mixtures and inclusion complexes with SBE 7
Sample

Wt. adjusted

Tpeak/°C

ΔHf (J/g)

RDC (%)

E2 Pure

179.22

100.5

100

E2-SBE 7 (1:1) physical mix

171.25

16.0

16

E2-SBE 7 (1:1) complex

178.29

2.9

3

E2-SBE 7 (1:2) physical mix

178.42

21.8

22

E2-SBE 7 (1:2) complex

no melt
peak

NA

complete
amorphization

III.C.2.2. Powder X-ray Diffraction (PXRD)
The diffractograms of E2 and its corresponding physical mixtures and complexes
with SBE 7 in different molar ratios are shown in Fig. III.7a and 7b. In the PXRD of E2,
the observed sharp characteristic peaks at diffracting angles (2θ) of 13.96°, 16.87°,
18.39°, 21.98°, and 26.01° indicate crystalline nature of the drug. PXRD of SBE 7
showed a single broad peak indicating its amorphous nature. Peaks due to E 2 crystallinity
were still detectable in the respective physical mixtures and complexes with SBE 7 in 1:1
molar ratio (Fig. III.7a). But, the complexes showed considerable reduction in the
diffraction peak intensities, suggesting that it was less crystalline than the physical
mixture (Fig. III.7a). The observed decrease in drug crystallinity or drug amorphization
was attributed to its complexation with SBE 7. However, a total drug amorphization was
observed in the diffractograms of E2-SBE 7 complexes of 1:2 molar ratios (Fig. III.7b) as
the characteristic peaks of the drug were not observed. These results are in complete
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agreement with the DSC results that showed complete drug inclusion at 1:2 molar ratios
in the solid state.

Figure III.7. Powder X-ray diffraction patterns of E2, SBE 7 and their binary systems. a)
E2 and SBE 7 (1:1 molar) physical mixture and complex, b) E 2 and SBE 7 (1:2 molar)
physical mixture and complex.
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III.C.2.3. Fourier Transform Infrared (FTIR) Spectroscopy
FTIR is typically used to characterize compounds containing functional groups
that show distinguishing IR bands, such as carbonyl or sulfonyl groups. In this study,
although E2 and SBE 7 lack such characteristic functional groups, FTIR was still used to
gather valuable information about the participation of hydrogen in the inclusion
complexation. Such an involvement generally shifts the absorbance bands to the lower or
higher frequencies and/or increases their intensity, etc. Infrared spectra of E 2, as well as
those of its solid binary mixtures with SBE 7 in the 2500-4000 cm-1 range are presented
in Fig. III. 8a and 8b. IR spectral overlay shown in Fig. III.8a revealed that there were no
variations in the spectrum of the physical mixture with respect to the spectra of the pure
components, but that there were variations in the IR spectrum of the complex. Namely,
the aromatic and aliphatic –CH, aliphatic –CH2 stretching vibrations of E2 in the range of
2600-3100 cm-1 were absent in the complex as they were masked due to inclusion of E 2
into the cavity of SBE 7. This proof is indicative of breakdown of the intermolecular
hydrogen bonds of the crystals associated with the inclusion of the drug into the
hydrophobic cavity of the carrier (SBE 7). Further, E 2 inclusion into the SBE 7 cavity in
their 1:1 molar complex caused the aliphatic -CH/-CH2 stretching vibration. In contrast, it
remained unaffected at 2929.2 cm-1 in the 1:2 molar complexes of E2 and SBE 7 (Fig.
III.8b), indicating the diminishing influence of drug on its interaction with SBE 7 at
higher SBE 7 ratios in their binary mixtures. In addition, the IR spectra of the complexes
(Fig. III.8a and III.8b) demonstrated close resemblance with the SBE 7, indicating drug
amorphization in the solid-state due to its inclusion into the hydrophobic cavity of SBE 7.
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Figure III.8. FT-IR spectra of E2, SBE 7 and their binary systems in 2500-4000cm-1
region. a) E2 and SBE 7 (1: 1 molar) physical mixture and complex, b) E 2 and SBE 7 (1:2
molar) physical mixture and complex.
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III.C.2.4. Scanning Electron Microscopy
Scanning electron microscopy (SEM) photographs (in Fig. III. 9a and III. 9b)
show the particle morphology of pure components E 2 and SBE 7 as plate-like and hollow
spherical particles, respectively. The physical mixtures in Fig. III.9c showed particles of
SBE 7 embedded with E2 particles. In contrast, the inclusion complexes of E2 and SBE 7
(in Fig. III.9d) showed a completely different morphology with columnar particles
formed as a result of molecular inclusion complexation.

Figure III.9. Scanning electron microscopy images of a) SBE 7, b) E 2, c) Physical
mixture, and d) Inclusion complex
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III.C.3. Characterization of in situ gel-forming E2 ophthalmic solution
III.C.3.1. Osmolality Testing
Solutions intended for administration in the eye should be isotonic with the
physiological fluids. Instillation of hypo or hypertonic solutions could elicit reflex tears
and reflex blinks in the eye due to discomfort and irritation. Hence, osmolality testing is
one of the key quality attributes to be tested for ophthalmic preparations. Based on the
preliminary osmolality measurements using vapor pressure osmometer, addition of 4.75
%w/v of mannitol along with the fixed amounts of other excipients resulted in
formulations that possessed osmolality in the desired or acceptable range. The osmolality
of different formulations is listed in Table III.7 below. Preservative type and content or
polymer amount in the formulations didn‘t show any significant influence on the resultant
osmolality.
Table III.7. In vitro characteristics of the developed in situ gel-forming E2 formulations
Preservative

Kelcogel

(%w/v)

(%w/v)

BKC
(0.015)
BDDR
(0.015)

pH

Osmolality

Clarity

(mOsm/Kg)

(% transmittance)

0.1

6.09 ± 0.03

277 ± 4

94.51 ± 0.18

0.3

6.06 ± 0.01

285 ± 2

90.13 ± 1.10

0.5

6.01 ± 0.02

279 ± 6

86.66 ± 0.92

0.1

6.18 ± 0.03

277 ± 4

99.89 ± 1.02

0.3

6.15 ± 0.02

277 ± 4

99.22 ± 0.09

0.5

6.09 ± 0.03

277 ± 4

98.76 ± 2.01
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III.C.3.2. Clarity Measurement
Turbidity or clarity of the formulations was quantitatively estimated by
transmittance measurements. Clarity measurement is critical because quaternary
ammonium class of preservatives tends to cause turbidity in the formulations as a result
of columbic interaction with the anionic gellan gum polymer. Evaluation of percent
transmittance as a measure of clarity of the formulations indicated varying degree of
interaction, i.e. clarity of formulation with benzododecinium bromide > benzalkonium
chloride. As shown in Table III.7, polymer concentration showed no effect on the clarity
of the formulations containing BDDR as the preservative, but caused decrease in the
clarity of the formulations containing BKC as the preservative. Such decrease in clarity
with BKC is because at the same preservative concentration (i.e., 0.015%w/v) the number
of molecules of BKC available in the solution to interact with anionic gellan gum
polymer relative to BDDR was higher due to its relatively lower molecular weight (i.e.,
354.08 g/mol for BKC and 384.51 g/mol for BDDR).

III.C.3.3. Formulation pH
Increasing the concentration of gellan gum in the formulation resulted in lower
pH values due to its anionic nature. All the developed formulations had pH in the
acceptable range of 6-7 units (Table III.7). However, formulations containing BDDR
preservative showed substantially different and higher pH values than the formulations
containing BKC because of the differences in the number of molecules present in the
formulations at the same preservative concentration based on the different molecular
weights.
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III.C.3.4. Potency of E2
Ethanol was found to be a suitable extraction solvent for E2 and the extraction
resulted in an acceptable assay values (i.e. 90-110% recovery). From the E2 assay values
shown in Table III.8, it was evident that increasing the polymer, especially in case of
formulations containing BKC as the preservative resulted in lower assay values. Lower
E2 potency values suggest that drug was strongly bound within the polymer matrix
formed due to greater propensity of BKC for columbic interactions with anionic gellan
gum polymer and SBE 7 relative to BDDR at same concentration.
Table III.8. E2 and preservative content in the ophthalmic formulations
Preservative

Kelcogel

E2 Assay

Preservative

(%w/v)

(%w/v)

(% recovery)

(% recovery)

0.1

96.87 ± 1.65

98.91 ± 0.87

0.3

93.79 ± 2.98

100.05 ± 1.98

0.5

92.62 ± 3.36

98.23 ± 1.16

0.1

98.72 ± 0.66

101.10 ± 2.13

0.3

96.07 ± 1.95

99.66 ± 2.15

0.5

97.11 ± 1.01

99.04 ± 0..88

BKC
(0.015)
BDDR
(0.015)

III.C.3.5. Preservative Content
The quaternary ammonium preservatives (BKC or BDDR) used in the
formulations was a mixture of different homologs of C12 & C14. Hence, one or more
peaks corresponding to the preservative were observed in the overlay of chromatograms
of BBDR and BKC calibration standards in Fig.III.10 and III.11.

High r 2 (>0.99)

obtained upon the least-square linear regression of the calibration data indicated good
correlation between the concentration of the preservative and its absorbance (Table III.9).
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Also, the high recovery values (>95%) obtained for preservatives in the formulations (as
shown in Table III.8) indicated suitability of the developed method for their estimation.

Figure III.10. Overlay of chromatograms of calibration curve of BDDR & E2 at 210 nm.

Figure III.11. Overlay of chromatograms of calibration curve of BDDR & E 2 at 210 nm.
Table III.9. Regression equation and calibration range of E 2, BKC and BDDR.
Sl.
No
1

2

Preservative
Benzalkonium
Chloride (BKC)
Benzododecinium
Bromide (BDDR)

BKC_1

Regression
Equation
Y= -2868+86521X

Calibration
range
1 - 4 μg/ml

Linearity
(r2)
0.9999

E2

Y= -9.8e5+1.76 e8X

1.5 - 6 μg/ml

0.9999

BKC_2

Y= -4175+41955X

1 - 4 μg/ml

0.9998

BDDR_1 Y= -1282+56996X

0.5 - 3 μg/ml

0.9994

E2

0.75 – 4.5 μg/ml

0.9999

0.5 - 3 μg/ml

0.9999

Peaks

Y= -2327+282017X

BDDR_2 Y=-2531+116385X
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III.C.3.6. USP Anti-microbial Efficacy
Anti-microbial efficacy through the use of preservatives was done to establish that
the formulation will not support bacterial growth during administration and storage since
Kelcogel CG-LA being a polysaccharide can sustain microbial growth. BDDR or BKC
were chosen as the preservatives of choice in this study due to their established evidence
of efficacy against both gram positive and negative microorganisms. These quaternary
ammonium preservatives (i.e., BDDR and BKC) being cationic in nature, prevent
microbial proliferation by emulsifying and disrupting the bacterial external membrane.
The preservative concentration in the formulations was fixed at 0.015% w/v based on
their maximum allowable concentration for use in pharmaceutical products for
administration in humans. However, addition of any of the two preservatives to the
formulations did not provide USP anti-microbial efficacy (shown in Table III.10).
Such loss in preservative efficacy could not be attributed to any loss in
preservative during manufacturing and handling, as the recovery values were well with-in
the acceptable limit of 95-105% recovery (Table III.8). However, such loss in the
efficacy could be a result of low amounts of free preservative available in the formulation
due to columbic interaction between the cationic preservative and anionic polymer and
solubilizing agent that possibly led to reduced accessibility of the preservative to the
microorganisms.
In order to test this hypothesis and to investigate role of excipients in causing
preservative inefficacy caused by binding, appropriate positive and negative formulation
controls were prepared and tested for antimicrobial effectiveness. All the formulations
were found to be sterile indicating that the method of preparation was aseptic.
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Table III.10. USP anti-microbial efficacy of the E2 ophthalmic formulations
Preservative

Kelcogel

(%w/v)

(%w/v)
0.3
0.3

BKC
(0.015)

0.3
0.3
0.3

BDDR
(0.015)

0.3
0.3
0.3

USP Anti-microbial Efficacy
Test Product

Sterility

Gram +ve

Gram -ve

S.aureus

E.coli

P.aureus

Yes

Yes

No

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Control†

Yes

No

No

No

Formulation

Yes

Yes

No

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

No

No

Formulation
Positive
Control-I#
Positive
Control-II*
Negative

Positive
Control-I#
Positive
Control-II*
Negative
Control†

#

Positive control –I: Preservative (0.015%w/v) solution
Positive control –II: Formulation without E2 and SBE 7
†
Negative control: Formulation without preservative
*

The results shown in Table III.10 indicate that the preservative solutions as alone
(Positive control–I) and in the presence of anionic gellan gum polymer in the formulation
(Positive control-II) demonstrated required USP anti-microbial efficacy. These findings
suggest, that despite their tendency for excipient-excipient ionic interaction, there was
still a required amount of free preservative available in the formulation (i.e., Positive
control-II) to provide anti-microbial efficacy. However, when preservatives are present in

91

the formulation together with the anionic gellan gum polymer and anionic SBE 7
complexing agent, its efficacy in inhibiting the growth of microorganisms was lost due to
increased excipient-excipient ionic interactions. Hence, in the next chapter use of a nonionic drug solubilizing agent and a new preservative system will be studied in an effort to
minimize excipient- excipient interactions that could influence product performance
characteristics.

III.C.3.7. Rheological Characterization
Small amplitude oscillatory rheometry (SAOR) was used for rheological
characterization of the formulations as it allows measuring the viscoelastic properties of
materials at low amplitudes without destroying the structure. The ―double concentric
cylinder‖ geometry was used in this study as its design maximizes the available surface
area over which the measurements can be obtained and improves sensitivity. Besides, it is
also the most sought after geometry to use with low-viscous preparations where sample
slip effects could be significant.
The ―oscillatory stress sweep‖ test was performed at a fixed angular frequency (5
rad/s) on all the formulations as alone and in a pre-defined mixture with STF, to identify
the linear viscoelastic region (LVE) within which the material under applied stress retains
structural integrity. The LVE for formulations containing different concentrations of
polymer or preservative type are listed in Table III.11 and III.12.
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Figure III.12. Oscillatory stress sweep of E2 ophthalmic formulation containing 0.5%w/v
Kelcogel CG-LA and 0.015%w/v BDDR performed at 5 rad/s angular frequency.

Figure III.13. Oscillatory frequency sweep of E2 ophthalmic formulation containing
0.5%w/v Kelcogel CG-LA and 0.015%w/v BDDR performed at 0.5 Pa oscillatory stress.
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Figure III.14. Oscillatory stress sweep of the mixture of E 2 formulation containing
0.5%w/v Kelcogel CG-LA and 0.015%w/v BDDR and STF in 30:7 (v/v) ratios
performed at 5 rad/s angular frequency.

Figure III.15. Oscillatory frequency sweep of the mixture of E 2 formulation containing
0.5%w/v Kelcogel CG-LA and 0.015%w/v BDDR and STF in 30:7 (v/v) ratios
performed at 0.5 Pa oscillatory stress
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The representative oscillatory stress sweep and frequency sweep plots for the
formulation containing 0.5%w/v Kelcogel CG-LA and 0.015%w/v of BDDR along with
other excipients listed in Table III.1 are shown in Fig. III.12 and III.13, respectively.
Similarly, Fig. III.14 and III.15 represent oscillatory stress sweep and frequency sweep
plots for the mixture of formulation containing 0.5%w/v Kelcogel CG-LA and
0.015%w/v of BDDR and STF in 30:7 v/v ratios.
In Fig. III.12, the loss modulus (G‖), which is a measure of liquid-like nature of
the material, was higher than (G‘), a measure of solid-like nature of the material,
throughout the entire stress range studied. However, the modulus values started to
decrease at the oscillatory stress >1 Pa, indicating a threshold stress value beyond which
the structural integrity of the material was lost. Thus, the LVE in this case was identified
as oscillatory stress <1 Pa and angular frequency of 5 rad/s. The oscillatory frequency
sweep generated in this LVE region (shown in Fig. III. 13) provides a way of probing the
morphology of the material without disturbing it and gives the dynamic moduli of G‘ and
G‖. From the Fig. III.13 and the summary of viscoelastic parameters listed in Table III.10
and III.11, it was clearly evident that all the formulations when tested alone indicated
viscoelastic or shear thinning behavior, where G‖>G‘ and phase angle (δ) was between 0
and 90°.
Increasing the polymer concentration in the formulations had significantly
increased the dynamic moduli values (Table III.11 and III.12) suggesting formation of a
stronger polymer network with higher strength. Also, formulations containing BKC as
the preservative produced higher moduli values compared to formulations containing
BDDR as the preservative, due to their higher propensity for columbic interaction with
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other excipients in the formulation. Relatively lower δ values observed in case of BKC
formulations further confirms that BKC interaction with the gellan gum polymer has
resulted in overall improvement in the morphology and structure of the formulations.
Table III.11. Linear viscoelastic region (LVE) and the corresponding viscoelastic
properties of E2 ophthalmic formulations containing BDDR preservative as alone, and in
the mixture with STF in 30:7 (v/v) ratios.

Preservative

Kelcogel

(%w/v)

(%w/v)

BDDR
(0.015)

(LVE) (formulations alone)

formulations

Frequency

(Pa)

(rad/s)

0.1

0.1

0.3
0.5
Kelcogel

(%w/v)

(%w/v)

(0.015)

Viscoelastic properties of the

Stress

Preservative

BDDR

Linear viscoelastic region

G‘(Pa)

G‘‘(Pa)

 (delta)

5

0.02

0.04

64

0.5

5

0.12

0.19

58

0.5

5

0.22

0.38

60

Linear viscoelastic region

Viscoelastic properties in the

(formulations + STF (30:7))

presence of STF (30:7)

Stress

Frequency

(Pa)

(rad/s)

0.1

0.1

0.3
0.5

G‘(Pa)

G‘‘(Pa)

 (delta)

5

0.11

0.06

29

0.5

5

0.39

0.22

29

1.0

5

1.02

0.35

19

However, when formulations were tested in the presence of STF, drastic change
in the morphology was observed. In both the oscillatory stress and frequency sweep plots
shown in Fig. III.14 and III.15, G‘>>G‖, δ<45° and there was a moderate to weak
dependency of dynamic moduli, especially G‘, on the angular frequency. These
viscoelastic characteristics reflected in situ gel structure formation due to gellan gum
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interaction with the cations in the STF. Increasing the polymer concentration in the
formulations resulted in the gels with stronger gel network and higher gel strengths (i.e.
higher G‘ and lower δ). Since, the volume and, hence, the ionic strength of the STF was
kept constant with all the formulations, such increase in viscoelastic behavior is simply a
result of increased interactions between the anionic gellan gum polymer and mono and
divalent cations in STF due to higher polymer in the formulation. The final preservative
and surfactant used will be discussed in the next chapter.

Table III.12. Linear viscoelastic region (LVE) and the corresponding viscoelastic
properties of E2 ophthalmic formulations containing BKC preservative as alone, and in
the mixture with STF in 30:7 (v/v) ratios.
Preservative
(%w/v)

BKC
(0.015)

Preservative
(%w/v)

BKC
(0.015)

Kelcogel
(%w/v)

Linear Viscoelastic Region

Viscoelastic Properties of

(LVE) (formulations alone)

the formulations

Stress

Frequency

(Pa)

(rad/s)

0.1

0.1

0.3
0.5
Kelcogel
(%w/v)



G‘(Pa)

G‘‘(Pa)

5

0.05

0.09

61

0.5

5

0.16

0.20

51

0.5

5

0.29

0.36

51

(delta)

Linear Viscoelastic Region

Viscoelastic Properties in

(formulations + STF (30:7))

the presence of STF (30:7)

Stress

Frequency

(Pa)

(rad/s)

0.1

0.1

0.3
0.5



G‘(Pa)

G‘‘(Pa)

5

0.24

0.09

21

0.5

5

0.46

0.25

29

0.5

5

1.21

0.41

19
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(delta)

In accordance with the earlier observation, formulations that contained BKC as
the preservative produced gels with stronger strengths and higher elastic modulus (Table
III.12) compared to formulations containing BDDR as the preservative due to their higher
propensity for columbic interaction with other anionic excipients in the formulation.
Similar observations were also reported by Carlfors et al., 1998 and Magny et al., 1994,
where they ascribed increase in the elasticity of the gel network to formation of micellar
aggregates of cationic surfactant at the oppositely charged carboxylic groups of the gellan
gum polymer which participates in the intermolecular gel network.
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III. D. CONCLUSIONS
Sulfobutylether 7β-cyclodextrin (SBE 7) was found to be a suitable solubility
enhancing agent for improving aqueous solubility of estradiol (E 2). An inclusion complex
of the E2 and SBE 7 was formed and it resulted in an increased aqueous solubility of the
drug. The fluorescence based HPLC method developed for estimation of E 2 was found to
be precise, accurate, and reproducible.
Characterization in the solution state using phase solubility study and ITC
revealed 1:1 stoichiometry between E2 and SBE 7 in the complex. The complexation
process was thermodynamically favored and resulted in increased order of the system.
The decrease in the apparent stability complex of the complex with increasing
temperature indicated the exothermic nature of the inclusion complexation.
Considerable chemical shifts in the aromatic protons of E 2 in the presence of SBE
7 indicated that the interaction was favored with A-ring entering the SBE 7 hydrophobic
cavity. Also, both DSC and XRPD results indicated the formation of amorphous systems
of E2 in the solid state due to inclusion complexation with SBE 7. The E 2 stock solution
in SBE 7 was then used to develop an in situ gel-forming ophthalmic solution.
Addition

of

mannitol

(4.75%w/v)

resulted

in

isotonic

formulations.

Benzalkonium chloride (BKC) and benzododecinium bromide (BDDR) were chosen as
suitable preservatives based on their established evidence of efficacy against
microorganisms. But, being cationic in nature, they showed tendency to interact with the
polymer and affect clarity of the preparations. The formulations containing BKC as the
preservative caused significant decrease in the clarity at higher polymer concentrations.
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USP anti-microbial efficacy study results indicated that the preservative solutions
alone and in the presence of gellan gum in the formulation demonstrated antimicrobial
efficacy. But, when preservative was present together with anionic gellan gum polymer
and anionic SBE 7 in the formulation, its efficacy in inhibiting the growth of
microorganisms was lost. This loss could be due to low amounts of free preservative
available as a result of excipient-excipient columbic interactions in the formulations.
Rheological characterization by small amplitude oscillatory amplitude showed
that Kelcogel CG-LA offers great potential as a vehicle for in situ gel-forming
ophthalmic system. All formulations exhibited viscoelastic behavior when tested as
alone, but when mixed with STF, in situ gel formation along with a drastic change in
morphology and viscoelastic behavior was observed. Polymer concentration was found to
have positive influence on the resulting dynamic moduli; where, increasing the polymer
concentration resulted in stronger polymer or gel networks with higher elastic modulus.
Also, formulations containing BKC as the preservative produced stronger gel structures
by interacting with the carboxylic acid groups of the gellan gum polymer and minimizing
electrostatic repulsion between the two successive polymer strands.
Although the developed formulation provided some desirable characteristics of an
ophthalmic formulation, it still failed to demonstrate the most important and critical
characteristic of anti-microbial efficacy due to excipient-excipient ionic interactions in
the formulation. Hence, in the next chapter, a new preservative system and drug
solubilizing agent are investigated and an optimized in situ gel-forming E2 ophthalmic
formulation were identified using statistically designed experiments.
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CHAPTER IV

DEVELOPMENT AND OPTIMIZATION OF THE IN SITU GEL-FORMING
OPHTHALMIC ESTRADIOL SOLUTION
IV. A. INTRODUCTION
The prototype in situ gel-forming estradiol solution described in Chapter III failed
to demonstrate antimicrobial efficacy due to potential excipient-excipient ionic
interactions between the preservative and other excipients in the formulation. Gellan gum
and SBE 7 being anionic in nature showed tendency to interact with cationic quaternary
ammonium preservatives. As a result, low amounts of free preservative were available in
the formulation to act against microbial growth and achieve required efficacy. In order to
overcome this challenge, the present work focused on identifying suitable excipients that
could minimize excipient-excipient interactions in the formulation and developing an
ophthalmic estradiol formulation with acceptable product performance characteristics.
Firstly, suitability of polysorbate 80 to enhance E2 aqueous solubility as well as
minimize potential interactions with other excipients in the formulation will be
investigated. Secondly, use of potassium sorbate as alone or in combination with EDTA
as a preservative system will be studied for their compatibility with other excipients in
the formulation and also for their capacity to overcome challenges related to antimicrobial efficacy. In addition, using a pre-optimization study design, optimum levels of
each of these preservatives that will demonstrate desired anti-microbial efficacy at all
polymer levels in the formulation will be identified. The successful formulation will then
be characterized using statistical design of experiments (DOE) to understand the
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influence of polymer and drug concentrations on the product performance characteristics
and identify an optimized in situ gel-forming E2 ophthalmic formulation.

IV. B. EXPERIMENTAL AND METHODS
IV.B.1. Solubilization of E2 by Polysorbate 80
Having observed the potential of the anionic drug solubilizing agent SBE 7 for
excipient-excipient ionic interaction with other excipients in the prototype formulation in
Chapter III, aqueous solubility enhancement of E2 was investigated using nonionic
polysorbate 80-water mixtures at concentrations between 0 and 114.5 mM (i.e. 0 to
15%w/v). Excess E2 was added directly into the surfactant-water mixture and agitated in
an incubator shaker operated at 250 rpm and fixed temperature (23 ± 2°C or 35 ± 2°C)
for 3 days until equilibrium was reached. After equilibration, the solutions were
centrifuged and the supernatant filtered through 0.45 µm nylon syringe filter and
analyzed for E2 concentration using a validated reverse phase HPLC method discussed
earlier. All the solubility experiments were carried out in triplicate.

IV.B.2. Anti-microbial Efficacy of New Preservative System
Formulation Preparation
Potassium sorbate as alone or in combination with EDTA were investigated for
their ability to provide satisfactory USP anti-microbial efficacy of the formulation.
Except for anti-microbial efficacy, the prototype in situ gel-forming E2 formulation
discussed in Chapter III provided acceptable characteristics of clarity, pH, osmolaity, and
viscoelasticity. Hence, the polymer, Kelcogel® CG-LA and the osmotic agent, mannitol

102

were retained as the suitable excipients. Formulations containing these excipients along
with potassium sorbate, alone or in combination with EDTA, were prepared according to
the composition shown in Table IV.1. The amount of potassium sorbate in the
formulation was fixed at 0.3%w/v based on its maximum allowable use; whereas, the
amount of EDTA (0.03%w/v) was chosen in the allowable range of 0.005-0.1%w/v.
These formulations, along with their negative controls (i.e., with out preservatives), were
prepared using the method described in section III.B.1, except that the E 2 stock solution
used was made in polysorbate 80. The positive controls of these formulations containing
potassium sorbate alone or in combination with EDTA in water were prepared aseptically
and tested along with other formulations for USP anti-microbial efficacy.

Table IV.1: Composition of E2 ophthalmic formulations containing new preservative and
solubilizing agents along with their positive and negative controls.
Concentrations (%w/v)
Ingredients

Formulations

Positive Controls

Negative

(A)

(B)

(A)

(B)

Control

Estradiol (E2)

0.01

0.01

---

---

0.01

Polysorbate 80

1.6

1.6

---

---

1.6

Kelcogel® CG-LA

0.3

0.3

---

---

0.3

Mannitol

4.75

4.75

---

---

4.75

Potassium Sorbate

0.3

0.3

0.3

0.3

---

---

0.03

---

0.03

---

Edetate disodium
dihydrate (EDTA)
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Preservative Efficacy Testing
The E2 ophthalmic formulations and their positive and negative controls shown in Table
IV.1 were tested for USP anti-microbial efficacy. The testing procedure used was similar
to the method described in III.B.3.2.

IV.B.3. Pre-optimization: Selection of Optimum Preservative Concentration
In situ gel-forming ocular formulations being part of USP class-I products, have
to demonstrate USP anti-microbial efficacy of the formulation in addition to the fact that
gellan gum is a polysaccharide which has the potential to support microbial growth in the
formulation. The higher the level of gellan gum, the susceptibility towards microbial
contamination is increased. Therefore, the optimization of preservative level in
conjunction with the polymer level was considered extremely important. Moreover,
potassium sorbate and EDTA are salts of potassium and sodium and high amounts of
these preservatives in the formulation can interact with gellan gum, by a similar gelation
mechanism described previously, to result in formulations that can be too viscous to flow.
In order to accommodate the role of the excipients, a 32 full factorial screening study was
designed to investigate the influence of polymer and preservative levels on some critical
product performance attributes, such as antimicrobial efficacy, clarity, osmolality, and
drug potency.
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Pre-Optimization Design of Experiment (DOE): Selection of Preservative (EDTA) and
Polymer Levels
A simple 32 full factorial design was employed and nine formulations (shown in
Table IV.2) containing three levels of Kelcogel® CG-LA (0.1, 0.3 and 0.5%w/v) and
three levels of EDTA (0.01, 0.03 and 0.05%w/v) were prepared using the method
described in section III.B.1. In these experiments the concentrations of the other
excipients in the formulation, i.e., mannitol (4.75%w/v), potassium sorbate (0.3%w/v),
polysorbate 80 (1.6%w/v), and E2 (0.01%w/v) were fixed.

Characterization of the DOE formulations
Since the primary aim was to identify an optimum level of preservative which
would provide anti-microbial efficacy across different polymer levels, all nine
formulations of the experimental design were characterized for anti-microbial efficacy
using the USP method. However, other critical attributes such as pH, clarity, osmolaity
and drug content of the formulations were monitored as well. All the above mentioned
formulations characteristics were measured in triplicate using their respective methods
described in III.B.3.2.
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Table IV.2. 32 factorial design E2 formulations prepared for pre-optimization studies
Kelcogel CG –LA

EDTA

Formulation

(%w/v)

(%w/v)

Label

0.02

K0.1_E0.02

0.03

K0.1_E0.03

3

0.05

K0.1_E0.05

4

0.02

K0.1_E0.02

0.03

K0.3_E0.03

6

0.05

K0.3_E0.05

7

0.02

K0.5_E0.02

0.03

K0.5_E0.03

0.05

K0.5_E0.05

Sl. No
1
2

5

8

0.1

0.3

0.5

9

IV.B.4. Effect of Polymer and Drug Concentrations on Performance Characteristics
of E2 Ophthalmic Solution
The objective of this study was to investigate the influence of E 2 and Kelcogel®
CG-LA concentrations on the critical product performance attributes, especially drug
release and viscoelasticity using statistical design of experiments. The utility of in situ
gel-forming system lies in its ability to form a gel upon administration and provide
viscoelastic behavior that prolongs the drug release and ocular contact times. Polymer
and drug concentrations in the in situ gel-forming formulations had been shown
previously to influence the ocular drug contact times, and hence, its bioavailability
(Sultana et al., 2006; Kalam et al., 2008; Gupta et al., 2007). Such functionality largely
depends on the level of polymer in the system. Also, drug release from these in situ gels
is the function of both the polymer and drug concentration in the formulation. Besides,
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investigation of estrogens potential in cataracts treatment requires understanding the
effect of E2 dose on their onset and severity.

IV.B.4.1. Design of Experiments: Selection of Drug and Polymer Levels
Having identified the levels of preservatives and polymer levels in the preoptimization experiments above, a 32 full factorial design for two factors at three levels
each was selected to investigate varied response variables. The goal is to identify
optimum drug and polymer levels that will provide desirable product performance
characteristics. The two factors, Kelcogel® CG-LA (X1) and E2 (X2) were varied in the
formulations, as required by the experimental design, and the factor levels suitably coded
(Table IV.3). In these experiments, the concentrations of the other excipients in the
formulation were fixed at mannitol (4.75%w/v), potassium sorbate (0.3%w/v), and
EDTA (0.03%w/v) based on their satisfactory results in pre-formulation and preoptimization studies. Different concentrations of E 2 in the formulations were achieved by
adding different volumes of E2 stock solution (1000 μg/mL) prepared in polysorbate-80
(16%w/v). Hence, along with E2, the concentration of the surfactant remains different
across the formulations. All these formulations were prepared using the method described
in section III.B.3.1 and analyzed in replicates.
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Table IV.3. A 32 full factorial design showing runs in standard order
Coded variables
Run

Actual Values
Kelcogel

Formulation

E2

Label

0.5

0.010

K0.5_MedE2

1

0.1

0.025

K0.1_HighE2

0

-1

0.3

0.001

K0.5_LowE2

4

-1

0

0.1

0.010

K0.1_MedE2

5

1

-1

0.5

0.001

K0.5_LowE2

6

-1

-1

0.1

0.001

K0.1_LowE2

7

1

1

0.5

0.025

K0.5_HighE2

8

0

0

0.3

0.010

K0.3_MedE2

9

0

1

0.3

0.025

K0.3_HighE2

X1

X2

1

1

0

2

-1

3

CG-LA

The desirable product performance characteristics considered in this study and
their acceptable range are listed in Table IV.4. Time taken to release 20% (t 20%) and 80%
(t20%) of E2, apparent viscosity (μ), elastic modulus (G‘), and phase angle(δ) were chosen
as the response variables. A second-order polynomial equation with added interaction
terms to correlate the studied responses with the examined variables model was initially
generated. Thereafter, second order quadratic model was assessed. The response (Yi) in
each run shown in Table IV.3 was measured by carrying out a multiple factorial
regression analysis using the quadratic model, Eq. IV.1, shown below.
2

Y  b0  b1 X 1  b2 X 2  b3 X 1 X 2  b4 X 1  b5 X 2
i

2

Eq. IV.1

Where, Yi is the dependent variable; bo is the arithmetic mean response of all the
runs; and bi is the estimated coefficient for factor Xi. The main effects, X1, X2, represent
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the average values of changing factor one at a time; X1X2 represent the interaction term
and the polynomial terms (X12 and X22) are used to assess nonlinearity.

Table IV.4. Acceptable characteristics of an ophthalmic in situ gel-forming E2 solution
Formulation Characteristic Acceptable Value
A. pH

6-7

B. Osmolality

275-325 mOsm/kg

C. Clarity

Visually clear (or) light transmittance >85% at
490 nm using water as reference

D. E2 Potency

90-110% assay

E. Anti-microbial efficacy

Compliance with USP for Class-I products

F. Rheology
a) Flow behavior

Shear

thinning

with

apparent

viscosity,

μ<50cps at shear rate of 100 s-1
Gel formation in the presence of simulated tear

b) Viscoelasticity

fluid i.e. G‘>>G‖, δ<45°, and G‘α ω n where
n<0.7

G. Drug Release

t20% ≤ 0.5 hr and t80% in 6-12 hr

IV.B.4.2. In vitro Characterization of the DOE Formulations
The formulations developed were characterized in the order shown in Table IV.3
for their critical attributes (i.e., pH, osmolaity, clarity, E 2 assay, and USP anti-microbial
efficacy) as well as design attributes (i.e., drug release and rheology) of the in situ gelforming E2 ophthalmic formulations. The methods used for testing critical attributes were
described previously in III.B.3.2. However, the methods developed to test for flow
behavior (i.e., apparent viscosity) of the formulation, viscoelasticity, and drug release are
discussed briefly in the following sections.
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IV.B.4.2.1. Rheological Characterization
A). Flow Behavior
Apparent viscosity of the DOE formulations was measured as a quality control
parameter to monitor the effects of formulations variables on the functionality of
ophthalmic E2 in situ gel-forming solutions. The precorneal tear film in the eye exhibits
pseudoplastic or shear thinning behavior. Any pharmaceutical preparation intended for
ocular administration should influence this ocular tear film as little as possible. Hence, to
minimize any discomfort in the eye, the developed formulations should also be shear
thinning in nature. Besides, shear thinning nature will allow for easy processing,
handling, and administration of the in situ gel-forming ophthalmic solutions (Zignani et
al., 1995; Dikstein, 1992). The formulation is considered shear thinning if its apparent
viscosity decreased with increase in the applied shear rate.
Rheological flow characterization of the developed formulations was conducted
with AR 2000 rheometer (TA Instruments, New Castle, Delaware, USA) using doubleconcentric cylinder geometry and steady state peak-flow method. The instrument was
operated as per the standard operating procedure. 6.5 mL of the formulation was
transferred to the geometry and apparent viscosity (ηapp) at 25°C was determined using
peak hold step, in which a constant shear stress was applied and the corresponding shear
rate was recorded for 45 seconds period. This peak-hold step was further repeated at
various constant shear stress and the corresponding apparent viscosities and shear rates
were recorded. The ranges of shear stress investigated were those that would result in
shear rates range of 10-1000 s-1 that a formulation typically experiences in the eye at rest
and during blinking (Dikstein et al, 1992). The flow behavior of the formulation was then
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characterized by fitting the data obtained to the Ostwald Power-law rheology model. The
magnitude of the flow index (n) will then be used to categorize the flow behavior of the
formulation as Newtonian (n=1) and Non-newtonian (i.e., shear-thinning (n<1) or shearthickening (n>1)).

μapp 

τ
 Kγ n 1
γ

Eq. IV.2

Where μapp is apparent viscosity, τ is shear stress, γ is shear rate, K is consistency
coefficient, and n is flow index.

B). Viscoelasticity
Ocular residence times of the gels are dependent on their viscoelastic properties
(Carlfors et al., 1998; Edsman et al., 1997). Successful design of an optimal in situ gel
system with reproducible in vivo performance requires thorough understanding of the
influence of various formulation variables on the rheological properties. Viscoelastic
characterization of the DOE formulations was conducted with AR 2000 Rheometer (TA
Instruments, New Castle, Delaware, USA) using double-concentric cylinder geometry
and dynamic small amplitude oscillatory rheometry (SAOR). The instrument was
operated according to the standard operating procedure. To evaluate in situ gel formation
and viscoelastic behavior, the formulation and the STF were pre-mixed in 30:7 v/v ratios
and 6.5 mL of the resulting mixture was transferred to the geometry and analyzed for
viscoelastic parameters. The geometry was preheated to 35C, to make measurements at
the physiological eye temperature. In this study, the oscillatory stress sweep
measurements were carried out first to determine the linear viscoelastic (LVE) region of
the sample and, therefore, the consequent choice of the stress or strain value to use in the
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oscillatory frequency sweep test. In situ gel structure formation and viscoelastic behavior
were then confirmed by analyzing the frequency dependency of the viscoelastic indices
obtained from the frequency sweep test by fitting to the power-law rheology model
shown below.

G' ()  n

Eq. IV.3

Where, G‘ is elastic modulus, ω is angular frequency, and n is power law coefficient.

IV.B.4.2.2. Drug Release Characterization
Drug release from the in situ gel-forming E2 ophthalmic solutions was studied
using modified USP-XXXII Type-II dissolution apparatus and Enhancer Cells™. The
test was performed at 100 rpm paddle speed and 35°C temperature. Simulated tear fluid
(200 mL, pH 7.4, and 30%v/v ethanol) maintained at 35 ± 0.2°C was used as dissolution
medium. 1mL of the test formulation was transferred to the Enhancer Cell™ reservoir
using a micropipette. The formulation was then covered by a thin CoTran™9711
polyethylene membrane (3M, St Paul, MN) previously soaked overnight in the
dissolution medium. The membrane was then secured in place using sealing ring and
patch retainer. The Enhancer Cell™ was then carefully transferred to the dissolution
vessel and drug release was measured at different time points of 0.5, 1, 2, 3, 4, 6, 8, 10
and 24 hr. At each time point, a fixed volume (i.e., 2 mL) of the dissolution medium was
sampled and replaced by the fresh dissolution medium. The drug (E 2) concentration in the
dissolution media at each time point was measured using a validated fluorescence-HPLC
assay method discussed earlier. Using the drug (E 2) release data obtained at different time
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points, release kinetics were characterized by treating the data to various drug release
kinetic models.
Firstly, the drug release data were fitted to a power-law model proposed by
Korsemeyer-Peppas, and Higuchi square-root kinetics, shown in Eq. IV.4 and Eq. IV.5.
The Korsemeyer-Peppas model is often used to describe drug release from polymeric
drug delivery systems when the mechanism is not well known or when more than one
type of release mechanism is involved (Boldhane SP, Kuchekar BS, 2009; Nagarwal et
al., 2009; Singh et al., 2010). Whereas, Higuchi square-root kinetics is used when
diffusion is considered the predominant mechanism of drug release.

Mt
 K tn
M

Eq. IV. 4

Mt
K t
M

Eq. IV.5

Where, Mt/M∞ is the fraction of drug released in time t, K is drug release rate constant,
which incorporates structural and geometrical characteristics of the controlled release
system, and n represents the release exponent indicative of mechanism of drug release.
When n=0.5, the drug diffuses through and is released by a quasi-Fickian diffusion
mechanism. For 0.5>n<1.0, non-Fickian solute diffusion is observed and when n=1, the
diffusion is swelling controlled and is termed pseudo-Case II solute transport.
In cases when n>0.5, drug release data was further treated to Peppas-Sahlin model
shown in Eq. IV.6. Using this model, Fickian (F) and non-Fickian or relaxation (R)
contribution to the overall drug release from the in situ gel-forming formulations can be
quantitatively estimated (Siepmann and Peppas, 2001). The F/R ratios obtained using Eq.
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IV.7 can then be used for better understanding of the influence of various formulation
variables on the overall drug release mechanism from the formulations.

Mt
 K1 t m  K 2 t 2m  F  R
M

Eq. IV.6

R K2 m

t
F K1

Eq. IV.7

Where, k1 and k2 are constants of Fickian and non-Fickian diffusional contribution, m is
purely Fickian diffusional exponent, F is Fickian contribution and R is case-II
relaxational contribution.

IV.B.4.3. Statistical Analyses
Statistical analyses were conducted on the results of the DOE using standard-least
squares regression to determine the factors that had a significant effect on the product
performance estimates especially, drug release and rheology. The polynomial regression
results were demonstrated for the studied responses. The significance level (α) for all
analyses was ≤0.05. All statistical analyses were conducted in JMP (version 8.0.1, SAS
Institute, Inc., Cary, NC).

IV.C. RESULTS AND DISCUSSION
IV.C.1. Solubilization of E2 by Polysorbate 80
Phase solubility curves for E2 and polysorbate 80 at 23°C and 35°C are shown in
Figure IV.1. Since the surfactant concentrations used were above CMC, E 2 solubility
increased linearly (r2>0.99) with increasing surfactant concentration, indicating that the
solubilization was related to micellization. E2 solubilization was higher at 35°C than at
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23°C. Such increase in the solubilizing capacity at higher temperature could be due to a)
an increased thermal agitation that caused an increase in the space available for drug
solubilization in the micelle (i.e., micellar growth), b) asymmetrical shaped micelle
formed at higher temperature caused the volume of inner micelle core to increase relative
to that of outer core, and c) an increase in E 2 intrinsic solubility in water at higher
temperatures (Atwood, Florence, 1983; Rangel-Yagui et al., 2005).
Phase solubility of E2 in the aqueous solutions of polysorbate 80 can be evaluated
using the common descriptors of the micellar solubilization, molar solubilization
capacity, χ, and molar micelle-water partition coefficient, PM. (Alvarez-Nunez et al.,
2000). The χ value is defined as the number of moles of the solute (drug) that can be
solubilized by one mole of micellar surfactant, and it illustrates the ability of the
surfactant to solubilize the drug. It can be calculated based on the general equation for
micellar solubilization (Eq. IV.8 or IV.9).
E2 Phase Solubility Study
6.0

P80-23°C

P80-35°C

5.0

Estradiol Conc (mM)

y35°C = 0.0472x + 0.0227
2

R = 0.9987

4.0
3.0
2.0

y23°C = 0.028x - 0.0719
2

1.0

R = 0.9984

0.0
0

20

40

60

80

100

120

Polysorbate 80 Conc (mM)

Figure IV.1. Aqueous solubility of E2 as a function of polysorbate 80 at 23 and 35°C
115

Solubilization of E2 by polysorbate 80 is given by the following equation:

STotal  So  (CSurfac tan t  CMC)

Eq. IV.8

Rearranging Eq.IV.1 for χ results in Eq. IV.2, shown below.



STotal  So 

Eq. IV.9

CSurfac tan t  CMC

Where STotal is the total concentration of E2 solubilized, So is the solubility of E2 in the
absence of surfactant, CSurfactant is the concentration of surfactant, CMC is the critical
micellar concentration of the surfactant.
On the other hand, the micelle-water partition coefficient is the ratio of drug
concentration in the micelle to the drug concentration in water for a particular surfactant
concentration, as follows:

P

(STotal  So )
So

Eq. IV.10

Combining Eq. IV.9 and IV.10 the two solubility descriptors can be related as shown
below. Where, for a given surfactant concentration:

P

(C surfac tan t  CMC)
So

Eq. IV.11

Further, to eliminate the dependence of P on the surfactant concentration, a molar
micelle-water partition coefficient, PM, can be defined as follows:

PM 

(1  CMC)
So

Eq. IV.12

Since the CMC of polysorbate 80 (0.012 mM) is significantly lower than the range of
surfactant concentrations studied, the solubility relationship in Eq. IV.8 simplifies to:

STotal  So  (CSurfac tan t )

Eq. IV.13
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Using the phase solubility data above, the values of ‗χ‘ and ‗PM‘ were then
calculated from the solubility curves for E 2 and polysorbate 80 (STotal vs. CSurfactant) and
Eq. IV.12 and IV.13. Molar solubilization capacity, χ, is equal to the slope of the linear
regression plot of STotal vs. CSurfactant shown in Figure IV.1. Using this value of χ, and
CMC of surfactant the molar micelle-water partition coefficient (PM) values were
calculated. Table IV.5 lists the estimated values of solubilization descriptors at 23°C and
35°C. The higher value of χ obtained at 35°C further reiterates the fact that increasing the
temperature increased the solubilizing capacity of the surfactant due to micellar growth.
On the contrary, ‗PM‘ values decreased with increase in the temperature. Higher P M value
at lower temperature suggests that the tendency of E2 to partition preferentially with the
polysorbate 80 micelle was higher at 23°C compared to 35°C. Since ‗PM‘ is related to the
water solubility of E2 (So) according to Eq. IV.11 and IV.12, such increase is presumably
due to the increase in the aqueous solubility of E 2 (i.e., 0.008 mM at 23°C and 0.024 mM
at 35°C) relative to its partitioning into micelles.
From thermodynamic point of view, micellar solubilization process can be
considered as a normal partitioning of the drug between micelle and aqueous phases, and
the standard free energy of solubilization (ΔG s°) can be represented by the equation
shown below.
G S   RT ln PM

Eq. IV.14

Where R is the universal gas constant, T is the absolute temperature, and PM is the molar
micelle-water partition coefficient.
0
S

values for E2 solubilization process at different temperatures are listed
0
S

117

was negative, indicating spontaneous

solubilization. The lowest value was observed at 23°C, confirming that E2 solubilization
by polysorbate 80 was energetically more favorable at low temperature.

Table IV.5. Micellar solubilization descriptors for the solubilization of E2 in polysorbate
80 aqueous solutions
Temperature

χ

PM

ΔGs°(KJ/mol*K)

23°C (296°K)

0.028

3500

-20.08

35°C (308°K)

0.047

2000

-19.46

IV.C.2. Anti-microbial Efficacy of New Preservative System
Selection of preservative type and amount remains a critical task especially when
non-ionic surfactant, polysorbate 80, was used as E 2 solubility enhancing agent in the
formulation due to its ability to take up the preservative into micelles and reduce
antimicrobial activity. Potassium sorbate was chosen based on the literature evidence that
it was hardly taken up by the micelles of polysorbate 80 surfactant and also provided
satisfactory preservative effect of ophthalmic solutions (Kawashima et al., 1996).
Addition of EDTA to the formulations containing potassium sorbate had shown to
increase preservative effect (Kawashima et al., 1996; Tsuji et al., 2004; Morishima et al.,
2007). Presumably, EDTA binds to the essential minerals in the microbial cytoskeleton
and disorganizes its assembly, thereby, enhancing the permeability of potassium sorbate
resulting in a synergistic anti-microbial effect.
USP anti-microbial efficacy test results of the E 2 ophthalmic formulations shown
in Table IV.1 are listed in Table IV.6. All the formulations and their appropriate controls
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were found to be sterile indicating that the method of preparation was aseptic. Lack of
efficacy shown by the negative control supports the need for a preservative in the
formulation and highlights the fact that, in the absence of a suitable preservative, the
polysaccharide polymer (i.e. Kelcogel CG-LA) in the formulations supports microbial
growth. In contrast, the efficacy shown by both the positive controls (i.e., with or without
EDTA) suggest the suitability of new preservative system in preventing microbial
proliferation.

Table IV.6. USP 31 <51> anti-microbial efficacy of the E2 ophthalmic formulations
containing new preservative and solubilizing agent
USP Anti-microbial Efficacy
Test Product

Sterility

Gram +ve

Gram -ve

S.aureus

E.coli

P.aeruginosa

Formulation A

Yes

Yes

No

No

Positive Control-A

Yes

Yes

Yes

Yes

Formulation-B

Yes

Yes

Yes

Yes

Positive Control-B

Yes
Yes

Yes

Yes

Yes

Yes

No

No

Negative Control

Although potassium sorbate (0.3%w/v) solution in water (Positive control-A)
demonstrated antimicrobial efficacy, when present at the same concentration in the
formulation, it failed to demonstrate required anti-microbial efficacy, especially against
gram negative bacteria. These results highlight the need for titration of the preservative
depending on the contents of the formulation. Because the amount of potassium sorbate
used was already at the maximum allowed dose for safe use in humans, EDTA
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(0.03%w/v) was added to the formulation to enhance preservative efficacy. Accordingly,
the Formulation-B which contained the mixture of potassium sorbate and EDTA
demonstrated the desired anti-microbial efficacy.

IV.C.3. Pre-optimization: Selection of Optimum Preservative Concentration
pH, Clarity and Osmolality: All the factorial design formulations exhibited acceptable
characteristics of pH, clarity, and osmolality (shown in Table IV.7). With the
preservatives used in the formulation being salts of sodium and potassium, increasing
their amounts may in turn increased the probability of interaction with the anionic gellan
gum polymer and affect the clarity of the formulation. As a result, the clarity of the
formulations decreased with an increase in the polymer as well as EDTA concentrations
(as shown in Table IV.7,). Further, Formulation K0.5_E0.05, containing highest amounts
of polymer (0.5%w/v) and EDTA (0.05%w/v) formed a gel that was too viscous to flow.
Hence, this formulation was discontinued and not tested for any other characteristics. The
pH of the formulations decreased with increasing concentrations of EDTA or polymer in
the formulations (shown in Table IV.7).
The osmolaity of the formulations was found to be with in the acceptable range of
275-325 mOsm/Kg (shown in Table IV.7). These values were noticeably higher than
those listed in Table III.6, due to difference in the type of preservative used in the
formulations. Potassium sorbate and EDTA being the salt forms contribute to the
osmolality of the formulation as opposed to benzalkonium chloride or benzododecinium
bromide.
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Potency of E2: The potency of E2 in the formulations was in the range of 97.3-99.7%
assay (as shown in Table IV.7). The potencies within the acceptable range of 90-110%
indicated that the recovery method and the HPLC assay used were suitable for extraction
and estimation of E2 from the formulation.

Anti-microbial Efficacy:

The anti-microbial efficacy of the factorial design

formulations in Table IV.7 was found to be the function of polymer and preservative
concentrations. At the lowest polymer level (0.1%w/v) studied, the formulations
demonstrated anti-microbial efficacy even at the lowest preservative concentration (i.e.,
0.02%w/v). However, as the polymer level was increased to 0.3% and 0.5% w/v,
Formulation K0.3_E0.02 and Formulation K0.5_E0.02, which contained the lowest
EDTA concentration (0.02%w/v) failed anti-microbial efficacy test. Lack of efficacy
could be due to greater susceptibility to microbial growth at higher gellan gum
concentrations. The observed loss in preservative efficacy stresses the need to adjust the
preservative concentration with the gellan gum polymer in the formulation.

In

accordance with the aim of this study, the preservative system containing 0.3%w/v
potassium sorbate and 0.03%w/v EDTA was identified as an optimum composition that
provides required anti-microbial efficacy to the formulations at all polymer levels.

121

Table IV.7. In vitro characteristics of the factorial design ophthalmic formulations
Clarity

E2 Assay

Osmolality

Anti-microbial

(% trans.)

(%)

(mOsm/Kg)

Efficacy

6.43 ± 0. 02

99 ± 2

98.7 ± 1.2

299 ± 2

Yes

K0.1_E0.03

6.38 ± 0.01

98 ± 1

98.0 ± 1.7

298 ± 5

Yes

K0.1_E0.05

6.19 ± 0.01

98 ± 2

98.3 ± 0.6

289 ± 1

Yes

K0.3_E0.02

6.19 ± 0.01

97 ± 2

97.8 ± 1.9

296 ± 3

No

K0.3_E0.03

6.08 ± 0.01

96 ± 1

98.6 ± 1.3

289 ± 2

Yes

K0.3_E0.05

6.00 ± 0.01

95 ± 1

99.7 ± 2.4

288 ± 8

Yes

K0.5_E0.02

6.05 ± 0.01

94 ± 2

98.1 ± 1.8

284 ± 0

No

K0.5_E0.03

6.02 ± 0.01

92 ± 1
97.3 ± 2.9
298 ± 2
Formulation was too viscous to flow

Formulation

pH

K0.1_E0.02

K0.5_E0.05

Yes

IV.C.4. Formulation Optimization: Effect of Polymer and Drug Concentrations on
Performance Characteristics of E2 Ophthalmic Solution
pH, clarity, and osmolality: All the factorial design formulations exhibited acceptable
characteristics of pH, clarity, and osmolality, as shown in Table IV.8. Both polymer and
E2 concentrations were found to have significant influence on the pH of the formulations
(p<0.05). Increasing the concentration of the anionic polymer (i.e., Kelcogel CG-LA) in
the formulation decreased its pH, whereas increasing the E2 concentration increased the
resultant pH. Polysorbate 80 being a non-ionic E2 solubilizing agent, increasing the drug
concentration did not cause any interactions with the ion-sensitive polymer in the
formulation and affect its clarity. Hence, all formulations in Table IV.8 were found to be
clear with percent UV transmittance (>92%) values well with in the acceptable range.
Similarly, the osmolaity of the formulations was found to be with in the acceptable range
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of 275-325 mOsm/Kg. Kelcogel CG-LA or E2 concentrations had no significant influence
on the resulting osmolality of the formulations.
Potency of E2: The potency of E2 in the formulations was >97% (as shown in Table
IV.8) and well within the acceptable range of 90-110% assay. Such high recovery values
indicate; drug content uniformity in the formulation, and suitability of the recovery
method and the HPLC assay for extraction and estimation of E 2 from the formulations.

Table IV.8. Summary of critical characteristics of E 2 ophthalmic formulations prepared
according to 3×3 full-factorial statistical design
Clarity

E2 Assay

Osmolality

Antimicrobial

(%trans)

(%)

(mOsm/Kg)

Efficacy

6.49 ± 0.03

97 ± 2

99.1 ± 2.1

292 ± 1

Yes

K0.1-Med E2

6.54 ± 0.02

97 ± 1

98.3 ± 1.1

296 ± 2

Yes

K0.1-High E2

6.61± 0.02

98 ± 2

98.6 ± 1.5

300 ± 4

Yes

K0.3-Low E2

6.21 ± 0.01

95 ± 1

97.7 ± 2.4

287 ± 2

Yes

K0.3-Med E2

6.30 ± 0.02

95 ± 1

96.6 ± 1.3

288 ± 3

Yes

K0.3-High E2

6.38 ± 0.01

96 ± 2

97.8 ± 1.9

291 ± 2

Yes

K0.5-Low E2

5.99 ± 0.03

92 ± 2

98.7 ± 3.2

281 ± 5

Yes

K0.5-Med E2

6.03 ± 0.03

92 ± 1

97.9 ± 2.9

285 ± 5

Yes

K0.5-High E2

6.11 ± 0.02

93 ± 2

98.6 ± 1.8

285 ± 2

No

Formulation

pH

K0.1-Low E2

Although, the preservative amounts (i.e., 0.3%w/v potassium sorbate and
0.03%w/v EDTA) in the formulation were pre-optimized for the studied polymer levels
(i.e., 0.1-0.5%w/v), the Formulation K0.5-High E2 , containing 0.5%w/v Kelcogel CG-LA
and 0.025%w/v E2, did not demonstrate USP anti-microbial efficacy. As mentioned
earlier, the required concentration of E2 in the formulation was achieved by addition of
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fixed volume of 1mg/ml stock solution prepared in 16%w/v polysorbate 80. To achieve
0.025%w/v E2 concentration, 25 mL of the stock solution was added to the formulation,
which resulted in 4%w/v polysorbate 80 compared to 1.6%w/v polysorbate 80 with the
mid E2 (0.01%w/v) concentration, in the formulation. Loss in anti-microbial efficacy of
the Formulation K0.5-High E2 could be due to greater potential for microbial growth at
higher polymer and non-ionic surfactant concentrations. But, the Formulation K0.3-High
E2, containing 0.3%w/v polymer and 0.025%w/v E2 dose was antimicrobially effective
and did not show this loss in efficacy due to relatively lower polymer concentration.
IV.C.4.1. Flow Behavior of DOE Formulations
The apparent viscosity of the DOE formulations decreased with increasing
applied shear rate (as shown in Figures IV.2 –IV.4). The high r2 (i.e., >0.96) values in
Table IV.9 further confirms the goodness of fit to the model and shear thinning behavior
of all 9 of the formulations. The power-law model exponent, n, is a flow index whose
magnitude classifies the material into Newtonian or non-Newtonian (i.e., shear thinning
or shear-thickening). The observed values of n<1 (shown in Table IV.9) in case of all the
formulations suggest shear thinning behavior (Balaji et al., 2007). Such shear-thinning
behavior was observed due to the presence of gellan gum polymer network in the
formulation that provided low-resistance to flow upon shear. The consistency coefficient,
K, is the slope of the flow curve and is a measure of the viscosity of the formulation at
shear rate of 1s-1. Kelcogel CG-LA and E2 concentrations in the formulation had
significant influence (p<0.05) on the observed K values (shown in Table IV.9). Change of
5-fold increase in the polymer concentration from 0.1 to 0.5%w/v caused ~ 40-fold
increase in observed K values for each E2 concentration of the formulation. Also, the
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apparent viscosity (μ) values estimated for the formulations at 100s -1 shear rate increased
with increasing polymer as well as E2 concentrations (shown in Table IV.9).

Figure IV.2. Flow curve for 0.1%w/v Kelcogel CG-LA formulations

Figure IV.3. Flow curve for 0.3%w/v Kelcogel CG-LA formulations
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Figure IV.4. Flow curve for 0.5%w/v Kelcogel CG-LA formulations

Table IV.9. Power-law rheology model fitting parameters and apparent viscosity of E2
ophthalmic formulations prepared according to 32 full-factorial statistical design
Formulation

Power law rheology model coefficients

Apparent viscosity

n

K (mPa.S)

r2

(mPa.S) at 100s-1

K0.1-Low E2

0.82

14

0.98

6.1

K0.1-Med E2

0.79

15

0.96

5.7

K0.1-High E2

0.78

20

0.97

7.3

K0.3-Low E2

0.75

45

0.99

14.2

K0.3-Med E2

0.73

55

0.99

15.9

K0.3-High E2

0.63

134

0.99

24.4

K0.5-Low E2

0.49

505

0.99

48.2

K0.5-Med E2

0.46

619

0.99

51.5

K0.5-High E2

0.42

889

0.99

61.5
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To gain better understanding of the influence of polymer and drug levels on the
apparent viscosity of the formulations, the data was treated to a second-order quadratic
model in Eq. IV.1 (page 108). The observed linearity (r2 = 1) in the correlation plots
between the observed and predicted values of μ shown in Figure IV.5 suggest that the
chosen model was a good-fit to the data. The model was found to be significant (p<0.05)
and accounts for 99% (Adj-R2 =0.99) of the error in the observed data. The quantitative
factor effects on the observed μ values are summarized in Table IV.13 (page 146). The
influence of the parameter effects of X1(Kelcogel CG-LA), X2 (E2), X1X2 and X12, on the
apparent viscosities of the formulations was found to be significant (p<0.05). Also, the
positive magnitude of their regression coefficients suggests that increasing their
concentrations increased the apparent viscosities of formulations. Polysorbate 80 being a
highly viscous (~300-500 mPa.s) solution, increasing its amount in the formulation along
with E2 increases formulations viscosity. Hence, the interaction term (X1X2) in Table
IV.13 was found to have significant influence on the apparent viscosity of the
formulations.
Response surface plots with contour lines were further generated for easy visual
interpretation of the influence of model factors on the apparent viscosity of the
formulations in Figure IV.6. Contour lines represent the pair of X1 and X2 values that
have the same response value of Y. The observed curvilinearity of the surface plot (in
Figure IV.6) in the direction of polymer was in accordance with earlier observation that
the quadratic term (X12) of the polymer had significant influence on the apparent
viscosity of the formulations.
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b)

a)

c)

d)

f)

e)

Figure IV.5. Correlation plots between observed and predicted values of a) K, b) t20%, c)
t80%, d) viscosity, e) G‘, and f) phase angle (δ)
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Figure IV.6. Response surface and contour plot showing the influence of polymer and
drug concentration on the apparent viscosity of the formulations.

IV.C.4.2.Viscoelasticity of DOE Formulations
Oscillatory measurements: These measurements were carried out to identify linear
viscoelastic region (LVE) for the characterization of in situ gels. For this study, the
conditions for LVE were identified as 3% strain and 5 rad/s angular frequency. At these
conditions, the DOE formulations in Table IV.3 were pre-mixed with STF in 30:7 v/v
ratios and tested for in situ gel formation using frequency sweep measurements.
Frequency Sweep Plots:

The corresponding frequency sweep plots for different

formulations in the presence of STF are shown in Figures IV.7-IV.9. A gel state, as
defined earlier in Table IV.4 is confirmed when G‘>G‘‘, δ<45° and G‘ shows moderate
to weak dependency on angular frequency according to power-law relation shown in
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Eq.IV.3, where n<0.7. The viscoelastic parameters along with power-law model fitting
parameters for factorial design formulations are summarized in Table IV.10.

10
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Low E2
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G'(Pa)

1

0.1

0.01
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Figure IV.7. Frequency dependency of formulations containing 0.1%w/v Kelcogel CGLA and different E2 levels in the presence of STF in 30:7v/v ratios.
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Figure IV.8. Frequency dependency of formulations containing 0.3%w/v Kelcogel CGLA and different E2 levels in the presence of STF in 30:7v/v ratios.
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Figure IV.9. Frequency dependency of formulations containing 0.5%w/v Kelcogel CGLA and different E2 levels in the presence of STF in 30:7v/v ratios.
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Table IV.10. Power-law rheology model fitting parameters and viscoelastic parameters
of E2 ophthalmic formulations prepared according to 32 full-factorial statistical design
Model fitting parameters and viscoelastic indices
measured in LVE of 5 rad/s and 3% strain

Formulation
G'(Pa)

G''(Pa)

δ (°)

n

r2

K0.1-Low E2

0.12

0.09

37

0.55

0.93

K0.1-Med E2

0.25

0.13

27

0.38

0.97

K0.1-High E2

0.36

0.19

28

0.34

0.91

K0.3-Low E2

0.37

0.28

38

0.34

0.93

K0.3-Med E2

0.55

0.31

29

0.22

0.92

K0.3-High E2

0.96

0.45

25

0.16

0.93

K0.5-Low E2

1.38

0.84

31

0.30

0.99

K0.5-Med E2

1.95

0.92

25

0.26

0.99

K0.5-High E2

2.68

1.18

24

0.18

0.99

All formulations showed evidence of phase transition and in situ gel structure
formation in the presence of STF as G‘>G‘‘ and δ<45° (shown in Table IV.10). The
mechanism of gelation as mentioned previously, involves formation of double helical
junction zones followed by aggregation of double helical segments to form three
dimensional networks by complexation with cations in the tear fluid and hydrogen
bonding with water (Nagarwal et al., 2009; Paulsson et al., 1999; Hagerstrom et al.,
2000). The values of the exponent ―n‖ obtained upon treating the data to the power law
rheology model were in the range of 0.16-0.55. The n value in this range further confirms
the nature of the material formed to be viscoelastic and that it corresponds to a gel state.
Lower the value of n, stronger will be the resulting gel structure. Increasing the polymer
or drug concentration increased the elastic contribution (i.e., higher G‘ and lower δ
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values) to the overall viscoelastic behavior. But, at higher polymer concentrations the
influence of E2 on the G‘ appeared minimal, and the width between the G‘ lines in
Figures IV.7-IV.9 corresponding to different drug loads at each polymer concentration in
the formulations also decreased.

Figure IV.10. Response surface and contour plots showing the influence of polymer and
drug concentrations on (a) elastic modulus, G‘; (b) Phase angle, δ of the formulations.

Second-order Quadratic Modeling: Influence of formulation variables on the observed
viscoelasticity was analyzed by treating the data to second-order quadratic model in
Eq.IV.1 (Page 108). The linearity (r2 = 1) in the correlation plots between the observed
and predicted values of G‘ and δ shown in Figure IV.10 suggest that the chosen model
was a good-fit to the data. The model was found to be significant (p<0.05) and accounts
for 100% (Adj-R2 =0.99) and 94% (Adj-R2 =0.94) of the error in the observed data of G‘
and δ, respectively.
The influence of the parameter effects of X1(Kelcogel CG-LA), X2 (E2), X1X2 and
X12, on the elastic modulus (G‘) of the formulations was found to be significant (p<0.05).
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But, in case of phase angle (δ), only X2 and X22 were found to be significant (P<0.05). In
addition, the positive and negative magnitude of the regression coefficients observed for
parameter effects on G‘ and δ respectively, in Table IV.13 indicated that higher levels of
polymer and drug level in the formulation result in overall improvement of the gel
network formed. Since the quadratic terms for polymer and drug levels were significant
in G‘ and δ, the response surface plot of G‘ and δ in Figure IV.10a and IV.10b, appeared
curvilinear in the direction of polymer and drug concentrations, respectively.

IV.C.4.3. Drug Release Characterization
Drug release from the gel systems has been previously studied using Enhancer
Cell®. In this study, Enhancer Cell® is used to characterize drug release kinetics from E 2
in situ gel-forming ophthalmic solutions. To separate the ophthalmic E 2 solution from the
dissolution medium, a thin (0.22 μm) PET membrane (3M, St.Paul, MN) was used.
Potential for E2 binding to the polymer membrane was evaluated by soaking the
membrane in the E2 stock solutions in ethanol containing different concentrations of E 2
and evaluating any decrease in its concentration due to adsorption to the polymer
membrane. Results indicated that the E2 binding to the PET membrane was negligible.
Simulated tear fluid (STF) containing 30 %v/v ethanol was chosen as the
dissolution medium based on E2 solubility to maintain sink conditions through out the
duration of the study. The paddle rotation speed of 100 rpm was chosen based on
preliminary studies that indicated that the dissolution method was discriminating at
higher paddle speeds (i.e., 100 rpm compared to 50 rpm).
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Drug release characterization from each of the formulations listed in Table IV.3
was performed at least in triplicate. The drug (E2) concentration in the dissolution media
at each time point was measured using a validated fluorescence-HPLC assay method
discussed earlier.
Using the cumulative drug (E2) released vs. time data, release kinetics from the in
situ gels were characterized by treating the data to Korsemeyer-Peppas, and Higuchi
square-root kinetic models shown in Eq. IV.4 and Eq. IV.5 (Page 113). The
corresponding drug release plots up to 60% of the drug release from the factorial design
formulations are shown in Figures IV.11-IV.16. The summary of model fitting
parameters, such as release rate constant (K), and release exponent, n, and drug release
parameter estimates calculated using these parameters, such as time to release 20% (t 20%)
and 80% (t80%) of the drug from the formulation, are listed in Table IV.11.
Table IV.11. Summary of model fitting parameters and drug release estimates obtained
upon treating the E2 drug release data of the formulations prepared according to 3 2 fullfactorial statistical design to Peppas and Higuchi drug release kinetic models.

K0.1-Low E2

K
(%h-n)
23.4 ± 0.9

Korsmeyer and Peppas Model
t80%
n
r2
(hr)
0.54 ± 0.01
0.99
9.6 ± 0.8

t20%
(hr)
0.75 ± 0.05

24.5 ± 0.8

0.99

K0.1-Med E2

28.1 ± 0.7

0.51 ± 0.01

0.99

7.8 ± 0.6

0.51 ± 0.02

28.9 ± 0.5

0.99

K0.1-High E2

31.6 ± 0.6

0.50 ± 0.01

0.99

6.4 ± 0.4

0.40 ± 0.01

33.2 ± 0.9

0.99

K0.3-Low E2

22.2 ± 0.9

0.55 ± 0.01

0.99

10.4 ± 1.2

0.83 ± 0.06

20.8 ± 0.4

0.99

K0.3-Med E2

25.3 ± 0.7

0.52 ± 0.01

0.99

9.0 ± 0.6

0.64 ± 0.03

25.4 ± 0.4

0.99

K0.3-High E2

27.7 ± 0.2

0.51 ± 0.01

0.99

7.9 ± 0.1

0.53 ± 0.01

27.4 ± 0.3

0.99

K0.5-Low E2

20.4 ± 0.9

0.48 ± 0.01

0.99

17.7 ± 2.1

0.96 ± 0.09

20.6 ± 0.5

0.99

K0.5-Med E2

21.8 ± 0.6

0.44 ± 0.02

0.99

19.8 ± 2.8

0.82 ± 0.05

20.3 ± 0.8

0.99

K0.5-High E2

24.8 ± 1.1

0.42 ± 0.01

0.99

16.4 ± 2.3

0.60 ± 0.06

22.2 ± 1.0

0.99

Formulation
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Higuchi Model
K
r2
(%h-0.5)

Figure IV.11. Cumulative percent E2 released vs. time plots of formulations containing
0.1%w/v Kelcogel® CG-LA and different E2 levels

Figure IV.12. Cumulative percent E2 released vs. time plots of formulations containing
0.3%w/v Kelcogel® CG-LA and different E2 levels
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Figure IV.13. Cumulative percent E2 released vs. time plots of formulations containing
0.5%w/v Kelcogel® CG-LA and different E2 levels
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Figure IV.14. Cumulative percent E2 released vs. t0.5 plots of formulations containing
0.1%w/v Kelcogel® CG-LA and different E2 levels
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Figure IV.15. Cumulative percent E2 released vs. t0.5 plots of formulations containing
0.3%w/v Kelcogel® CG-LA and different E2 levels
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Figure IV.16. Cumulative percent E2 released vs. t0.5 plots of formulations containing
0.5%w/v Kelcogel® CG-LA and different E2 levels
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An ideal sustained release ophthalmic delivery system is one which provides a
burst release of drug to achieve required therapeutic concentrations at the site of action
followed by sustained drug release for prolonged durations of time. E2 release from in
situ gels-formed in the presence of STF was sustained (Table IV.11) as the estimated
time for 80% drug release (i.e. t80%) was in the range of 6-19 hr. Burst release of the drug
from in situ gel-forming solutions was also observed with 20% of the drug released (i.e.
t20%) in 0.4-1 hr. Such burst release was expected in the presence of STF due to lag time
in the formation of complete gel structure due to interaction with the ions of the tear
fluid.
Increasing the gellan gum concentration in the formulation decreased the release
rate constants and increased the time taken for 20% and 80% of drug release from the
gels formed in the presence of STF (Table IV.11). The observed decrease in the drug
release rate could be explained by the fact that increasing the gellan gum concentration in
the formulation caused concomitant increase in the gel strength as shown in Table IV.10.
This effect was expected as at higher gel strengths the gel network formed would be
stronger and it would take longer time for the drug molecules to diffuse out of the gel
matrix into the dissolution medium.
In contrast, increasing the drug load increased the release rate constants and
decreased the time taken for 20% and 80% of drug release from the gels. Such a result
can be explained based on the fact that with increasing drug loading, the gel-matrix
formed would become more relaxed to allow easy solvent penetration and enhance drug
diffusion. However, at higher gellan gum concentrations (i.e., 0.5%w/v), the effect of
drug loading on the E2 release was found to be minimal, with only small differences in
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the observed E2 release rate constants in Table IV.11 for different drug loadings (i.e.,
Low, Med and High E2).
The magnitude of the release exponent n obtained upon treating the drug release
data to Kormeyer-Peppas model was in the range of 0.42-0.55. The closeness of these n
values to 0.5, justifies treating the drug release data to Higuchi square-root kinetic model,
which assumes the value of n to be 0.5. The observed linearity (r2>0.99) in the Higuchiplots in Figures IV.14.-IV.16 and closeness of the K values for different formulation in
Table IV.11 further confirms it.
The cut-off value of n, the release exponent in Eq. IV.4, for a purely Fickian
diffusion mechanism in case of gel systems with aspect ratio of 3.6 (i.e., 2a = 21.34mm
and l = 5.96mm), according to Figure IV.17, was 0.45. The n values >0.45 obtained using
Korsmeyer-Peppas model in case of some formulations in Table IV.11 suggest that E 2
release from the gels followed non-Fickian mechanism or anomalous diffusion. The
observed deviation from the Fickian mechanism could be attributed to the reason that the
formulations during gelation imbibe large amount of dissolution media leading to a
swollen state of the gel. In such case, E2 release would be function of its diffusion from
the polymer gel matrix as well as polymer relaxation. Hence, the data was further treated
using Peppas-Sahlin model to estimate the Fickian (F) and relaxation (R) contribution to
the overall drug release.
The summary of model fitting parameters obtained upon treating the E 2 drug
release data to Peppas and Sahlin drug release kinetic model are listed in Table IV.12.
Also, the drug release plots in Figures IV.18-IV.20 display Fickian and relaxational
contribution to the overall E2 release from the factorial design formulations. In Table
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IV.12, the magnitude of the Fickian diffusion constant (k1) decreased with increasing
polymer concentration for each E2 concentration due to concomitant increase in the
strength of the gel network formed. Whereas, the magnitude of relaxation constant (k2)
increased with increasing drug concentration. As reasoned earlier, this could be due to
formation of more void space or pores in the gel network due to dissolution of more
amount of drug at high drug loads. Thus, the greater void space allows for greater solvent
penetration and polymer relaxation. Hence, the ratio of relaxation to diffusion
contribution (k2/k1) values in Table IV.12 increased with increasing drug concentration in
the in situ gel-forming E2 formulations.

Table IV.12. Summary of model fitting parameters obtained upon treating the E 2 drug
release data of the formulations prepared according to 3 2 full-factorial statistical design to
Peppas and Sahlin drug release kinetic model.

Formulation

Peppas and Sahlin Model Parameters
k1(%h-0.45)

k2(%h-0.9)

r2

k2/k1

K0.1-Low E2

21.86

1.57

0.93

0.06

K0.1-Med E2

26.23

1.89

0.92

0.07

K0.1-High E2

27.96

3.59

0.99

0.13

K0.3-Low E2

21.44

0.73

0.94

0.03

K0.3-Med E2

23.42

1.92

0.96

0.08

K0.3-High E2

25.08

2.61

0.90

0.10

K0.5-Low E2

19.61

0.75

0.99

0.04

K0.5-Med E2

---

---

---

---

K0.5-High E2

---

---

---

---
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Figure IV.17. Variation of the Fickian diffusional exponent, m, with the aspect ratio, 2a/l,
where 2a is the diameter and l is the thickness (height) of the device (Peppas et al., 1989)

Figure IV.18. Fickian diffusional and relaxational contribution to the overall E 2 release
from the formulations containing 0.1%w/v Kelcogel® CG-LA and different E2 levels
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Figure IV.19. Fickian diffusional and relaxational contribution to the overall E 2 release
from the formulations containing 0.3%w/v Kelcogel® CG-LA and different E2 levels

Figure IV.20. Fickian diffusional and relaxational contribution to the overall E2 release
from the formulations containing 0.5%w/v Kelcogel® CG-LA
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The results of the drug release kinetics summarized in Tables IV.11 and IV.12
indicated that E2 release from the in situ gel formulations was function of polymer and
drug concentrations. To further understand the influence of these formulation variables,
drug release data was analyzed by treating the data to second-order quadratic model in
Eq.IV.1 (page 108). The linearity (r2 = 1) in the correlation plots between the observed
and predicted values of K, t20% and t80% in Figure IV.5 (page 128) suggests that the
chosen model was a good-fit to the data. The model was found to be significant (p<0.05)
and accounts for >98% of the error in the observed data of different drug release
parameter estimates.
The quantitative factor effects and their associated p-values for drug release
parameter estimates are summarized in Table IV.14. The positive and negative
magnitudes of the regression coefficients observed for polymer and drug factors in Table
IV.14 reflects their positive and negative influence on the drug release parameter
estimates, respectively. Positive coefficient for the polymer indicates that increasing its
concentration increased the t 20% and t80% values. Similarly, negative coefficient for the
drug indicates that increasing its concentration decreased the t 20% and t80% values. The
influence of the parameter effects of X1(Kelcogel CG-LA), X2 (E2), and their quadratic
term X12 or X22, on the drug release parameter estimates, t20% and t80% was found to be
significant (p<0.05). The response surface plots showing the influence of formulation
parameters on the product characteristics are shown in Figure IV.21. Since the quadratic
terms of drug and polymer concentrations in the formulation were significant in case of
t20% and t80%, respectively, their response surface plots in Fig. IV. 21a and IV. 21b
appeared curvilinear in the direction of polymer and drug concentrations, respectively.
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Figure IV.21. Response surface and contour plots showing the influence of polymer and
drug concentrations on (a) time taken for 20% E 2 release, t20%; and (b) time taken for
80% E2 release, t80%, and (c) E2 release rate constant, K, from the formulations.
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Table IV.13. The quantitative factor effects and associated p-values for flow and
viscoelasticity parameter estimates

Factor

Flow Parameter
Estimates
Viscosity at 100s-1
(Y1)
Effect
p-value

G’
(Y2)
Effect
p-value

Phase angle (δ)
(Y3)
Effect
p-value

Intercept

-22.33

0.0003*

-1.03

0.0006*

35.92

0.0004*

X1(polymer)

118.42

<.0001*

4.40

<.0001*

-10.00

0.0982

X2(E2)

320.03

0.0046*

29.98

0.0013*

-472.53

0.0085*

X1X2

1274.66

0.0119*

109.69

0.0045*

153.06

0.7430

X12

297.08

0.0007*

12.42

0.0020*

-50.00

0.2641

X22

11512.35

0.1486

-200.62

0.6204

34876.50

0.0496*

Viscoelastic Parameter Estimates

Table IV.14. The quantitative factor effects and associated p-values for drug release
parameter estimates
Drug Release Parameter Estimates
K
(Y4)
Factor

t20%
(Y5)
Effect
p-value

Effect

p-value

Intercept

26.515802

<.0001*

0.56

X1(polymer)

-13.41667

0.0025*

X2(E2)

263.30247

X1X2
X1

2

X2

2

t80%
(Y6)
Effect

p-value

0.0001*

3.31

0.0525

0.67

0.0007*

24.00

0.0016*

0.0020*

-15.00

0.0004*

-83.18

0.1270

-363.9456

0.0849

-11.05

0.1009

198.98

0.4340

-1.25

0.9254

0.83

0.1314

90.00

0.0177*

-5956.79

0.2040

555.56

0.0194*

-3549.38

0.5756
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IV.D. CONCLUSIONS
Polysorbate-80 was found to be a suitable non-ionic solubility enhancing agent
for improving the aqueous solubility of estradiol (E 2). Pre-optimization studies identified
the need for titration of the preservative concentrations with the gellan gum
concentrations in the formulations. Preservative system composed of potassium sorbate
(0.3%w/v) and EDTA (0.03%w/v) provided USP antimicrobial efficacy to the in situ gel
formulations containing Kelcogel CG-LA in the range of 0.1-0.5%w/v. The preservatives
being the salts of potassium and sodium showed some degree of interaction with the
gellan gum polymer and influenced the clarity of the formulations. Also, it was observed
that increasing the level of potassium sorbate (>0.3%w/v) or disodium EDTA
(>0.03%w/v) in the in situ gel formulations containing ≥0.5%w/v gellan gum polymer
resulted in the gel formation and the preparations were too viscous to flow.
Statistical design of experiments performed to investigate the influence of
formulation variables on the product performance characteristics of the in situ gel E2
formulations indicated polymer and drug concentrations to be significant. The measured
values of the performance characteristics such as pH, clarity, osmolality, E 2 potency, and
viscoelasticity of all the formulations were within the pre-defined acceptable range.
However, in case of formulations containing 0.5%w/v Kelcogel CG-LA, the apparent
viscosities were outside the acceptable range and, at high drug loading of 0.025%w/v, the
anti-microbial efficacy was not observed. Besides, the drug release from the formulations
containing 0.5%w/v Kelcogel CG-LA was slow, sustained and not within the acceptable
criteria. In contrast, formulations containing 0.1-0.3%w/v Kelcogel CG-LA and 0.0010.025%w/v E2 concentrations demonstrated acceptable characteristics of in situ gel –
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forming ophthalmic solutions. Hence, these formulations were further used for in vivo
evaluation of product safety and efficacy in animal models.
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CHAPTER V

ESTABLISHING ESTROGEN ROLE IN CATARACTS: INVESTIGATION OF
IN SITU GEL-FORMING E2 OPHTHALMIC FORMULATIONS IN ERΔ3
TRANSGENIC MOUSE MODEL

V. A. INTRODUCTION
ER3 mice are a transgenic mouse model which expresses a dominant negative
estrogen receptor that results in cataract formation in the presence of high doses of
estradiol (i.e., endogenous levels in intact females and exogenously administered
estrogen in males, ovariectomized females, and immature mice). Kirker and Davis
previously demonstrated that estrogen activation of the ER3 repressor in ER3 mouse
model would inhibit the activity of wild-type ER in lens and results in lens opacity and
induction of genes important to lens transparency only in the presence of estrogen.
However, in these studies high doses (~1000 μg/kg) of estradiol (E 2) was required by
systemic administration to provide sufficient estrogen levels in the avascular lens tissue
to activate ER3 repressor and block estrogen action. Hence, in this study, the benefits of
topical estradiol delivery using in situ gel-forming eye drops over systemic delivery in
terms of ocular safety, enhancing ocular drug absorption with limited systemic
bioavailability, systemic side effects, and onset and severity of cataracts in ERΔ3 mouse
model was investigated. The main goals of this study were to a) verify if topical estrogen
delivery can induce known estrogen responses in lens by examining cataract induction
and lenticular gene expression in the ER3 mice; b) to verify if estrogen responses in the

149

lens are increased at the same estrogen dose via ocular delivery over systemic delivery; c)
to identify topical estrogen doses that provide low to no systemic effects using
uterotrophic assay while providing E2 action in lens; d) to improve estrogen
responsiveness in the lens with in situ gel-forming E2 eye drop formulations containing
higher polymer concentrations.

V. B. EXPERIMENTAL AND METHODS
V.B.1. Animals
All animal procedures were performed in accordance with the Animal Welfare
Act and were approved by the Institutional Animal Care and Use Committee at Duquesne
University. All study mice (FVB/n strain) were produced from breeding colonies
established in our facility. The ERΔ3 mice used in this study were generated on the
FVB/n background strain. All mice were housed in a well-ventilated, controlled
environment; temperatures ranging from 22-25 °C and humidity between 50-75% with a
standard 12hr:12hr light:dark cycle. The breeding colonies were maintained on standard
rodent chow and water was available ad libitum. A semi-purified, isoflavone-free diet
(Harlan Teklad, Indianapolis, IN) was used to generate and maintain all study mice in
order to eliminate the exposure to estrogenic soy isoflavones that are present in standard
rodent chow (Thigpen et al., 1999; Degen et al., 2002). Ear punches were used to
designate animal numbers. All mice were euthanized by carbon dioxide asphyxiation
followed by cervical dislocation to assure death.
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V.B.2. Cataract Induction Study
In this study, male and female mice with ERΔ3 transgene in the FVB/n strain
were used. At day19 after the birth (i.e., prepubescent age), mice were randomly divided
into different groups (n ~ 8 mice/group) containing both males and females. Female
mice in each group were ovariectimized (i.e., ovaries were surgically removed) to
eliminate production of endogenous estrogens at puberty (around 25 days) which would
result in cataracts developing spontaneously (Davis et al., 2002) and confound the
induction study. The procedure for ovariectomy is described below. Mice in each group
were given one of the treatments listed in Table V.1 followed by visual examination
every week for onset and severity of cataracts up to 2 months. All mice were weaned at
the age of 19 days. In the case of ophthalmic treatments, 2 μL of the vehicle or E2 in situ
gel-forming solution was administered in both the eyes once a day for 6 days. In the case
of injection treatments, 0.1 mL of the vehicle (i.e., 95% ethanol in corn oil) or E2
preparation was administered subcutaneously once a day for 6 days. Mice in each
treatment group were visually examined every week for ocular irritation and onset and
severity of cataracts up to 2 months after treatment. At the end of 2 months or 8 weeks,
eyes from each mouse were collected at necropsy and fixed in 4% paraformaldehyde for
6 hr at 4°C and processed for histological analysis. The procedure used for mouse lens
collection and histology was briefly described below.

Treatment Preparation
Ophthalmic in situ gel-forming E2 formulations that were prepared according to
the procedure listed in III.B.3.1 and identified in the previous chapter to provide
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acceptable product performance characteristics were used in this study. Ophthalmic
vehicle formulation containing 0.3%w/v polymer and 4%w/v polysorbate-80 without the
drug was similarly prepared and used. For injection study, a primary stock solution of
17β-estradiol was prepared by dissolving 5 mg/mL of 17β-estradiol (Sigma-Aldrich, St.
Louis, MO) in 95% ethanol. Secondary stock solutions of different E 2 concentrations
were then prepared by making dilutions in corn oil. These concentrations were chosen
based on 0.1mL per 10 g mouse to match the E 2 dose administered by in situ gel-forming
ophthalmic solution treatments. As a vehicle for injection treatments, 95% ethanol was
dissolved in corn oil at the same ratio of ethanol to corn oil as with the appropriate E2
dose.
Table V.1. Treatment groups for cataract induction study in ERΔ3 mouse.

Treatment

Ophthalmic
eye drops

Subcutaneous
injection

E2 Conc.

CG LA (%w/v)

(μg/ml)

0.1

10

2 μL /eye

0.04

4

0.1

100

2 μL /eye

0.4

40

0.1

250

2 μL /eye

100

0.3

10

2 μL /eye

1
0.04

0.3

100

2 μL /eye

0.4

40

0.3

250

2 μL /eye

1

100

0.3

0 (control)
0.4

0
0.04

0

----NA----

2 μL /eye
0.1 mL/mouse

----NA----

4

0.1 mL/mouse

0.4

40

----NA----

40

0.1 mL/mouse

4

400

----NA----

0 (control)

0.1 mL/mouse

0

0
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Volume

Dose

Kelcogel

(μg/
Mouse)

Dose/day
(μg/kg)

4

4

Ovariectomy Surgery
Female mice were placed in an induction chamber under the nose cone of the
isoflurane vaporizer and anesthetized with 3% isoflurane in oxygen by inhalation. The
hair over the mid-back of the mouse was shaved and the skin was treated with betadine
solution. A single incision was made in the skin followed by bilateral incisions in the
abdominal wall to expose ovaries on each side. The fat pad containing the ovary was
pulled through each opening and the ovarian pedicle was isolated and the ovary was
excised. The fat was then pushed back through the opening and the skin incision was
closed with wound clips. Mice were then placed under a heat lamp to warm, given
subcutaneous warmed saline (0.1 mL/10g body weight) to rehydrate and watched for
recovery from anesthesia. After the mice were moving around and trying to stand, they
were administered an analgesic, buprenorphine hydrochloride, at a dose of 0.1 mg/kg (2
μg/20g mouse given as 0.1 mL) to ease pain and returned to cages. After the animals
appeared fully recovered, they were returned to the room where they were housed.
Wound clips were removed within 7-10 days post surgery.

Mouse Lens Collection
At necropsy, each animal was euthanized by CO2 inhalation. Enucleated eyes
were microdissected. To harvest the whole lens, a stab incision using a 27-gauge needle
was made along the cornea. Using fine scissors, the cornea and iris were removed leaving
the posterior cup. The whole lens was scooped out using curved forceps. All tissues
collected were flash-frozen with liquid nitrogen and stored at -80° C.
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Histology
At necropsy, each animal was euthanized by CO 2 inhalation. Eyes were
enucleated and fixed in 4% ice-cold paraformaldehyde fixative prepared no more than 2
weeks in advance and stored at 4°C until use. Eyes were fixed in 4% paraformaldhyde for
6 hr at 4° C, rinsed with 70% ethanol and then immediately processed and embedded.
The fixed eyes from cataract induction studies were processed using the Pathcentre
(Shandon, ThermoFisher Scientific, Waltham, MA) under the following conditions
(Table V.2) and then embedded in paraffin (Tissue Infiltration Medium, Surgipath®,
Richmond, IL) using the Histocentre-2 (Shandon, ThermoFisher Scientific, Waltham,
MA) the following morning. The paraffin-embedded eyes were then shipped to Mass
Histology Service, Inc. (Worcester, MA), where they were cut into 5 μm sections, placed
onto a glass slide and stained with hematoxylin and eosin. The slides and blocks were
then shipped back to the laboratory and the ocular sections were observed for
morphological changes associated with cataracts in the lens of all study animals.
Table V.2. Processing conditions for lens samples (hr)
Reagent
70% Ethanol
80% Ethanol
90% Ethanol
95% Ethanol
100% Ethanol
100% Ethanol
Xylene
Xylene
Xylene
Paraffin
Paraffin
Paraffin

Time (hr)
1:00
0:30
0:30
0:30
0:30
0:30
0:30
1:00
0:30
0:30
0:45
0:45
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V.B.3. Gene Expression Study
To evaluate if the E2 dose and delivery route influenced the upregulation of
estradiol-regulated genes in the ERΔ3 mice (i.e., pax6, six3, six2), gene expression study
was conducted. In this study, pre-pubertal ERΔ3 mice of pre-pubescent age (i.e., age 19
days) were randomly divided into different treatment groups (n = 3-4/gender/group)
according to Table V.3. These groups contained both male and female mouse. In this
study, the female mice were not ovariectimized considering they were of pre-pubescent
age and expected to be euthanized at the end of study which was less than 1 day duration.
Prior to puberty, mice in the ophthalmic treatment groups in Table V.2 received 2 μL of
the topical eye drops containing vehicle or one of the E2 doses of 0.002, 0.02 or 0.2
μg/eye (~ 0.004, 0.04 or 0.4μg/mouse). Similarly, mice in the injection treatment groups
received a single sc injection (0.1 mL) of vehicle, or one of the E2 doses (0.004, 0.04 or
0.4 μg/mouse). At 5.5-6 hr post-treatment, these mice were euthanized by CO2 inhalation
and their eyes were enucleated. Immediately post-enucleation, the lenses were dissected,
flash frozen with liquid nitrogen, and stored at -80° C prior to RNA isolation. RNA
expression in the lens was examined by real-time, reverse transcriptase-polymerase chain
reaction (RT –PCR).
Table V.3. Treatment groups for gene expression study
Treatment
Ophthalmic
eye drops
sc
injection

Kelcogel
CG LA (%w/v)
0.1
0.1
0.1
0.1
----NA-------NA-------NA-------NA----

E2 Conc.
(μg/ml)
1
10
100
0 (vehicle)
0.04
0.4
4
0 (vehicle)
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Volume
2μL/eye
2μL/eye
2μL/eye
2μL/eye
0.1mL/mouse
0.1mL/mouse
0.1mL/mouse
0.1mL/mouse

Dose (μg/
mouse)
0.004
0.04
0.4
0
0.004
0.04
0.4
0

Dose/day
(μg/kg)
0.4
4
40
0
0.4
4
40
0

RNA Isolation from Ocular Tissue
RNA was isolated from the ocular tissues from individual animals (i.e., both
whole lenses) using the Absolutely RNA® Miniprep Kit (Stratagene, La Jolla, CA)
according to the manufacturer‘s protocol. Briefly, 5-20 mg of frozen lens tissue was
homogenized in a ratio of 7μL:1mL β-mercaptoethanol:lysis buffer. Tissue homogenates
were centrifuged for 60 seconds at 13,200 rpm using a microcentrifuge filter spin-cup
provided in the kit. Additional lysis buffer was added to the spin cup and spun again for 2
min at 13200 rpm. The filtrate was combined with equal parts 70% ethanol and
transferred to the RNA spin-cup to bind RNA. Samples were then treated with RNasefree DNase and incubated for 20 min in a 37°C air incubator to remove DNA
contamination that may interfere with amplification.
Following incubation, samples were washed with a high-salt wash buffer (60
seconds at 13,200 rpm) and two subsequent low-salt wash buffer applications (60
seconds at 13,200 rpm; 120 seconds at 13,200 rpm) to prepare them for downstream PCR
applications. RNA spin columns were transferred to

nuclease-free 1.5 mL

microcentrifuge tubes. To elute total RNA, two-50 μL aliquots of 60°C elution buffer
was added to the spin column and centrifuged at 13,200 rpm for 60 seconds. RNA
concentrations were determined spectrophotometrically and RNA integrity was
calculated using the 260:280 nm ratios. High quality-RNA possessing a ratio between 1.8
and 2.1 was used for the subsequent real-time RT-PCR analysis.
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cDNA Reverse Transcriptase (RT) Reaction
First-strand cDNA was synthesized from total RNA using qScript TM cDNA
Synthesis Kit (Quanta Biosciences, In., Gaithersburgh, MD) under the manufacturer‘s
suggested protocol. Briefly, 250 ng of the RNA template was mixed with 4 μL of
qScriptTM reaction mix (5X), 1 μL of qScriptTM RT, and the volume was made up to 20
μL with sterile nuclease-free water in a PCR tube sitting on ice. The reaction mixture in
the tube was gently vortexed and centrifuged for 10 seconds prior to incubation. The
reaction mixture was incubated at 22°C for 5 min, and 42°C for 30 min to synthesize the
cDNA strand followed by 85°C for 5 min to inactivate the reverse transcriptase. In
addition to the RT reaction, a ―No RT‖ reaction consisting of RNA and all other reagents
except the qScript TM RT (substituted with equal volume of sterile nuclease-free water)
was prepared to serve as a control to identify if the RNA sample had DNA
contamination.

Real-Time RT-PCR
Real-time detection of relative RNA levels was performed using the iCycler iQTM
Real-Time PCR detection system (Bio-Rad Laboratories, Hercules, CA) using SYBR®
green detection. cDNA samples, from the RT reactions described above, were used for
real-time PCR analysis. Lens tissue from immature ERΔ3 male and female mice were
analyzed for expression of pax6, six3, and sox2 gene transcripts. Primers were designed
to span at least one intron/exon boundary to ensure the amplification of cDNA versus
potential contaminating genomic DNA. All reaction mixes (25 μL total volume) included
the following: 2x SYBR green master mix, forward primer (200 nM), reverse primer (200
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nM), cDNA template (1/20 dilution of the RT reaction) and nuclease-free water. Primer
sequences are found in Table V.4.
Real-time RT-PCR amplification of the cDNA from immature ERΔ3 mice was
performed to quantify the expression of the above mentioned estrogen-regulated genes in
the lens using B-R SYBR® Green SuperMix for iQTM (Quanta BioSciences,
Gaithersburg, MD) with the following PCR conditions: enzymatic activation at 95°C for
1.5 min followed by 50 cycles of denaturation (95°C for 15 seconds) and
annealing/extension (60°C for 45 seconds).
All samples were run in duplicate and additional wells consisting of ―no RT‖ for
each sample and no template (water in the place of the RT enzyme) for each gene tested
to identify amplification of genomic DNA or other contaminants. In addition to the
experimental genes, a housekeeping gene, ppia (cyclophilin A), was examined as an
internal control for each set of genes in each run. The use of a control gene allows
normalization for data analysis by the ΔΔCt method of relative expression addressed
below. The ppia gene has been validated as an endogenous control gene for RT-PCR in
studies previously performed in cell lines and tissues such as in primary breast tissue
(McNeill RE et al., 2007), mouse liver (Tatsumi et al., 2008), and tissues from brain,
breast, colon, kidney, ovary, pancreas, prostate, skin, and vascular origin (FerozeMerzoug et al., 2002). A melting curve was performed following all real-time RT-PCR
runs to confirm the presence of a single product in each cDNA sample. Additionally, gel
electrophoresis was completed on a subset of the samples to visualize amplification of the
correct product based on base pair size for each gene.
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Table V.4. Oligonucleotide primers and anticipated sizes of amplified cDNA products
using real-time RT-PCR
Mouse
Gene

Accession
No.

ppia

NM_008907

pax6

six3

sox2

Orientation

Nucleotide Sequence

Forward

TAT CTG CAC TGC CAA GAC TG

Amplified
Product Size
(bp)
145

Reverse

ACA GTC GGA AAT GGT GAT CT

Forward

TCT AAT CGA AGG GCC AAA TG

Reverse

AGG AGG AGA CAG GTG TGG TG

Forward

GTT TAA GAA CCG GCG ACA G

Reverse

CTG GAG GTT ACC GAG AGG AT

Forward

ACT AGG GCT GGG AGA AAG AA

Reverse

AGT GCA ATT GGG ATG AAA AA

NM_013627

151

NM_011381

219

NM_011443

281

Relative Gene Expression using the 2-ΔΔCt method
Relative expression was calculated using the 2 -ΔΔCt method with ppia (mouse) as
the housekeeping or normalizing gene. First, the ΔCt value was calculated by subtracting
the threshold value (Ct) for the housekeeping gene from the Ct value for the gene of
interest for each sample. The Ct value is defined as the number of cycles required for the
fluorescent signal to cross the designated threshold value; therefore, the fewer cycles
needed to cross the threshold would indicate higher levels of mRNA for that gene. The
ΔCt value for each individual sample/group/gene of interest was averaged to obtain the
average ΔCt ± standard error of the mean (SEM). Relative gene expression between
treatment groups and the control group was determined by the equation 2 -ΔΔCt; ΔΔCt
values were calculated by subtracting the average ΔCt value for the control group from

159

the average ΔCt value for the treatment group. Values were expressed as a relative fold
change; 2-ΔΔCt. Statistical analyses were performed on the ΔCt values using GraphPad®
Prism Version 5.

V.B.4. Uterotrophic Assay in Mice and Rats
An uterotrophic assay in immature mice was performed to determine if E2
delivery resulted in stimulation of the estrogen-responsive uterus. In this study, the
influence of E2 dose as well as its delivery route was investigated. Female mice of prepubescent age (19 day-old) were weighed and randomly divided into different treatment
groups according to Table V.5. All mice were treated with either control (i.e., vehicle
formulation containing 0.1%w/v polymer and 4%w/v polysorbate 80) or E2 by injection
(sc) or ophthalmic drops, once daily for 3 days. The polymer (Kelcogel® CG-LA)
concentration in these ophthalmic in situ gel-forming E2 eye drops was fixed at 0.1%w/v.
On the 4th day, all mice were weighed and euthanized by carbon dioxide inhalation and
pneumothorax. The uterus was excised, trimmed, and weighed. The uterine stimulation or
change in uterine wet weight in response to systemic E 2 concentration was recorded and
normalized with the body weight.
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Table V.5. Treatment groups for uterotropic assay in mouse species
Treatment

Ophthalmic
eye drops

sc injection

Kelcogel®

E2 Conc.

CG LA (%w/v)

(μg/ml)

0.1

0 (vehicle)

0.1

Volume

Dose (μg)/

Dose/day

mouse

(μg/kg)

2 μL /eye

0

0

1

2 μL /eye

0.004

0.4

0.1

2.5

2 μL /eye

0.01

1

0.1

10

2 μL /eye

4

0.1

25

2 μL /eye

0.04
0.1

10

0.1

100

2 μL /eye

0.4

40

0.1

250

2 μL /eye

1.0

100

---

0 (vehicle)

0.1mL/mouse

0

0

---

0.04

0.1mL/mouse

0.004

0.4

---

0.4

0.1mL/mouse

0.04

4

---

4

0.1mL/mouse

0.4

40

---

40

0.1mL/mouse

4

400

Similarly, uterotropic study was also performed in Sprague-Dawley rats to
understand the influence of E2 dose, E2 delivery route, as well as the concentrations of
Kelcogel® CG-LA in the eye drop on the uterine stimulation due to the bioavailable E2
systemic concentration. Ophthalmic in situ gel-forming formulations containing 0.1%w/v
or 0.3%w/v Kelcogel® CG-LA and injectable solutions containing different
concentrations of E2 along with their appropriate controls were prepared in a similar
manner as discussed in previous sections. Female Sprague-Dawley rats were weighed and
randomly divided into different treatment groups (n=4/group) as shown in Table V.6. All
rats were treated with either control (vehicle) or E 2, by injection (sc) or ophthalmic drops,
once daily for 3 days. On the 4th day, all rats were weighed and euthanized by carbon
dioxide inhalation and cervical pneumothorax. The uterus was excised, trimmed, and
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weighed. The uterine stimulation or change in uterine wet weight in response to systemic
E2 concentration was recorded and normalized with the body weight.

Table V.6. Treatment groups for uterotropic assay in rat species
Kelcogel®

E2 Conc.

CG LA (%w/v)

(μg/ml)

0.1

20

0.1

Dose

Dose/day

(μg)/rat

(μg/kg)

5 μL/eye

0.2

4

50

5 μL/eye

0.5

10

0.1

200

5 μL/eye

2

40

0.3

0

5 μL/eye

0

0

0.3

20

5 μL/eye

0.2

4

0.3

50

5 μL/eye

0.5

10

0.3

200

5 μL/eye

2

40

sc

---

0

0.1 mL/rat

0

0

injection

---

2

0.1 mL/rat

0.2

4

Treatment

Ophthalmic
eye drops
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Volume

V.C. RESULTS AND DISCUSSION
V.C.1. Cataract Induction Study
Previous studies by Kirker and Davis established that spontaneous cataracts
develop in female ERΔ3 mice exposed to endogenous estrogen and high doses (i.e., 1000
μg/kg) of exogenously administered estrogen in males, ovariectomized females, and
immature mice. They demonstrated that age of initial exposure to estrogen was critical
for rapid induction of cataracts and that the lens was most sensitive to the effects of
ERΔ3 repressor in a small window of time prior to or at puberty in ERΔ3 mouse. Hence,
for rapid cataract onset in this study, both male and female ERΔ3 mouse of pre-pubertal
age (i.e., 19 days old) were treated with different doses of estradiol (E 2) once a day for 6
days, starting at day 19 to day 25, as day 25 typically corresponds to the age at which
these mice reach puberty. Since the endogenous estrogen produced post-puberty could
cause spontaneous cataracts and confound the results, the female mice were
ovariectomized prior to treatment. Male mice were left intact as they do not develop
cataracts from endogenous estrogen exposure.
In this study, the effect of E2 route of delivery (ophthalmic vs. systemic), E 2
doses, and gellan gum concentration in the in situ gel-forming E2 eye drops on the
incidence of cataracts in ERΔ3 mice was investigated by gross observations and lens
histopathology. In addition, all ERΔ3 mice were observed for any signs of ocular
irritation (i.e., redness, swelling or watering of eyes) and gross cataracts over time with
the naked eye. The incidence of observed gross cataracts in these mice is listed in Table
V.7. Incidence is considered when at least one of the eyes per animal appears cataractous.
The results indicated that cloudiness, characteristic of the ERΔ3-induced cataract (see
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Figure V.3), were observed only in the eyes of ERΔ3 mice treated with E 2 by ocular as
well as systemic route, but not in the mice treated with vehicle controls by either means
of delivery (see in Table V.7). These results suggest that estrogen was required to
interfere with the estrogen signaling mechanism in ERΔ3 mice and cataract induction
was a result of expression and activation of the ERΔ3 inhibitor. In addition, no signs of
ocular irritation were observed in any of the estradiol-treated or vehicle-treated mice,
indicating the safety of the developed formulations (see in Table V.7). However, further
testing of potential for ocular irritation in rabbits is required as it is the official method for
evaluation of acute ocular irritation of ophthalmic products and also it is the only reliable
model for predicting human responses in the eye.

Table V.7. Gross observation for ocular irritation and cataract incidence in ERΔ3 mice
Treatment

Kelcogel®

E2 dose

CG-LA

(μg/kg)

n

Ocular

Gross Cataracts Incidence (%)

Irritation

4 weeks

6 weeks

8 weeks

0

8

No

0

0

0

4

8

No

37.5 %

37.5 %

62.5%

40

9

No

11.1 %

33.3 %

77.8 %

Ocular

100

8

No

25 %

37.5 %

100 %

eye drops

0

9

No

0

0

0

4

9

No

44.4 %

77.8 %

100 %

40

8

No

87.5 %

100 %

100 %

100

8

No

100 %

100 %

100 %

0

4

No

0

0

0

4

4

No

0%

25 %

50 %

40

8

No

12.5 %

37.5 %

100 %

400

6

No

50 %

66.7 %

100 %

0.1%w/v

0.3%w/v

sc
injection

-----
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The variability chart and bar graph in Figure V.1 and V.2 illustrate the effect of E 2
dose and delivery route on the incidence of cataracts at different time points posttreatment. Cataracts were induced by all 3 E2 doses by ophthalmic (i.e., of 4, 40, and 100
μg/kg) or systemic (i.e., of 4, 40, and 400 μg/kg) delivery. The ophthalmic dose was
determined based on delivery to both eyes, with each eye receiving half the injected E 2
dose. By both means of E2 route of delivery, the number of animals with gross cataracts
and percent gross cataract incidence increased with E 2 doses and duration of time. Higher
cataract incidence with increasing E2 dose is expected because higher doses are required
for ERΔ3 repressor to be activated and dimerize to block estrogen action and to cause
cataracts. Accordingly, the increase in cataract incidence and severity with time suggest
that the cascade of events that lead up to the noticeable morphological changes in lens
pathophysiology (i.e., cataracts) post-activation of ERΔ3 repressor by E2 is a timedependent or kinetic phenomenon. However, when compared at equivalent E 2
dose/mouse (i.e., μg/kg) and same time post-treatment, the percent gross cataract
incidence remained higher in the case of ocular eye drop formulations containing
0.3%w/v gellan gum relative to systemic injection treatments (see Figure V.1 and V.2).
The increase in incidence is most noticeable with all 3 E 2 doses at 4 and 6 weeks posttreatment. Higher estrogen responsiveness observed in the lens with topical delivery at
half of the systemically administered doses demonstrates the efficiency of topical
delivery in supplying sufficient estrogen levels to the lens compared to systemic delivery.
In the later case, higher doses are required to show similar response in the lens as the
drug administered has to bypass blood-retinal barrier and vitreous humor before reaching
the avascular lens tissue.
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Lens opacities were observed by gross examination as early as 4 weeks with the
ocular E2 treatments at all investigated doses and gellan gum concentrations, but with the
systemic sc injection treatments, cataracts were not observed at E2 dose of 4 µg/kg (see
Table V.7). In addition, 100% incidence was observed by 4 weeks with higher E 2 dose
(100 μg/kg) and gellan gum concentration (0.3%w/v) only by the ophthalmic delivery
(see Table V.7). At 40 μg/kg E2 dose, cataracts were evident in both eyes by 6 wks posttreatment in all 8 animals with the eye drop formulation containing 0.3 %w/v gellan gum,
with 6 of the mice having strong cataracts (as shown in Figure V.3). However, none of
the mice treated with this E2 dose using either eye drops containing 0.1 %w/v gellan gum
polymer or systemic sc injection had strong cataracts, but 3 of 8 had opacities in both
eyes by 6 wks post-treatment. These data demonstrate that ophthalmic delivery of E 2 with
in situ gel-forming eye drops containing 0.3 %w/v gellan gum polymer concentration
results in an earlier cataract onset vs. eye drops containing 0.1 %w/v gellan gum polymer
concentration or systemic treatment. The better efficacy with ophthalmic in situ gelforming eye drops containing higher polymer concentration (i.e., 0.3%w/v Kelcogel®
CG-LA) is likely due to its better gelling (shown in Table IV.10) and sustained drug
release behavior (shown in Table IV.11).
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Figure V.1: Schematic showing variability in percent cataract incidence by gross
examination in ERΔ3 mice across different treatments and time intervals. The
incidence at each time point in weeks, post-treatment of the 6 daily treatments by either
delivery route, is shown for each estradiol dose, polymer concentration, and delivery
route. (O) ophthalmic delivery and (Inj) for subcutaneous injection delivery. Two
polymer concentrations were tested, 0.1% (0.1) and 0.3% (0.3) at 3 estradiol doses, 4, 40,
40, and 400
ocular delivery route.
A few mice in some treatment groups did not show develop grossly detectable
cataracts by maximum time of 2 months post-treatment (see in Figure V.1). In the case of
ophthalmic treatments (shown in Table V.7), 100% gross cataract incidence was
observed with formulations containing 0.3% w/v polymer at all E 2 doses; whereas using
0.1% w/v polymer formulations, the incidence increased with E 2 dose: 62.5% (4 μg/kg),
77.8% (40 μg/kg), and 100% (100 μg/kg). Similarly, the incidence of cataracts in ERΔ3
mice 2 months post-treatment increased with E2 dose in injection treatments: 50% (4
μg/kg), 100% (40 μg/kg), and 100% (400 μg/kg) by gross observation (shown in Table
V.7). These data as well as data obtained at earlier time points comparing the ocular
formulation containing 0.1% w/v gellan gum and systemic delivery especially for the
highest E2 dose, suggest that the eye drops formulation containing 0.1% w/v gellan gum
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polymer may have a similar or lesser efficacy to the systemic injection. Estrogen dose
dependency in the incidence of cataracts was also reported by Davis and colleagues in
their previous studies using ERΔ3 mouse model (Davis et al., 2000). Such dose
dependency underscores the need for sufficient levels of estrogen in the eye tissues to
activate the ERΔ3 repressor and cause morphological changes in the lens
pathophysiology leading to its opacification and cataract formation. However, the lack of
detectable gross cataracts in some mice may be due to decrease in severity of the cataract
(i.e., cataract has not progressed to be visible by the unaided eye); therefore, the lack of
gross cataracts does not rule out the possibility of immature cortical cataracts. To confirm
the presence or lack of cataracts, eyes from all the mice were also examined by
histopathology at the end of 2 months. Representative microscopic images of lens
histological sections obtained from ERΔ3 mice subjected to the different treatments are
shown in Figures V.4 –V.7. Histopathology on lenses from E 2-treated ERΔ3 mice at 2
months of age, confirmed gross observations with the presence of cortical vacuoles in the
lenses of all mice treated with E2. In contrast, no abnormalities were observed in the
lenses of ERΔ3 mice treated with either the ophthalmic or injection vehicles up to 2
months after the 6 days of treatment (Figure V.4).
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Figure V.2: Percent cataract incidence by gross examination in ERΔ3 mice across
different treatments and time intervals. The incidence at each time point in weeks,
post-treatment of the 6 daily treatments by either delivery route, is shown for each
estradiol dose, polymer concentration, and delivery route. (O) ophthalmic delivery and
(I) for subcutaneous injection delivery. Two polymer concentrations were tested, 0.1%
into both eyes). Injected estradiol doses were 4
injected dose for the highest dose compared to the ocular delivery route.

Vehicle drop
E2 drop
Figure V.3: Grossly detectable cataracts in ER3 mice after ophthalmic E2
administration. Daily treatments were given for 6 days in immature males and females
(ovariectomized prior to puberty to prevent the endogenous estrogen‘s ability to induce
cataracts). Photograph in the right panel shows an example of a strong cataract with E 2
drops compared to the vehicle drops (left panel) > 6 weeks after treatment.
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The severity of the histologically-detected cataracts (i.e., qualitative estimate of
the number or area of the lens covered by the cortical vacuoles or globules) was greater
with increasing E2 doses (Figures V.5 - V.7). In accordance with gross observations, the
ERΔ3 mice treated with ophthalmic formulations containing 0.3%w/v Kelcogel® CG-LA
showed stronger and more severe cataracts compared to formulations containing 0.1%
w/v polymer as well as injection treatments due to reasons previously discussed
(representative lens histopathology images are shown in Figures V.5 - V.7). Thus, these
results demonstrate that a) ophthalmic delivery resulted in earlier onset of cataracts in
ERΔ3 mouse compared to systemic delivery, presumably due to the availability of
sufficient levels of E2 in the eye tissues and lens to activate the ERΔ3 repressor and b)
ophthalmic formulations containing 0.3%w/v Kelcogel® CG-LA and higher E2 doses
accelerated the onset of gross cataracts and resulted in more severe cataracts compared to
0.1%w/v Kelcogel® CG-LA, indicating higher ocular bioavailability to induce the dosedependent ERΔ3 cataracts due to the demonstrated stronger gel structure and sustained
drug release behavior (discussed in Section(s) IV.C.4.2 and IV.C.4.3) in the eye.
Considering the significant influence the Kelcogel® CG-LA concentration in the
formulation has on the strength of the in situ gel structure obtained in the presence of tear
fluid (as shown in Table IV.10) and, the efficacy in inducing rapid and severe known
estrogen responses in the eye (as shown in Table V.7), patients suffering from dry eyes
would need to be considered. This is because with the insufficient tear fluid, the in situ
gel-forming solution eye drop formulation medium could provide an environment that
would supplement the insufficient tear fluid. Since the apparent viscosity of the
developed in situ gel-forming solution (as shown in Table IV.9) are higher than that of
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water (as shown in Table IV.9), it could still be effective in prolonging drug‘s contact
time and providing higher ocular drug absorption compared to conventional ophthalmic
solutions. Since use of tear substitutes is a common practice in patients with dry eyes,
pre-administration of the tear substitutes before the use of the developed in situ gelforming eye drops may maintain the treatment efficacy. Future formulation consideration
could include a blend of polymers that would alleviate the dry eye condition while still
providing in situ gel formation for delivery of estrogen.

Retina

Iris
Cornea

Lens

Figure V.4: Representative lens histological sections of ERΔ3 mice treated with
vehicle controls. Tissue sections are from mice treated with A) Injection control B) In
situ gel-forming eye drops control, shown at 40X (left panels) and 400X (right panels)
magnification. The box in the right panel represents the clear areas of the cortical region
of the lens. All histological sections were stained using hematoxylin and eosin stain
(H&E) in formalin-fixed eyes.
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Figure V.5: Representative lens histological sections of ERΔ3 mice treated with
estradiol (E2) sc injections. Tissue sections are from mice treated with sc injection of A)
4 μg/kg E2 dose B) 40 μg/kg E2 dose, and C) 400 μg/kg E2 dose shown at 40X (left
panels) and 400X (right panels) magnification. The box in the right panel represents the
cortical region of the lens where ERΔ3-induced cortical vacuoles are observed.. As E 2
dose increases cataracts progress and greater area of lens is involved.
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Figure V.6: Representative lens histological sections of ERΔ3 mice treated with
estradiol (E2) in situ gel-forming eye drops containing 0.1 %w/v Kelcogel® CG-LA.
Tissue sections are from mice treated with eye drops of A) 4 μg/kg E 2 dose B) 40 μg/kg
E2 dose, and C) 100 μg/kg E2 dose, shown at 40X (left panels) and 400X (right panels)
magnification. The box in the right panel represents the cortical region of the lens where
ERΔ3-induced cortical vacuoles are observed and as E 2 dose increases cataracts progress
and greater area of lens are involved.
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Figure V.7: Representative lens histological sections of ERΔ3 mice treated with
estradiol (E2) in situ gel-forming eye drops containing 0.3 %w/v Kelcogel® CG-LA.
Tissue sections are from mice treated with eye drops of A) 4 μg/kg E 2 dose B) 40 μg/kg
E2 dose, and C) 100 μg/kg E2 dose, shown at 40X (left panels) and 400X (right panels)
magnification. The box in the right panel represents the cortical region of the lens where
ERΔ3-induced cortical vacuoles are observed. Notice increase in vacuoles and the area of
lens affected at higher E2 doses indicating more severe cataracts.
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V.C.2. Gene Expression Study
Davis and colleagues, in their previous studies, implemented cDNA microarray
analysis to identify the gene expression changes with potential to be related to lens
pathology observed in the ERΔ3 transgenic mouse model. They reported that pax6, sox2
and six6 among other genes were differentially expressed in the lens of immature (i.e., 21
day-old) ERΔ3 female mice at 6 hr post-treatment treatment with 1000 μg/kg E2 sc
injection (results not shown). Gene analysis in the lens was performed at 6 hr posttreatment based on an estimate of time it may take for the systemically administered drug
to cross blood-retinal barrier and vitreous humor before reaching the avascular lens tissue
to elicit its effects. Gene analysis provides a rapid and short-term approach to examine
early changes or effects of estrogen treatments in the lens as a result of likely estrogen
actions via lenticular ER receptors. Hence, in the current study, differential expression of
the above mentioned genes in the ERΔ3 mouse lens was examined as a valuable tool to
compare the effect of different estrogen treatments (i.e., ophthalmic vs. systemic) and
relate it to their ability to induce rapid estrogen-dependent responses in the lens.
Accordingly, immature ERΔ3 mice were treated with the vehicles or different doses of E 2
by ophthalmic or systemic routes and the lenses harvested at 6-hrs post-treatment. The
ophthalmic dose was determined based on delivery to both eyes, with each eye receiving
half the injected E2 dose. The gene expression in the lens was measured by real-time RTPCR analysis. In the case of ophthalmic treatments, in situ gel-forming eye drops
containing only 0.1%w/v Kelcogel® CG-LA are used to verify if 6 hr post-treatment
represents a suitable time course for differential expression of genes involved in ERΔ3induced cataracts in the mouse lens. Based on the results obtained, future studies can then
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investigate the effect of different polymer concentrations in the topical in situ gel-forming
eye drops on the estrogen-induced gene expression in the ERΔ3 mouse lens.

Table V.8. Relative expression levels of candidate genes in premature ERΔ3 lenses
Mouse

Ophthalmic Treatments (n=4/gene/treatment)
0.4 μg/kg

4 μg/kg

40 μg/kg

(Mean ± SEM)

(Mean ± SEM)

(Mean ± SEM)

pax6

0.90 ± 0.07

1.14 ± 0.14

*2.32 ± 0.18

sox2

1.00 ± 0.20

1.33 ± 0.35

2.80 ± 0.92

six3

1.10 ± 0.18

1.20 ± 0.41

1.64 ± 0.50

Gene

Mouse

Injection Treatments (n=4/gene/treatment)
0.4 μg/kg

4 μg/kg

40 μg/kg

(Mean ± SEM)

(Mean ± SEM)

(Mean ± SEM)

pax6

1.15 ± 0.05

1.38 ± 0.10

1.29 ± 0.10

sox2

1.40 ± 0.38

1.23 ± 0.36

1.50 ± 0.52

six3

1.27 ± 0.31

1.10 ± 0.18

1.29 ± 0.35

Gene

*p<0.05
The relative expression levels (i.e., ΔCt) of these candidate genes in the lens of
ERΔ3 mice obtained in response to different treatments are summarized in Table V.8.
The relative expression levels of pax6 gene, shown in Table V.8 and Figure V.8, indicate
that at 6 hr post-treatment, only mice treated with higher E 2 dose of 40 μg/kg ophthalmic
eye drops showed significant upregulation of pax6 in the lens compared to control and
equivalent dose of sc injection treatments (p<0.05). The ophthalmic dose was determined
based on delivery to both eyes, with each eye receiving half the total body dose and
equivalent to half the injected E2 dose. Since the systemically delivered E 2 gets
distributed to other tissues in the body and only small amounts may cross the blood-
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retinal barrier and reach the avascular lens tissue to induce estrogen responses, lack of
significant upregulation at sc injection dose of 40 μg/kg is expected. Therefore, this data
concur with previous studies by Kirker and Davis demonstrating that significant
upregulation of pax6 gene in the ERΔ3 mouse lens by sc delivery requires high E2 doses
(~ 1000 μg/kg). These results reinforce our earlier suppositions that a) E2 delivered
locally to the eye (i.e. ophthalmic delivery) can act directly on the lens by binding to
specific estrogen receptors localized in the cells of the lens and/or retina and regulate the
expression of genes involved in its growth and maintenance and b) high E2 doses are
required for ERΔ3 repressor to activate and dimerize to block estrogen action and cause
differential expression of lenticular genes likely involved in cataracts. Based on the pax6
gene expression results obtained with eye drops containing 0.1%w/v Kelcogel® CG-LA
(Table V.8), and cataract onset data (shown in Table V.1) for both it can be expected
that, future investigations of E2-regulated gene expression in ERΔ3 mice using in situ
gel-forming eye drops containing 0.3%w/v Kelcogel® CG-LA will result in significant
upregulation of pax6 gene at much lower E2 doses (i.e., < 40 μg/kg), due to stronger gelstructure (as shown in Table IV.10), sustained drug release (as shown in Table IV.11) and
better drug disposition in the ocular tissues.
In the case of sox2 and six3 genes, no significant difference in their expression
levels relative to vehicle controls was observed in the ERΔ3 mouse lenses treated with
either ocular or systemic E2 treatments (shown in Figure V.9 and V.10). Lack of
significant upregulation of these genes could be because the 6 hr time point may not be
the time of peak gene responses for the ophthalmically vs. systemically delivered E 2. This
time point was chosen based on the previous studies in the laboratory by Davis, where
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significant upregulation of all three genes was observed when mice were administered
with very high systemic E2 dose of 1000 μg/kg. Since the E2 doses used in this study was
25 to 250-fold lower, significant upregulation of all the genes may require a higher dose
for either delivery method and/or different times for gene analysis post-treatment for
comparing ocular vs. systemic delivery.
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Figure V.8: Expression of estrogen-responsive pax6 gene in ERΔ3 mouse lens.
Expression of pax6 was evaluated in RNA prepared from mouse lenses 6 hr after sc
injection (I) and ophthalmic (O) eye drops containing 0.1%w/v Kelcogel® CG-LA
treatments using real-time RT-PCR
T values reflect higher expression
levels. The relative expression was calculated by the 2 method. Expression of pax6
was increased 2.3 fold over the vehicle control (refer to Table V.8). * indicates
significance compared to all the other groups (1-way ANOVA, p=0.0003; it was
significantly different than sc E2 treatments and both control groups by Tukey‘s test,
n=4).
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Figure V.9: Expression of estrogen-responsive sox2 gene in ERΔ3 mouse lens.
Expression of sox2 was evaluated in RNA prepared from mouse lenses 6 hr after
ophthalmic (O) and injection (I) treatments using real-time RTT
values reflect higher expression levels. Data was graphed as mean ± SEM (n=4). There
was no significant difference in sox2 expression as a result of E2 treatment. (GraphPad®
Prism, 1-way ANOVA, Tukey‘s test, p=0.3759).
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Figure V.10: Expression of estrogen-responsive six3 gene in ERΔ3 mouse lens.
Expression of six3 was evaluated in RNA prepared from mouse lenses 6 hr after
ophthalmic (O) and injection (I) treatments using real-time RTT
values reflect higher expression levels. Data was graphed as mean ± SEM (n=4). There
was no significant difference in six3 expression as a result of E2 treatment. (GraphPad®
Prism, 1-way ANOVA, Tukey‘s test, p=0.9123).
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V.C.3. Uterotropic Assay in Mice and Rats
Unopposed systemic estrogen is associated with an increased risk of endometrial
cancer in women (Naunton et al., 2006; Johnson et al., 2005). Hence, estradiol
formulations intended for chronic use should reduce the amount of drug systemically
available to minimize estrogen-induced side effects on estrogen-responsive tissues (i.e.,
endometrium). The rodent uterotrophic assay has been traditionally used to establish the
estrogenic activity of sex steroids and suspected environmental estrogens because of the
sensitivity of uterus to the exposed estrogen (Evans et al., 1941; Reel et al., 1996; Markey
et al., 2001). As exposure to estrogen results in uterine stimulation, change in wet uterine
weight is measured as a marker of systemic E 2 exposure. Since in situ gel-forming
estradiol eye drops are specifically designed to maximize ocular drug absorption and
minimize system bioavailability low to no uterine stimulation is expected with the topical
eye drops. Hence, in this study, rodent uterotrophic assay was performed to verify if low
amounts of estrogen are systemically absorbed from the developed topical eye drops
compared to systemic treatments and to identify an estrogen dose that doesn‘t result in
any uterine stimulation, but provides E2 action in the lens.
After 3 daily treatments with E2 by injection (sc) or ophthalmic drops, in
immature ERΔ3 female mice, uterine wet weight (normalized to body weight) was
measured on day 4. Uterotropic response (i.e., change in uterine wet weight) obtained
with different estrogen (E2) doses by ophthalmic or systemic routes of delivery was
compared and summarized as dose-response curve (shown in Figure V.11). The
sigmoidal shape of the dose-response curve obtained with systemic as well as ophthalmic
treatments indicate that, at smaller E2 doses (i.e., <0.4 μg/kg), the uterine stimulation was
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minimal and comparable with the control treatments; and, with increases in the E2 dose,
the stimulation increased linearly and reached a maximum or plateau at E 2 doses of ≥ 40
μg/kg. At all the tested E2 doses, higher uterine response or greater change in uterus wet
weight was observed in mice treated with systemic estrogen treatments compared to
ophthalmic treatments and vehicle controls. In the case of ophthalmic E 2 treatments using
in situ gel-forming eye drops, only the two higher E 2 doses (4 and 40 μg/kg) significantly
increased the wet uterine weight compared to vehicle-treated mice (p<0.05) (see Figure
V.12). However, with the 4 μg/kg ophthalmic E 2 dose, the level of stimulation was
significantly reduced compared to the equivalent dose delivered by systemic route (see
Figure V.13). In addition, the 0.4 μg/kg E2 ophthalmic dose did not cause any uterine
stimulation, unlike the same dose administered by sc injection. Since the uterine response
to E2 treatment was measured as a marker of the amount of E 2 available in the systemic
circulation upon treatment, no (i.e. with ≤0.4 μg/kg E 2 dose) to low (i.e. with 4 μg/kg E2
dose) uterine stimulation observed with ophthalmic treatments suggest that they result in
little to no systemic estrogen-related side effects compared to systemic estrogen
treatments. Mice are highly sensitive to low levels of E 2 due to the lack of peripheral
aromatization; therefore, the systemic E 2
topical dose of in situ gel-forming eye drops may not result in a similar effect in women.
However, in the mice, 0.4 μg/kg E2 dose did not cause uterine stimulation and it may be
an effective dose in humans for cataract prevention.
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Figure V.11: Dose-response curve showing the effect of E2 on uterine stimulation in
immature ERΔ3 female mice. After 3 daily treatments with different E 2 doses by
injection (sc) or ophthalmic drops containing 0.1% w/v gellan gum polymer, in immature
ERΔ3 female mice, uterine wet weight (normalized to body weight) was measured on
day 4. Vehicle (I) used for sc injection contained corn oil; where as vehicle (O) for
ocular drops was similar in contents to the E 2 eye drops except the drug.
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Figure V.12: Uterine stimulation of estrogen ophthalmic and systemic treatments in
immature ERΔ3 female mice. All three doses of E2 administered by sc injection (I)
resulted in significant uterine stimulation; whereas, only the two higher doses delivered
to the eye significantly increased uterine weight compared to vehicle-treated mice.
Vehicle (I) used for sc injection contained corn oil; where as vehicle (O) for ocular drops
was similar in contents to the E2 eye drops except the drug. No uterine stimulation is
evident with 0.4 g/kg E2 dose by ocular eye drops (GraphPad ® Prism, 1-way ANOVA,
p<0.0001, * indicates significance vs. vehicle by Tukey‘s test).
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Figure V.13: Comparing the effect of systemic and ophthalmic estrogen treatments
on the uterine stimulation in immature ERΔ3 female mice. Vehicle (I) used for sc
injection contained corn oil; where as vehicle (O) for ocular drops was similar in contents
to the E2 eye drops except the drug. Significantly lower uterine weights are evident only
at the 4 μg/kg E2 dose with ophthalmic eye drops vs. sc injection (GraphPad® Prism, 1way ANOVA p<0.0001, * indicates significance vs. sc treatments by Tukey‘s test).
In addition to the effects of E 2 dose and delivery method in mice, influence of
Kelcogel® CG-LA concentrations in the in situ gel-forming eye drops on the uterine
stimulation as a measure of the amount of drug systemically absorbed was evaluated in
immature female Sprague-Dawley rats. Rats were used instead of mouse primarily due to
their availability and also to understand species-related differences on systemic drug
absorption upon ocular drug delivery. The normalized uterine weight data obtained with
different E2 doses ( 4, 10, and 40 μg/kg) and eye drop formulations (i.e., containing either
0.1% w/v or 0.3% w/v gellan gum polymer) indicate that unlike in the mice where both 4
and 40 μg/kg E2 dose resulted in significant stimulation compared to vehicle treatments
(see Figure V.12), only rats treated with 40 μg/kg E2 dose of 0.3%w/v Kecogel® CG-LA
formulations resulted in significant uterine stimulation compared to vehicle treatments
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(p<0.05) (Figure V.14). Also, the uterine stimulation in rats treated with 4 and 10 μg/kg
E2 using eye drops containing higher polymer concentration (i.e., 0.3% w/v gellan gum)
was not significant (p>0.05) compared to the uterine stimulation obtained with eye drops
containing 0.1 %w/v gellan gum, except at 40 μg/kg E 2 dose. In addition, the magnitude
of the normalized uterus weight/ body weight in response to same E 2 topical ocular
concentrations are lower in case of rats compared to the mice (see Figures V.12 and
V.14). These results indicate that rats are less sensitive to similar systemic estrogen
concentrations compared to mice or the systemic E 2 bioavailability from the topical eye
drops differs between the species.
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Figure V.14: Comparing the effect of ocular estrogen treatments on the uterine
stimulation in immature female Sprague-Dawley rats. (0.1) and (0.3) represents eye
drops containing 0.1% w/v and 0.3% w/v gellan gum concentrations. Vehicle (O) for
ocular drops was similar in contents to the E 2 eye drops except the drug. Significantly
higher uterine weights are observed only at the 40 μg/kg E2 dose with ophthalmic eye
drops containing 0.3% w/v gellan gum polymer. (GraphPad® Prism, 1-way ANOVA
p<0.0001, * indicates significance vs. vehicle treatments by Tukey‘s test).

184

In addition to the effects of E2 dose, influence of E2 route of delivery was
evaluated for 4 μg/kg E2 dose in immature female Sprague-Dawley rats using ophthalmic
eye drops containing either 0.1% w/v or 0.3%w/v gellan gum or sc injection. Only a
single E2 dose was investigated due to the limited availability of animals. Since the E2
dose of 4 μg/kg was the only dose in previous studies in mice uterotrophic assay that
resulted in significant uterine stimulation between ocular and systemic estrogen
treatments (Figure V.13), the same dose was tested and compared again as the most likely
dose to be able to identify differences between the polymer concentrations and systemic
delivery in the rats. The normalized uterine wet weights obtained with ocular as well as
injection treatments at 4 μg/kg

E 2 dose indicated that only the injection treatment

resulted in higher and significant uterine stimulation compared to vehicle treatments
(p<0.05). Unlike in the mice where the ocular treatment at the 4 μg/kg E2 dose resulted in
significant uterine stimulation compared to vehicle-treatment (p<0.05) (see Figure V.12),
the uterine stimulation in the rats at 4 μg/kg E 2 dose with eye drops containing different
gellan gum concentrations was not statistically significant compared to vehicle treatment
(p>0.05) (Figure V.15). This result indicate that rats are less sensitive to similar estrogen
concentrations and the amount of drug systemically absorbed upon ocular delivery is
lower and results in lower systemic estrogen-related side effects (i.e., uterine stimulation)
compared to systemic E2 delivery.
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Figure V.15. Uterine stimulation by E2 ophthalmic and systemic treatments in
immature female Sprague-Dawley rats. An uterotropic assay in immature Sprague
Dawley rats compared the ocular treatments containing 0.1% and 0.3% polymer
concentrations with the sc injection treatment for the same E 2 dose (4 g/kg). As a
vehicle treatment, the animals were given an ocular eye drop not containing drug as well
as an injection of corn oil. Neither formulation containing E 2 resulted in significant
stimulation of the uterus compared to the vehicle, unlike the 4 g/kg E2 sc injection
(GraphPad® Prism, 1-way ANOVA, p<0.03, * indicates significance vs. vehicle
treatments by Tukey‘s test).
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V.D. CONCLUSIONS
Cloudiness or lens opacities, characteristic of the ERΔ3-induced cataracts were
observed by gross examination only in the eyes of ERΔ3 mice treated with E2 by ocular
as well as systemic route, but not in the mice treated with vehicle controls by either
means of delivery (Table V.7). These results suggest that estrogen was required to
interfere with the estrogen signaling mechanism in ERΔ3 mice and cataract induction
was a result of expression and activation of the ERΔ3 inhibitor as previously reported.
Cataracts are observed in ERΔ3 mice in all treatments groups (i.e., at E 2 doses of 4, 40,
and 100 μg/kg). But, the severity and percent gross cataract incidence varied depending
on the particular estrogen treatment dose and delivery route, as sufficient estrogen levels
were required in the lens to activate and dimerize ERΔ3 repressor and block estrogen
action to cause cataracts. The percent gross cataract incidence was found to be higher in
the case of ophthalmic treatments compared to systemic treatments; especially strong
cataracts were observed at all tested E 2 doses with in situ gel-forming eye drops
containing 0.3%w/v Kelcogel® CG-LA polymer (Table V.7 and Figure V.3). Also, no
signs of ocular irritation were noticed by gross observations in any of the estradiol-treated
or vehicle-treated mice, indicating the safety of the developed formulations (Table V.7).
However, further testing of potential for ocular irritation in rabbits is required as it is
more reliable model for predicting human responses in the eye.
Histopathology on the lenses from ERΔ3 mice at 2 months post-treatment
confirmed gross incidence of cataracts in different treatment groups and cortical vacuoles
characteristic of ERΔ3-induced cataracts, were present only in the estrogen-treated mice.
The lens, however, remained transparent without any abnormalities in the case of vehicle-
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treated ERΔ3 control mice up to the maximum time of 2 months post-treatment (Figure
V.4). Histological analysis also confirmed that the severity of the cataracts (i.e., estimated
qualitatively based on the area of the lens that appeared cataractous) was highest in mice
treated with ophthalmic in situ gel-forming eye drops containing 0.3%w/v Kelcogel® CGLA compared to eye drops containing 0.1%w/v Kelcogel® CG-LA due to stronger gel
structure and sustained drug release in the eye (Figure V.7).
Gene analysis provided a rapid and short-term approach to examine early changes
in the lens as a result of likely estrogen actions via lenticular ER receptors. At 6 hr posttreatment, only ERΔ3 mice treated with higher E2 dose of 40 μg/kg ophthalmic eye drops
(i.e., each eye received half the total body dose and equivalent to half the injected E2
dose) showed statistically significant upregulation of the pax6 gene relative to the vehicle
controls or equivalent dose of sc injection (Figure V.8). The short-term gene expression
studies demonstrated that a) E2 delivered by ophthalmic route using in situ gel-forming
eye drops was able to permeate the cornea and induce a known, rapid estrogen response
in the lens at much lower doses compared to systemic doses (1000 μg/kg ) as previously
reported (unpublished data), and b) higher ocular E2 doses (i.e., 40 μg/kg) were required
in the short-term studies to provide sufficient estrogen levels in the lens to rapidly
activate ERΔ3 repressor and cause early changes in the expression of a lenticular gene.
Therefore, in the future long-term gene expression studies (i.e., upon multiple
administration of eye drops for several days), significant upregulation of estrogenregulated lenticular genes and known estrogen actions in the lens may likely be induced
at much lower E2 ocular doses (i.e., 0.4 or 4 μg/kg) using in situ gel-forming eye drops
containing 0.3%w/v Kelcogel® CG-LA.
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Uterotrophic assay in mice indicated that uterine stimulation in immature ERΔ3
female mice is a function of systemic exposure to estrogen. The sigmoidal shape of the E 2
dose-uterine response curve (Figure V.11) suggested existence of a minimum through
maximum dose range for the uterine stimulation as reported in the literature (Evans et al.,
1941; Reel et al., 1996; Markey et al., 2001). At all the investigated E 2 doses (0.4, 4, and
40 μg/kg), uterine stimulation was lower with ocular treatments compared to systemic
treatments (Figure V.11). These results indicated that the amount of drug that could
potentially be absorbed into systemic circulation and cause systemic estrogen related side
effects was minimal with in situ gel-forming eye drops. Significant lower wet uterine
weights were observed in mice treated with 4 μg/kg ophthalmic dose compared to
equivalent systemic (sc) injection dose (Figure V.13). Whereas, in the case of the mice
treated with 0.4 μg/kg E2 dose, in situ gel-forming eye drops did not increase the uterine
weight, unlike the same dose administered by sc injection (Figure V.12). Hence, this dose
may be used as an effective dose in humans for cataract prevention and to prevent
systemic estrogen-induced side effects on non-ocular estrogen-responsive tissues.
Uterotrophic assay in immature female Sprague-Dawley rats indicated that, unlike
in the mice, where ocular treatment at 4 μg/kg E 2 dose resulted in significant uterine
stimulation, the uterine stimulation in the rats at the same dose using in situ gel-forming
eye drops containing different gellan gum concentrations was not statistically significant
compared to vehicle treatments, unlike systemic delivery (Figure V.15). These results
suggest that rats are less sensitive to similar systemic estrogen concentrations compared
to mice or the systemic E2 bioavailability from the topical eye drops differs between the
species.
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In summary, these findings indicate that the developed in situ gel-forming E2 eye
drops are effective in inducing known estrogen responses in the eyes of ERΔ3 mice and
can be used in future testing for cataract prevention in preclinical models (such as MNUinduced cataracts model in rats) and clinical trials. At the lowest E2 dose of 0.4 μg/kg in
ERΔ3 mice, the ophthalmic eye drops containing 0.3%w/v polymer did not stimulate the
uterus; but, were not tested for cataract induction. Therefore, additional testing is needed
to determine if sufficient estrogen levels can be delivered to the eye to influence a known
estrogen response in the lens without evidence of systemic bioavailability and identify
ocular E2 therapeutic concentrations for cataract prevention. However, as the ophthalmic
E2 dose of 4 μg/kg did not stimulate uterus in rats and induced cataracts in ERΔ3 mice,
this dose may not result in systemic bioavailability in humans while still protecting the
lens. These data suggest that estrogen in situ gel-forming eye drops could be given to
women and men without the adverse side effects similar to what would be observed in
systemic delivery, such as feminization of males or stimulation of non-ocular estrogen
target tissues in women.
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CHAPTER VI

IN VIVO EVALUATION OF OCULAR SAFETY AND PHARMACOKINETICS
OF OPTIMIZED IN SITU GEL-FORMING E2 OPHTHALMIC FORMULATION
IN RABBITS

VI. A. INTRODUCTION
Pharmaceutical preparations intended for ocular administration should be safe
and non-irritating to the eye upon multiple administrations. Hence assessment of the
potential for ocular irritation and toxicity of ophthalmic solutions represents an extremely
important step in the development of a commercially acceptable ophthalmic drug
product. Modified Draize eye irritation test in rabbits was widely used for this purpose as
it is the official method for the evaluation of acute ocular irritancy (Draize, 1944 and
1955; York and Steiling, 1998; Bruner et al., 1991 and 1992). Also, it is the only reliable
model that captures the full complexity of the eye and the ocular response of its intricate
biochemical and physiological processes. The primary goal of this study is to establish
ocular safety of the developed product so that it can be used in future testing in humans.
Since most of the excipients in the formulation are GRAS (generally regarded as safe)
listed and previously used in approved commercial ophthalmic products, we expected the
optimized formulation to be safe and non-irritating to the eye.
Upon ocular administration, drug in the formulation simultaneously remains in
contact with three absorptive membranes; the cornea, the conjunctiva and the nasal
mucosa to cause ocular as well as systemic drug absorption. Corneal pathway via the

191

aqueous humor is the major route for ocular absorption; whereas, drug uptake via
nasolacrimal drainage and conjunctival sclera route contributes to systemic absorption,
which, when solution eye drops are used, can be up to 70-100% of the instilled dose
(Zignani et al., 1995). Adverse systemic side effects induced by ocular administration are
often observed and several cases of such side effects are reported in the literature
(McMahon et al., 1979; Kumar et al., 1986; Chang et al., 1987; Urtti et al., 1984). As E 2
is a potent hormone with wide range of systemic effects on various organs and tissues of
the body (e.g., breast and endometrium), measurement of ocular and systemic estrogen
concentrations is critical.
In this chapter, the ocular irritation potential of the optimized in situ gel-forming
E2 formulation (Formulation K0.3-High E2 in Section IV.C.4) was evaluated in rabbits.
The primary goal is to establish ocular safety of the developed product so that it can be
used in future testing in humans. Since most of the excipients in the formulation are
GRAS listed and previously used in approved commercial ophthalmic products, the
formulation is expected to be safe and non-irritating to the eye. Further, estradiol (E2)
pharmacokinetics upon ocular and systemic estrogen delivery in rabbits was studied and
the absolute bioavailability of E2 from the optimized in situ gel formulation was
estimated. The pharmacokinetic studies (PK) that reveals maximal ocular and minimal
systemic drug absorption will underscore the utility of in situ gel-forming E2 delivery
system.
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VI. B. EXPERIMENTAL AND METHODS
VI. B.1. Animals
All procedures were designed to minimize animal suffering in accordance with
the Animal Welfare Act. All experiments were carried out under veterinary supervision
and were approved by the Institutional Animal Care and Use Committee (IACUC) at
Duquesne University. Specific pathogen-free (SPF), 6 weeks-old, New Zealand white
male rabbits were purchased from Myrtle‘s Laboratory Inc. (Thompsons Station, TN) for
this study. Each rabbit was tattooed with a serial number on their ear for easy
identification. The rabbits were housed in individual cages with free access to food
(Purina ProLab Diet) and water in a well ventilated controlled environment; with
temperatures ranging from 22-25°C; with humidity between 50-75%; and with a standard
12hr:12hr light:dark cycle. All rabbits were acclimatized to laboratory conditions for 3-5
days prior to the beginning of experiments.

VI. B.2. Ocular Irritation in Rabbits: Modified Draize Test
Six male, pathogen-free New Zealand white rabbits, each weighing 1.0–2.0 kg,
were used in this study. The animals were evaluated prior to treatment to ensure their
eyes were normal. After screening, the rabbits were randomly assigned one eye as the test
eye and the contra-lateral eye as the matched control (i.e., untreated). Therefore, six eyes
were used for treatment and the other six eyes as control. Fixed volume (30 μl) of the
optimized in situ gel-forming E2 eye drops (Formulation K0.3-High E2 in Section IV.C.4)
was instilled into the lower cul-de-sac of the treatment eye of each animal via a
micropipette twice a day for 3 days; whereas, the control eye was left untreated. This
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optimized formulation will be used henceforth and will be referred as the optimized in
situ gel-forming eye drops. Immediately after administration, the upper and lower eyelids
of the treated eye were gently held closed for 10 seconds to maximize drug cornea
contact.
Pre-and post treatment, observation of ocular tissue (i.e., cornea, iris, and
conjunctiva) was performed at 0.25, 1, 2, 3, 6, and 7 days after the initial treatment for
signs of irritation such as redness, swelling, or discharge. Any observed ocular irritation
was graded according to the modified Draize scale of weighted scores (shown in Table
VI.1). The total ocular irritation scores for each rabbit were calculated by adding the
weighted sum of irritation scores for the cornea, iris, and conjunctiva. The maximum
mean total score (MMTS) of eye irritation was obtained by dividing the maximum total
score obtained for any rabbit at any time point by the total number of rabbits used in the
study (i.e., n=6). The test formulations were then classified for their ocular irritation
potential based on the eye irritation score (i.e., MMTS), according to Table VI.2.
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Table VI.1. Draize scale for scoring ocular irritation/toxicity/lesions in rabbits using the
optimized in situ gel-forming eye drops
Score

I. Cornea
A. Opacity-degree of density
No Opacity
Scattered or diffuse area, details of iris clearly visible
Easily discernible translucent areas, details of iris slightly obscured
Opalescent areas, no details of iris visible, size of pupil barely discernible
Opaque, iris invisible
B. Area of cornea involved
One quarter (or less) but not zero
Greater than one quarter, but less than half
Greater than half, but less than three quarters
Greater than three quarters, up to whole area
A×B×5
Total Maximum = 80
II. A. Iris
Normal
Folds above normal, congestion, swelling, iris still reacting to light
No reaction to light, hemorrhage, gross destruction
A×5
Total Maximum = 10
III. Conjunctivae
A. Redness
Vessels normal
Vessels definitely injected above normal
More diffuse, deeper crimson red, individual vessels not easily discernible
Diffuse beefy red
B. Chemosis
No swelling
Any swelling above normal
Obvious swelling with partial eversion of lids
Swelling with lids about half-closed
Swelling with lids about half-closed to completely closed
C. Discharge
No discharge
Any amount different from normal (does not include small amounts observed in
inner canthus of normal animals)
Discharge with moistening of the lids and hairs just adjacent to lids
Discharge with moistening of the lids and hairs, and considerable area around
the eye
(A+B+C) ×2
Total Maximum = 20
Total Maximum Score: 110
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0
1
2
3
4
1
2
3
4
Score
0
1
2
Score
0
1
2
3
4
0
1
2
3
4
0
1
2
3

Table VI.2. Classification of formulations based on irritation score
MMTS

Classification

Symbol

0.0 – 0.5

Non-irritating

N

0.6 – 2.5

Practically non-irritating

PN

2.6 – 15.0

Minimally irritating

M1

15.1 – 25.0

Mildly irritating

M2

25.1 – 50.0

Moderately irritating

M3

50.1 – 80.0

Severely irritating

S

80.1 – 100.0

Extremely irritating

E

100.1- 110.0

Maximally irritating

Mx

VI.B.3. Estimation of Ocular and Systemic E2 Bioavailability from the Optimized In
situ Gel-forming Eye Drops
VI.B.3.1. Pharmacokinetics of Intravenous Estradiol in Rabbits
Six male, pathogen-free New Zealand white rabbits were used in this study. E 2
stock solution of 20 μg/mL concentration was prepared in polysorbate 80 (0.32 %w/v)
and sterilized by filtering through 0.22 μm sterile filter (FiltrareTM). Each rabbit was preweighed and administered an E2 dose of 7.5 μg/kg by an IV bolus injection of sterile
stock solution in a fixed volume through marginal ear-vein using a 25-gauge needle and
sterile disposable syringe. Each rabbit was pre-treated with topical lidocaine 15-30 min
prior to sampling or injection to reduce pain. Also, each rabbit was restrained
individually using a towel to provide warmth and comfort during injection or blood
collection.
Blood samples were withdrawn from each rabbit at time zero (i.e., before E 2
injection) and at fixed time points of 0.25, 0.5, 1, 2, 3, 4 hr post-administration via one or
more of the blood sampling sites (i.e., central artery of the ear, the marginal ear vein, the
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jugular vein, the cephalic vein, lateral saphenous vein). 1-2 mL of the blood was
immediately transferred to microcentrifuge tubes containing serum-gel clotting activator
(Sarstedt Inc., Newton, NC) and placed on ice. The centrifuge tubes were then stored in
the refrigerator for 24 hr to allow clotting and clot retraction for serum collection. At the
end of this period, these tubes were centrifuged at 13,000 rpm for 5 min to separate serum
and stored at -20ºC until the time of measurement. E 2 concentration in the serum samples
were determined by radioimmunoassay (RIA) using Coat-A-Count® Estradiol kit
(Siemens Healthcare Diagnostics Inc., Deerfield, IL) according to the manufacturer‘s
recommended procedure (described below). RIA was used in this study as it provides
simple and rapid approach for estimation of E 2 in the biological fluids as opposed to other
existing spectroscopic techniques such as GC/MS (Dickinson et al., 1997; Setnikar et al.,
1997) and LC-ESI-MS (Msagati and Nindi, 2006; Shivprakash et al., 2006) which
requires complex sample processing and expensive instrument.
Using serum RIA data, E2 concentration-time profiles were generated and PK
parameters such as maximum serum E2 concentration (Cmax), area under the
concentration–time curves (AUC) from zero to the last time point (AUC0-t), the time to
reach Cmax (Tmax), the time taken for serum E2 to be reduced by 50% (t 1/2), and the
fraction of E2 eliminated per unit time or elimination constant (Ke) were calculated by
non-compartmental model-independent analysis using WinNonlin Professional® (version
5.2) software (Phasrsight Corporation, Mountain View, CA).
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RADIOIMMUNOASSAY (RIA)
Coat-A-Count® Estradiol kit (Siemens Healthcare Diagnostics, USA) is a noextraction solid-phase

125

I radioimmunoassay kit used for the quantitative estimation of

estradiol in serum. In this procedure, fixed volume of 125I-labeled estradiol solution was
added to rabbit serum or aqueous humor sample in a polypropylene tube coated with
rabbit antibodies to estradiol. The mixture was then allowed to incubate for 3 hrs at room
temperature, during which known amount of

125

I-labeled estradiol competes with

unknown quantity of estradiol in the sample for antibody sites on the antibody-coated
tubes. After incubation, the tubes were decanted to separate bound from free estradiol.
The tubes were then counted for radioactivity in a gamma counter, the counts being
inversely related to the amount of estradiol present in the test sample. The amount of
estradiol in the sample was determined by comparing the counts to a calibration curve.
The RIA kit had a sensitivity of 8 pg/mL and a range of 20 to 3600 pg/mL. The intra-and
inter-assay coefficients of variance were between 4-8%. The recovery of the added
standards was between 93-101%.
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VI.B.3.2. Pharmacokinetics of E2 in Aqueous Humor and Serum upon Topical
Delivery of In situ Gel-Forming Eye Drops
A total of 18 male, pathogen-free, New Zealand white rabbits, including the six
rabbits previously tested in the ocular irritation and E 2 pharmacokinetic study, were used
in this study. Prior to this experiment, these rabbits were given 7-10 days of washout
period to eliminate the previously administered exogenous estrogen. All the rabbits were
weighed and divided into 6 different groups, each containing 3 rabbits, in order that the
average body weight of each group was similar. In this study, each rabbit in 5 of the 6
groups was administered a 30 μL of the optimized in situ gel-forming E2 eye drops
(Formulation K0.3-High E2 in Section IV.C.4) into the lower cul-de-sac of both the eyes
(~ 7.5 μg/kg) using a micropipette. Although E 2 dose/body weight of the rabbit was
similar to IV treatment, each eye of the rabbit received only half of the total body dose.
Immediately after administration, the upper and lower eyelids of the treated eyes were
gently held closed for 10 seconds to maximize drug cornea contact. Rabbits in the
untreated group served as a control for baseline E2 levels.
Post-instillation, at fixed time point‘s of 0, 0.25, 1, 2, and 4 hr, three rabbits per
group were anesthetized by intramuscular injection of ketamine (44 mg/kg) and
acepromazine (1 mg/kg), 10-15 minutes prior to euthanasia. The rabbits were euthanized
by intra-cardiac puncture using sodium pentobarbital (100 mg/kg). Post euthanasia, 3-5
mL of the blood was withdrawn by intra-cardiac puncture using 20-G needle, and
transferred to microcentrifuge tubes containing serum-gel clotting activator (Sarstedt Inc.,
Newton, NC) and frozen on dry-ice. After blood collection, 150-200 µL of the aqueous
humor was withdrawn from both the eyes by inserting a 25-G needle attached to a
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tuberculin syringe through the corneoscleral junction and slightly upward into the
anterior chamber, and the pooled sample was transferred to plain microcentrifuge tubes,
frozen on dry ice and stored at -80ºC until the time of measurement. At the end of the
experiment, the centrifuge tubes containing blood samples were stored in the refrigerator
for 24 hr to allow serum formation. At the end of this period, these tubes were
centrifuged to separate serum, and stored at -20ºC until analyzed. E2 concentration in the
serum as well as aqueous humor at different time points was determined by
radioimmunoassay (RIA) using Coat-A-Count® Estradiol kit (Siemens Healthcare
Diagnostics Inc., Deerfield, IL) according to the procedure described earlier.
Based on the RIA assay data, E2 absorption from the eye drops at different time
points was calculated and concentration-time profiles in aqueous humor as well as serum
were generated. Relevant PK parameters (i.e., Cmax, Tmax, AUC, Ke, and t1/2) were then
calculated from the group mean concentrations by standard noncompartmental method of
analysis (NCA) with extravascular input using WinNonlin Professional® (version 5.2)
software

(Phasrsight

Corporation,

Mountain

View,

CA).

Absolute

systemic

bioavailability of E2 from the optimized in situ gel-forming eye drops was calculated
according to Eq. VI.1 below, using the administered E 2 dose and serum AUC0-t obtained
upon ocular and systemic E2 delivery.

Absolute Bioavailability (F) =

AUCocular
Doseiv

 100
AUCiv
Doseocular
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Equation VI.1

VI.C. RESULTS AND DISCUSSION
VI. C.1. Ocular Irritation Study in Rabbits: Modified Draize Test
Rabbits in this study were treated with 30 μL of the optimized in situ gel-forming
eye drops; this volume was found to be the maximum fluid that the rabbit eye could hold
without overflowing in the preliminary trials using the formulation control. Additionally,
this volume falls within the practical range of volumes that can be administered by a
typical eye dropper in humans (i.e., 30-50 μL) (Lang et al., 2002). During the 7 days of
the study, rabbits did not show any clinically relevant signs of irritation in their treated
eyes relative to the control or untreated eyes (Table VI.3). Representative pictures of the
treated eye and untreated eye in one rabbit at different times post-treatment are shown in
Figure VI.1. No visible ocular damage or clinically abnormal signs were observed in the
cornea or iris (i.e., scores of 0) of the rabbits. These results are in complete agreement
with previous studies (Mazuel and Rozier et al., 1989) that gellan gum containing
solution eye drops are well tolerated.
Table VI.3. Draize ocular irritation score of the optimized formulation in rabbits
Ocular Tissue

Irritation Score

I. Cornea
A. Opacity-degree of density
B. Area of cornea involved
A×B×5
II. A. Iris

0
0
0
0

A×5
III. Conjunctivae

0

A. Redness
B. Chemosis
C. Discharge
(A+B+C) ×2
Total Maximum Score: I+II+III

0
0
2
4
4
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However, at some time points, white conjunctival discharge with moistening of
the lids and hairs just adjacent to lids was observed in few of the rabbits and resulted in a
maximum irritation score of 4 out of 110 according to Draize scale (Table VI.3). Since,
the total number of rabbits used in this study was 6; the maximum mean total score
(MMTS) obtained was 0.7. According to Draize classification in Table VI.2, this score
corresponds to the formulation that is practically non-irritating to the eyes. Such excellent
ocular tolerance was expected as the excipients used in the optimized in situ gel-forming
formulation are GRAS (generally regarded as safe) listed and has been previously used in
FDA approved drug products. Lack of ocular irritation upon repeated administrations in
the rabbits also indicates that E2 concentration in the formulation did not have any
harmful effects on the ocular tissues and is safe to be delivered by the ophthalmic route.
Since rabbits are used as the predictors for human response (Lang et al., 2002), it can be
expected that the optimized in situ gel-forming E2 solution eye drops will be safe and
non-irritating to the patients in future clinical testing.
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Figure VI.1. Lack of ocular irritation upon administration of the optimized in situ
gel-forming E2 eye drops in a male New Zealand white rabbit. Panels in A, B, C, and
D illustrate representative ocular irritation in control eye (left panel) and treatment eye
(right panel) at fixed time points of 0.25, 1, 3, and 7days, respectively, from one of the
six rabbits tested. Treated eyes were given 30 μL of Formulation K0.3-High E2 and
control eyes were untreated.
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VI.C.2. Pharmacokinetics of Intravenous Estradiol in Rabbits
Investigation of E2 pharmacokinetics upon intravenous bolus injection in rabbits
was performed as only limited reports of E 2 pharmacokinetics in rabbits exist in the
literature. Moreover, the PK data obtained would serve as a reference that would allow
for accurate estimation of absolute bioavailability of E 2 upon ocular delivery.
Serum E2 concentrations after single bolus dosing (7.5 μg/kg) in rabbits was
measured at different time points using radioimmunoassay (shown in Table VI.4). RIA
was used as it is simple and more sensitive for estimation of low systemic concentrations
of estradiol. The bolus treatment resulted in a rapid spike in serum estradiol levels within
15 min after administration with mean peak serum E 2 concentration (Cmax) of 1136 ± 201
pg/mL (Figure VI.2 and Table VI.5). But, within 2 hr the detectable serum levels drop to
levels approaching the 0 time point and return to baseline levels by 4 hr (Figure VI.2).
The bolus treatment resulted in the total drug exposure (i.e., mean area under the serum
concentration time curve (AUC0-t)) of 1014 hr.pg/ml. The serum E 2 elimination rate
constant (Ke) and elimination half-life (t1/2) upon bolus treatment was estimated to be
1.63/hr and 26 min, respectively (shown in Table VI.5). These data indicate E 2 is rapidly
eliminated in serum due to extensive hepatic metabolism and has a short half-life, as has
been previously reported (i.e., 15-30 min) (Tremblay et al., 1977; Dickinson et al., 1997;
White et al., 1998; Bawarshi-Nassar et al., 1988; Hussain, et al., 1988). Since E 2 was
administered intravenously, its bioavailability (i.e., fraction of administered dose of
unchanged drug that reaches the systemic circulation) is 100%. Hence, in this study, the
AUC obtained reflects the measure of total systemic drug exposure upon treating with 7.5
μg/kg of E2. This AUC and dose information will be used according to Eq. VI.1 to
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measure the absolute bioavailability of E2 from the optimized topical in situ gel-forming
eye drops in the next section.

Table VI.4. Serum E2 concentration-time data after single IV bolus injection of 7.5 μg/kg
E2 in rabbits
Time

Mean Serum E2

(hr)

Conc. (pg/ml)

0

29.3

7.02

0.25

1136.3

201.80

0.5

445.8

25.02

1

127.5

11.55

2

56.3

5.92

3

33.4

8.93

4

30.6

13.00

SEM

Figure VI.2. Serum E2 concentration-time profile after single IV bolus injection of
7.5 μg/kg E2 in rabbits. The levels of E2 in the serum rapidly drop to base line levels
within 2 hr after injection. Serum concentration is shown as mean ± SEM (n=6).
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Table VI.5. Serum pharmacokinetic parameters of E2 after single IV bolus injection of
7.5 μg/kg E2 in rabbits
PK parameter

Value

Cmax

1136 pg/mL

tmax

0.25 hr

Ke

1.63/hr

AUC0-t

1014 (hr.pg/mL)

t1/2

26 min

VI.C.3. Pharmacokinetics of E2 in Aqueous Humor and Serum upon Topical
Delivery of In Situ Gel-Forming Eye Drops
For the drug delivered by ophthalmic route to reach the lens, it must permeate the
cornea and acquire detectable levels in the aqueous humor (AH). Hence, the purpose of
this study was to determine if E2 from the topical in situ gel-forming eye drops permeates
the cornea, if higher levels reach the aqueous humor compared to systemic circulation, if
drug levels in AH remains higher for longer periods due to the in situ gel not being
washed out of the eye, and to compare the systemic drug absorption with IV treatment at
equivalent dose/rabbit and estimate absolute drug bioavailability.
In this study, rabbits were administered 30

L of the optimized in situ gel-

forming eye drops in both eyes with the total body dose (7.5 μg/kg) equivalent to the IV
dose given to each rabbit in earlier study (VI.B.3.1). Serum and aqueous humor E 2
concentrations achieved from topical eye drops in rabbits were measured at different time
points using radioimmunoassay (results shown in Table VI.6). E 2 concentration-time
profiles in AH and serum (shown in Figure VI.3 and VI.4) indicate that topical
ophthalmic delivery result in a rapid spike in estradiol levels in AH and serum within 15
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min after administration causing maximum E 2 concentrations (Cmax) of 188.2 ± 63.3
ng/mL, and 176.8 ± 83.6 pg/mL, in aqueous humor and serum, respectively. The peak E 2
concentration (Cmax) in serum at 15 min was 1000-fold lower than the AH (note the
difference in concentration units). Such a rapid spike in aqueous humor E2 levels (i.e.,
188.2 ng/mL) compared to base levels (i.e., 0.006 ng/ml or 6 pg/ml) initially was likely
due to the lag-time for gel-formation during which large amounts of drug probably leaked
out in the eye and got rapidly absorbed into the aqueous humor owing to its high corneal
permeability (logP-3.5). Faster ocular drug absorption immediately upon administration
is highly beneficial in topical therapies to cause rapid onset of therapeutic effect and
relieve patients of immediate disease symptoms. Within 30 min of topical administration,
E2 concentration decreased rapidly to 6.3 ± 2 ng/mL (~30-fold decrease from Cmax) in AH
compared to 89.8 ± 3 pg/ml in serum (~2-fold decrease from Cmax) (shown in Figure VI.3
and VI.4). Such rapid decrease in E 2 concentrations in AH was likely due to; a) drainage
of the instilled drug solution from the conjunctival sac and nasolacrimal duct, b) the
turnover of AH and the rapid distribution of E2 into the posterior tissue of the eye, and/or
c) the gel that was formed sustained the drug (E 2) release and subsequent absorption into
the AH. But, within 2 hr the detectable serum E 2 levels drop to levels approaching the 0
time point and returns to baseline levels by 4 hr (see in Figure VI.4) causing the total
systemic drug exposure (i.e., mean area under the serum concentration time curve (AUC 0t))

of 219.5 hr.pg/mL. In contrast, E2 levels drop more slowly in the aqueous humor and

are still ~30-fold higher (i.e., 200 pg/mL) compared to its low baseline levels (i.e., 6
pg/mL) at the end of 4 hr (see in Figure VI.3) resulting in the total ocular drug exposure
(i.e., area under the serum concentration time curve (AUC0-t)) of 53.1 hr.ng/mL. High E2
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levels in AH at the end of 4 hr suggest that E 2 contact time in the eye was prolonged and
the drug release from the in situ gel was sustained. Based on the obtained data, the E 2
elimination rate constant (Ke) and elimination half-life (t1/2) was estimated to be 1.0/hr
and 42 min in AH and 0.8/hr and 51 min, respectively (shown in Table VI.7). Faster E 2
elimination in AH was likely due to rapid distribution into the posterior tissues of the eye.
The large difference (~250-fold) in the total drug exposure in AH (i.e., AUC0-t of 53.1
hr.ng/mL) and serum (AUC0-t of 219.5 hr.pg/mL) upon topical ophthalmic E2 delivery
indicates 1) that the drug was able to permeate cornea and was preferentially absorbed
into the eye and 2) only low drug levels are systemically absorbed compared to the high
levels that are present in the aqueous humor.
Due to the effective delivery of high E2 doses to the aqueous humor (Cmax of
188.2 ng/mL vs. 0.006 ng/ml base levels) of the male rabbits using the optimized in situ
gel-forming eye drops, future studies should investigate lower doses and identify
minimum effective therapeutic E2 aqueous humor concentrations. These levels would not
result in detectable serum levels and still be effective in inducing estrogen-regulated
responses and in protecting lens transparency.

Table VI.6. Serum and aqueous humor E2 concentration-time data after topical
administration of 30 μL of the optimized in situ gel-forming eye drops in rabbits
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Serum

Time

Mean E2

(hr)

Aqueous Humor
SEM

(pg/ml)

Mean E2

SEM

(ng/ml)

0

29.3

7.02

0.006

0.001

0.25

176.8

83.6

188.23

63.3

0.5

89.8

2.99

6.32

2.1

1

81.2

6.76

3.76

2.9

2

34.9

5.51

0.44

0.07

4

28.4

4.49

0.20

0.05

Aq. Humor E 2 Concentration (ng/ml)

100

10

1

0.1

0.01

0.001
0

0.5

1

1.5

2

2.5

3

3.5

4

4.5

Time (hr)

Figure VI.3. Aqueous humor E2 concentration-time profile after topical
administration of 30 μL of the optimized in situ gel-forming eye drops in rabbits.
The levels of E2 in the aqueous remain elevated up to 4 hr after ophthalmic delivery.
Aqueous humor concentration is shown as mean ± SEM (n=5).
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Serum E 2 Concentration (pg/ml)

280
240
200
160
120
80
40
0
0

0.5

1

1.5

2

2.5

3

3.5

4

4.5

Time (hr)

Figure VI.4. Serum E2 concentration-time profile after topical administration of 30
μL of the optimized in situ gel-forming eye drops in rabbits. The levels of E2 in the
serum drop to base levels within 3 hr after ophthalmic delivery. Serum concentration is
shown as mean ± SEM (n=5).
Serum E2 levels in the rabbits treated with ophthalmic drops were substantially
lower compared to animals receiving the IV injection at equivalent dose/rabbit (i.e., 7.5
μg/kg); plus, these levels also decline to baseline levels within the 4 hr test period (see in
Figure VI.5). In both cases, the serum E 2 concentrations spike in 15 min and peak
concentrations (Cmax) upon ophthalmic delivery (i.e., 177 ± 84 pg/mL) was
approximately 7-fold lower compared to IV treatment (i.e., 1136 ± 201 pg/mL). In
addition, E2 delivery by ophthalmic route (i.e., AUC - 219.5 hr.pg/mL) resulted in 5-fold
lower total systemic drug exposure compared to IV injection (AUC of 1014 hr.pg/mL).
Since low systemic E2 doses resulted in lower uterine stimulation in previous studies in
mice and rats (shown in Section V.C.3), lower systemic E2 exposure observed in the
rabbits using topical in situ gel forming eye drops will similarly minimize systemic E2
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related side effects on estrogen-responsive tissues. Using the administered E2 treatment
dose and observed systemic drug exposure (AUC 0-t) data upon topical and systemic E 2
treatments, the absolute systemic E 2 bioavailability (BA) was estimated (using Eq.VI.1).
The absolute bioavailability of E2 from the optimized in situ gel-forming eye drops was
found to be 20% of the administered E 2 dose. The result concurs with previous studies
where low systemic BA was similarly observed with ophthalmic formulations containing
gel-forming agents or viscosity enhancing agents (Kumar et al., 1986; Kyyronen and
Urtti, 1990; Urtti et al., 1993; Folk et al., 1996; Wei et al., 2007). Using conventional
solution eye drops 50-100% of the administered dose is systemically absorbed
(Nanjawade et al., 2007; Martens-Lobenhoffer and Banditt, 2002). Thus, low systemic E 2
BA observed in this study was likely due to the in situ gel formation that increased the
viscosity of the preparation in the eye and reduced its mucociliary clearance or drainage
through the nasolacrimal duct.

Table VI.7. Pharmacokinetic parameters of E2 in serum and aqueous humor after topical
administration of 30 μL of the optimized in situ gel-forming eye drops in rabbits
PK parameter

Value
Serum

Aqueous humor

Cmax

176.8 pg/mL

118.2 ng/mL

tmax

0.25 hr

0.25 hr

Ke

0.82/hr

1.0/hr

AUC0-t

219.5(hr.pg/mL)

53.1 (hr.ng/mL)

t1/2

51 min

42 min
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Figure VI.5. Serum E2 concentration-time profiles after topical (■) and systemic
delivery (♦) of 7.5 μg/kg E2 in rabbits. Serum E2 levels at 15 min after IV injection was
10-fold higher compared to eye drops. E 2 levels rapidly drop to base levels within 3 hr
after administration by either method. Serum E 2 concentration is shown as mean ± SEM.
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VI.D. CONCLUSIONS
The optimized in situ gel-forming E2 eye drops (Formulation K0.3-High E2) was
well tolerated and did not show any clinically relevant signs of irritation or toxicity in the
eyes or other ocular tissues in rabbits. Based on the Draize irritation score in rabbits, the
developed in situ gel-forming eye drops formulation can be classified as practically nonirritating. The radioimmunoassay was found to be sensitive enough to monitor the
changes in the serum levels and aqueous humor E2 concentrations during the study.
Following a single IV bolus injection, E 2 was rapidly eliminated from the body with
serum half-life of 26 min. Upon ocular instillation of the optimized in situ gel-forming
eye drops, large amounts of E2 was preferentially absorbed into the aqueous humor of the
eye and resulted in the area under the curve (AUC) that was 250-fold higher than in case
of E2 in the systemic circulation or serum. Additionally, the E2 concentrations in the
aqueous humor of the eye remained ~30-fold above the base levels at the end of 4 hr
suggesting that the drug contact time in the pre-corneal area was prolonged and the drug
release from the in situ gel was sustained. However, the E2 concentrations in serum
reached the base levels within 2 hr due to rapid hepatic metabolism and resulted in
absolute bioavailability (BA) of 20% of the administered dose. Such low observed BA
using in situ gel-forming solution eye drops was a result of viscoelastic nature of the gel
formed that reduced drug drainage through nasolacrimal duct and minimized systemic
drug absorption. Lower systemic E2 levels will reduce the incidence of harmful side
effects on estrogen-responsive tissues (i.e., breast, endometrium). Due to the effective
delivery of high doses to the aqueous humor, future studies should investigate lower

213

doses that do not result in detectable serum levels, yet will be effective in inducing
estrogen-regulated responses in the lens and preserve lens transparency.
In summary, the studies in rabbits demonstrated that the optimized in situ gelforming E2 solution eye drop formulation is practically non-irritating to the eyes with
maximum ocular drug absorption and minimal systemic drug bioavailability.
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CHAPTER VII

STABILITY TESTING OF THE OPTIMIZED IN SITU GEL-FORMING E2
OPHTHALMIC SOLUTION

VII. A. INTRODUCTION
Stability of a pharmaceutical drug product is performed to gather evidence on
how the quality of a drug substance or drug product varies with time under the influence
of a variety of environmental factors, such as temperature, humidity, and light, and to
establish a retest period for the drug substance or a shelf life for the drug product and
recommended storage conditions (FDA, 1987; ICH Q1A (R2), 2003a). Stability testing
also allows evaluation of the impact of short-term excursions outside the labeled storage
conditions that might occur during shipping and for predicting the shelf-life under normal
storage conditions. Further, the U.S. Food and Drug Administration (FDA) requires that a
tentative shelf life (i.e., expiration dating period) be indicated for every human drug and
biologic drug product prior to their testing in humans.
For the purpose of worldwide stability testing, USA is geographically classified
into Zone II (i.e., subtropical with possible high humidity climatic) based on the prevalent
annual climatic conditions. For drug products intended for storage in this climatic zone,
its stability should be evaluated at long-term (25°C ± 2°C/60% ± 5% RH), intermediate
(30°C ± 2°C/ 65% ± 5% RH) and accelerated conditions (40°C ± 2°C/75% ± 5% RH).
Exposing the product to such exaggerated storage conditions will accelerate the reaction
rate and allow a) identification of likely drug degradation products and elucidate the
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mechanism of the drug‘s degradation pathway b) establishment of relationships between
the kinetic parameters, such as drug degradation rate and storage conditions, and c)
predictions of drug product shelf-life by extrapolation of the degradation rate at market
place storage conditions.
In the present work, stability of the optimized in situ gel-forming eye drops
(Formulation K0.3-High E2 in Section IV.C.4) that previously demonstrated acceptable in
vitro and in vivo product performance characteristics will be evaluated at the conditions
pre-defined in the ICH Q1A (R2) guideline on stability testing of new drug substances
and drug products (see Section VII.B.2).

VII.B. EXPERIMENTAL AND METHODS
VII.B.1. Stability-Indicating HPLC Assay Method Development & Validation
As part of developing a stability indicating analytical assay, forced degradation
studies were carried out to induce possible estradiol degradation products, to elucidate
degradation mechanism, and to detect the degradation products. The optimized in situ
gel-forming formulation containing E2 (0.01%w/v), Kelcogel CG-LA (0.3%w/v) along
with other excipients was prepared (procedure described in III.B.3.1) and subjected to: a)
thermal degradation at 70°C for a week and b) being autoclaved at 120°C and 15psi
pressure for 30 min. At the end of this study, samples were withdrawn and analyzed
using HPLC. To identify and confirm the formation of a particular estradiol degradation
product, USP reference standards of drug and other related substances were used.
The US Pharmacopoeial regulations recommend monitoring of estrone, an
oxidative degradation product of estradiol that has the potential to cause cancers
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(Nygaard et al., 2004). In addition, literature evidence indicated estriol to be one of the
major hydrolytic degradation products of estradiol (Mazellier et al., 2008; Shareef et al.,
2006). Hence, a UV based stability-indicating gradient-HPLC method was developed for
accurate measurement of E2 in the presence of E1 and E3 in the solution. The developed
method was validated for specificity, linearity, accuracy and precision, limit of detection
(LOD), and quantitation (LOQ) according to ICH Q2 (R1) guidelines as described below.
Further, the drug samples from forced degradation studies were analyzed using the
developed method to demonstrate its stability-indicating nature and also to confirm the
formation of estrone and estriol as potential drug degradation products in the formulation.

Instrumentation
The HPLC system consisted of a Waters Alliance (Waters Corporation, Milford,
MA, USA) equipped with a Waters 2690 separation module and Waters 2475
fluorescence detector. Data acquisition was performed by the Empower TM 2 Pro software.
Analysis was carried out at UV absorption wavelength of 280 nm with a Luna C18 (2)
reversed-phase column of 250 mm  4.6mm i.d., 5 m dimensions (Phenomenex,
Torrance, CA, USA) at ambient temperature. The mobile phase consisted of a gradient of
acetonitrile and water 35:65 (v/v) ratios from 5.5 min to acetonitrile and water 50:50
(v/v) ratios in 18 min set at a flow rate of 1mL/min.

Preparation of Solutions
Standard stock solutions of 30 μg/mL of Estradiol (E2), Estrone (E1), and Estriol
(E3) were prepared by dissolving accurately weighed amounts in ethanol. Calibration
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standards were then prepared at concentrations of 1, 1.5, 2, 2.5 and 3 μg/mL from the
respective standard solution by appropriate dilution with ethanol.

Linearity and Range
The calibration curves were constructed for E2 and its impurities E1 and E3 in the
range of 1-3 μg/mL. The UV absorbance units of the solutions were considered for
plotting the linearity graph. The linearity was evaluated by linear regression analysis,
which was calculated by least square regression method.

Specificity
Specificity of the developed method was evaluated to accurately measure E 2 in
the presence of related substances E1 and E3. Six replicates of the test sample containing
theoretical concentration of 2 μg/mL were used for the analysis. Specificity was reported
as the mean peak retention times along with standard deviation.

Accuracy and Precision
Accuracy and precision of the assay method were evaluated for both intra-day and
inter-day variations at three different concentrations (i.e., 1, 2, and 3 μg/mL) for three
consecutive days. Accuracy and precision were expressed in terms of percent mean
recovery and percent relative standard deviation (%RSD or %CV), respectively.
Repeatability or intra-assay precision refers to the variations in the recovery values
obtained upon analyzing the above samples within the laboratory over a short period of
time during the same day. Whereas, intermediate precision represents inter-assay
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variations measured across different days (i.e., 3 days). Analysis of variance (ANOVA)
was used to identify statistical differences in the intra- and inter-day recovery values.

Limit of Detection and Quantitation
LOD and LOQ were calculated based on the standard deviation of the response
(σ) and slope (S) of the calibration curve obtained from multiple calibration curves. LOD
being given by the 3.3σ/S and LOQ given by 10σ/S: Where σ is the standard deviation of
the intercept of the calibration curves and S is the mean slope of the calibration curves.

VII.B.2. Stability of the Optimized In Situ Gel-Forming E2 Eye Drops
Formulation Preparation and Testing
The optimized formulation containing E 2 (0.025%w/v), Kelcogel CG-LA
(0.3%w/v), mannitol (4.75%w/v), potassium sorbate (0.3%w/v), EDTA (0.03%w/v)
(Formulation K0.3-High E2 in Section IV.C.4) was prepared and sterilized according to
the procedure previously described in III.B.3.1. 20 mL of the sterile formulation was then
aseptically transferred into sterile glassvials under the laminar fume hood and sealed. The
vials containing the optimized formulation were evaluated for drug stability at the storage
conditions (shown in Table VII.1.) defined in ICH Q1A (R2) guideline on stability testing
of new drug substances and drug products. The summary of product performance
characteristics, the time points at which they were tested, and specifications of the
parameters estimates monitored during storage are listed in Table VII.2.
The procedures for testing the characteristics such as pH, osmolality, clarity, and
antimicrobial efficacy were previously discussed in Section III.B.3.2. Whereas, the
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procedures for rheological characterization and drug release testing are outlined in
Section IV.B.4.2. However, drug potency during storage was measured using the
validated stability-indicating HPLC method discussed earlier in this chapter.

Table VII.1. Storage conditions used in stability study of the optimized in Situ gelforming E2 eye drops
Storage Condition

Temperature

Relative Humidity

Accelerated (ACC)

40°C ± 2°C

75% ± 5%

Intermediate (INT)

30°C ± 2°C

65% ± 5%

Long Term (Real-Time)

25°C ± 2°C

60% ± 5%

Data Analysis and Interpretation
The

parameter

estimates

obtained

for

different

product

performance

characteristics at different time points and storage conditions were compared with
specifications and analyzed for statistical significance by ANOVA. The significance level
(α) for all analyses was ≤0.05.
In case of E2 potency, drug degradation upon storage at different temperatures at
different time points was characterized by treating the data to zero and first order reaction
kinetic models. The integral forms of the zero-order and first-order reaction rates are
shown in Eq. VII.1 and VII.2.

C t  Co  K o  t

Equation VII.1.

ln C t  ln C o  K  t

Equation VII.2.

Where Co and Ct are the concentrations at initial time and at time t. Ko and K are
the zero-order and first-order reaction rate constants in units of concentration/time and
(1/time), respectively. Accordingly, based on the order of the reaction, the shelf-life
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defined as the time taken to reach 90% of the initial drug concentration or time taken for
10% drug degradation was given by:
For zero-order reaction, shelf life (t 90%) = 0.1Co/Ko

Equation VII.3.

For first-order reaction, shelf-life (t90%) = 0.105/K

Equation VII.4.

In case of drug release testing, the drug release data was characterized using the
power-law model proposed by Korsemeyer-Peppas in Eq. IV.4 and the t20 and t80 were
compared for statistical significance using ANOVA. Also, the differences in the drug
release profiles at different storage conditions and times during storage were analyzed by
computing similarity factor, f2 proposed by Moore and Flanner (1996). The similarity
factor is a statistic that measures the closeness of between two dissolution profiles and is
given by Equation VII.5.
0.5


  1  n

2
f 2  50  log 1    R t  Tt    100



  n  t 1


Equation VII.5

Where n is the number of time points, Rt is the dissolution value of the reference product
at time t, and Tt is the dissolution value of the test product. The larger the value of f2 or
the closer the value of f2 is to 100, the smaller is the difference between the two curves.
The FDA suggests that the two dissolution profiles are considered to be similar if the f2
similarity factor is between 50 and 100 (SUPAC-IR, 1995). The lower acceptable value
(i.e., 50) corresponds to 10% average absolute difference between a reference product
and a test product at each time point.
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Table VII.2. List of product characteristics monitored for stability during storage
Formulation
Characteristic
A. pH
B. Osmolality
C. Clarity
D. E2 Potency

Acceptable Value

Testing Frequency
(months)

6-7

0, 2, 4, 6

275-325 mOsm/kg

0, 2, 4, 6

Visually clear (or) light transmittance
>85% at 490 nm using water as reference

0, 2, 4, 6

90-110% assay

0, 2, 4, 6

Compliance with USP for Class-I products

0, 3, 6

a) Flow behavior

Apparent viscosity (μ)< 50cps at 100 s-1

0, 2, 4, 6

b) Viscoelasticity

G‘>>G‖, and δ<45°

0, 2, 4, 6

G. Drug Release

t20% ≤ 0.5 hr and t80% in 6-12 hr and

0, 2, 4, 6

E. Anti-microbial
efficacy
F. Rheology
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VII.C. RESULTS AND DISCUSSION
VII.C.1. Stability-Indicating HPLC Assay Method Development & Validation
The least squared regression analysis of the calibration curve data of E 1, E2, and
E3 in the range of 1-3 μg/mL was shown in Figure VII.1. The observed high correlation
coefficient (r2=1) indicated good agreement and linearity between increasing levels of E 1,
E2, and E3, and their corresponding peak areas. The appearance of well resolved peaks for
E1 (peak retention time (RT) of 15.1±0.3), E2 (peak RT of 11.4±0.7) and E3 (peak RT of
5.5±0.5) in the overlay of the chromatograms of the calibration standards in Figure VII.2
demonstrated the specificity of the developed gradient-HPLC method for accurate
estimation of E2 in the presence of its impurities E1 and E3. The stability-indicating nature
of the developed method was confirmed as the method accurately identified both the drug
degradation products E1 and E3 along with E2 in the forced degradation samples shown in
Figure VII.3 and VII.4. Based on the results, it was observed that estrone (oxidative
degradation product of E2) was the prominent impurity upon thermal degradation;
whereas, estriol (hydrolytic degradation product of E 2) was found to be the significant
drug degradation product upon steam sterilization of the drug product in the autoclave.
The gradient-HPLC method was further validated in compliance with ICH Q2
(R1) guidelines. The results of validation studies are shown in Table VII.3. It was
observed that the developed method was accurate (% mean recovery: 99.2 ± 0.7, 99.1 ±
1.5, 97.9 ± 0.9 for E1, E2, and E3, respectively), precise (CV :< 0.7 %,< 1.5%, and <0.9%
for E1, E2, and E3, respectively) and highly reproducible with low intra-day (CV: <1.2%,
<2.4%, and <2.4% for E1, E2, and E3, respectively) and inter-day variation (CV: <2.6%,
<3.3%, <3.4% for E1, E2, and E3, respectively). Two-way ANOVA analysis indicated no

223

significant differences between the intra- and inter-day recoveries at different analyte
(i.e., E1 or E2 or E3) concentrations (p>0.05). The limits of detection were found to be
0.2, 0.1, and 0.1 μg/mL for E1, E2, and E3, respectively. Similarly, the limits of
quantitation of E1, E2 and E3 using the developed method were found to be 0.6, 0.4, and
0.4 μg/mL, respectively.
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Figure VII.1. Regression plots of calibration standards of E1, E2 and E3
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Figure VII.2. Overlay of HPLC chromatograms of E1, E2 and E3 calibration standards

Figure VII.3. HPLC chromatogram of E2 (2 g/mL) upon forced degradation at 70C
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Figure VII.4. HPLC chromatogram of E2 (2 g/mL) upon autoclave at 120C and 15 psi
for 30 minutes
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Table VII.3. Validation parameters of stability-indicating E2 gradient-HPLC assay
method
Lineari

E1

1 - 3μg/ml (r2-0.99)

ty and

E2

1 - 3μg/ml (r2-0.99)

Range

E3

1 - 3μg/ml (r2-0.99)

E1

2μg/ml solution of E1 has retention time (RT) of 15.1 ± 0.3 min

E2

2μg/ml solution of E2 has retention time (RT) of 11.4 ± 0.7 min

Specifi
city

E3
Con
c.

Accura
cy and

Intra-day

Inter-day

Intra-day

Inter-day

Preci

Accu

Preci

Accu

Preci

Accu

Preci

Accu

Preci

Accu

Preci

ml)

racy

sion

racy

sion

racy

sion

racy

sion

racy

sion

racy

sion

1
2

99.5
± 1.1
98.3
± 0.9
99.2
± 1.2

1.1
1.0
1.2

98.7
± 2.2
100.2
± 2.6
99.5
± 1.1

2.2
2.6
1.1

100.1
± 0.7
101.5
± 2.4
99.3
± 2.2

0.7
2.4
2.2

98.1
± 1.9
97.3
± 3.2
98.2
± 0.7

Limit

E1

0.2μg/ml

of

E2

0.1μg/ml

E3

0.1μg/ml

Limit

E1

0.6μg/ml

of

E2

0.3μg/ml

E3

0.3μg/ml

Detecti
(LOD)

Quantit
ation

Inter-day

Accu

3

on

Intra-day

(μg/

Precisi
on

2μg/ml solution of E3 has retention time (RT) of 5.5 ± 0.4 min
E2
E3

E1

(LOD)
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1.9
3.3
0.7

98.6
± 1.1
97.9
± 2.4
97.2
± 1.6

1.1
2.4
1.6

96.8
± 2.9
97.8
± 3.4
99.2
± 1.9

3.0
3.4
1.9

VII.C.2. Stability of the Optimized In Situ Gel-Forming E2 Eye Drops
pH, clarity and osmolality: The summary of critical product performance characteristics
of the optimized in situ gel-forming E2 solution eye drops obtained during storage at
different conditions and time points are summarized in Table VII.4.


The pH of the formulation during stability study was well within the specification
limits and varied between 6.35-6.36 units. Storage conditions had no significant
influence on the corresponding pH of the preparation at different time points
(p>0.05, one-way ANOVA).



The clarity of the solution eye drops remained clear throughout the study period.
The percent light transmittance of the eye drops in the visible range, at 490 nm
wavelength, was >95% at all storage conditions and time points (Table VII.4).



The osmolality of the optimized formulation during storage as shown in Table
VII.4 was within the acceptable range of 275-325 mOsm/Kg. Analysis of the
osmolaity data obtained at different time points during storage at different
conditions using one-way ANOVA indicated no significant differences (p>0.05).

Antimicrobial Efficacy: The results of USP antimicrobial efficacy of the optimized in
situ gel-forming E2 solution eye drops are summarized in Table VII.4. The optimized
formulation was found to be antimicrobially effective against the test microorganisms Pseudomonas aeruginosa, Escherichia coli, and, Staphylococcus aureus throughout the
study duration. The sterility of the formulation was maintained during storage for 6
months at room temperature, intermediate, and accelerated storage conditions. The
observed evidence of antimicrobial efficacy demonstrated that the preservative mixture
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composed of potassium sorbate and EDTA at the concentrations used in the formulation
was optimum.

Table VII.4. Summary of critical characteristics of the optimized in situ gel-forming E2
eye drops at different storage conditions
pH (units)
Storage Condition

0

2 month

4month

6month

Long Term (RT)

6.36±0.01

6.36±0.02

6.35±0.01

6.36±0.02

Intermediate (INT)

6.36±0.01

6.36±0.02

6.35±0.03

6.36±0.03

Accelerated (ACC)

6.36±0.01

6.36±0.02

6.35±0.03

6.35±0.04

Osmolality (mOsm/Kg)
Storage Condition

0

2 month

4month

6month

Long Term (RT)

289±3

291±2

289±2

290±4

Intermediate (INT)

289±3

289±4

287±3

288±4

Accelerated (ACC)

289±3

288±4

292±5

291±5

Clarity (%UV transmittance)
Storage Condition

0

2 month

4month

6month

Long Term (RT)

97±2

96±2

96±3

95±2

Intermediate (INT)

96±1

95±2

96±2

95±2

Accelerated (ACC)

96±2
95±3
Antimicrobial efficacy

97±2

95±2

Storage Condition

0

3month

6month

Long Term (RT)

Yes

Yes

Yes

Intermediate (INT)

Yes

Yes

Yes

Accelerated (ACC)

Yes

Yes

Yes
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Apparent Viscosity:
The apparent viscosity of the optimized formulation measured at the shear rate of
100s-1 during storage was summarized in Table VII.5. The apparent viscosity of the
formulation varied in the range of 12.5-23.2 cps depending upon the storage condition.
The viscosity of the formulation decreased with increases in the storage temperature.
However, the apparent viscosities were within the acceptance criteria (i.e., <50cps at
100s-1) through out the study duration. Statistical one-way ANOVA analysis of the
viscosity data using Prism® indicated that long-term storage conditions of 25°C/60%RH
did not have statistically significant (p>0.05) influence on the apparent viscosity of the
formulation. Whereas, intermediate and accelerated storage conditions of 30°C/65%RH
(INT) and 40°C/75%RH, respectively, showed statistically significant influence on the
apparent viscosity of the formulation at 4 and 6 months (p<0.05). But, the apparent
viscosities were still within the specification limits, and hence, formulations are
considered stable. The influence of storage condition on the rheological flow curve of the
optimized formulation at day 0 and day 180 (6 months) was shown in Figure VII.5. The
decrease in apparent viscosities with increases in the applied shear rate confirmed that the
shear thinning or pseudoplastic nature of the formulation was conserved during storage.

Table VII.5. Apparent viscosity of the optimized in situ gel-forming E2 eye drops at
different time points during storage at different conditions
Apparent Viscosity (cps) at 100s-1
Storage Condition

0

2 month

4 month

6 month

Long Term (RT)

23.2±1.2

22.7±0.5

21.6±0.9

21.0±1.1

Intermediate (INT)

23.2±1.2

21.9±0.3 *20.4±0.2

*19.6±0.3

Accelerated (ACC)

23.2±1.2

20.9±0.3 *15.7±0.3

*12.5±0.6

*p<0.05; n=3 in all cases
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Figure VII.5. Flow curves showing the effect of storage conditions on apparent viscosity
of the optimized in situ gel-forming formulation
Viscoelasticity:
Frequency sweep plots of the optimized in situ gel-forming E2 solution eye drops
measured in the presence of STF (30:7 v/v ratios) at different time points during storage
at real-time and accelerated conditions are shown in Figure.VII.6 and VII.7, respectively.
The power-law rheology model fitting parameters and the viscoelastic parameter
estimates of the optimized formulation obtained during storage are similarly summarized
in Table VII.7. The optimized formulation showed evidence of phase transition and in
situ gel-structure formation in the presence of STF at all time points during storage as
G‘>G‘‘, δ<45° (shown in Table VII.6). Further, the frequency sweep plots at room
temperature and accelerated storage conditions (Figure VII.6 and VII.7) showed
moderate to weak dependency of elastic modulus (G‘) on angular frequency according to
power-law rheology model with the model exponent ―n‖ values in the range of 0.3-0.4
(Table VII.7). The n value in this range further confirms the nature of the material formed
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to be viscoelastic and that it corresponds to a gel state according to the acceptance
criteria.
The magnitude of viscoelastic parameter estimates (i.e., G‘ and G‘‘) decreased
with change in storage condition as well as length of storage (Table VII.4). The modulus
of elasticity (G‘) values reflective of the strength of the gel structure formed varied in the
range of 0.85-0.92 Pa and 0.92-0.66 Pa during storage for 6 months at long-term (RT)
and accelerated (ACC) conditions, respectively. Statistical one-way ANOVA analysis of
the elastic modulus data using Prism® indicated that long-term storage conditions of
25°C/60%RH did not have statistically significant (p>0.05) influence on the gel strength
or viscoelasticity of the formulation throughout the study duration. In contrast, storage at
accelerated conditions of 40°C/75%RH, resulted in statistically significant decrease in the
gel strength or elastic modulus of the formulation at 4 and 6 months (p<0.05). Such
decrease in gel strength of the formulation upon accelerated storage indicate the
susceptibility of the polymer in the formulation to physically degrade and lose capacity to
form stronger gel structures in the presence of simulate tear fluid at higher temperature
and relative humidity (i.e., > 40°C/75%RH).
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Table VII.6. Summary of viscoelastic parameter estimates and power-law rheology
model fitting parameters of the optimized in situ gel-forming E2 eye drops at different
accelerated storage conditions
Storage

Time

Condition (month)

Viscoelastic Indices
G‘ (Pa)

G‖ (Pa)

Model-fitting Parameters
δ (°)

n

r2

---

0

0.92±0.01

0.49±0.01 27.7±0.5

0.3

0.99

RT

2

0.92±0.07

0.50±0.01 28.5±2.1

0.3

0.99

ACC

2

0.84±0.01

0.46±0.02 28.7±1.3

0.3

0.99

RT

4

0.85±0.02

0.40±0.01 25.2±0.2

0.4

0.96

ACC

4

*0.77±0.01 0.40±0.01 27.2±0.1

0.3

0.99

RT

6

0.84±0.01

0.46±0.02 28.7±1.3

0.3

0.99

ACC

6

*0.66±0.01 0.33±0.01 26.6±0.2

0.3

0.99

*p<0.05 (1-wayANOVA); n=3 in all cases
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Figure VII.6. Effect of storage at 25°C/60%RH on the frequency dependency of the
elastic modulus of the optimized in situ gel-forming E2 solution eye drops
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Figure VII.7. Effect of storage at 40°C/75%RH on the frequency dependency of the
elastic modulus of the optimized in situ gel-forming E2 solution eye drops.
Potency of E2:
The results of potency of E2 in the in situ gel-forming solution eye drops during
storage at RT, INT, and ACC conditions are summarized in Table VII.7. E 2 potency at
day 0 and day 180 varied in the range of 100.3%-99.3%, 100.3%-97.7%, and 100.3%96.6% at RT, INT, and ACC storage conditions, respectively. The change in E2 potency
with time at different storage conditions was illustrated in Figure VII.8. At any tested
condition, the degradation was <5% and no degradation products were detected using the
stability indicating assay, suggesting the stability of the optimized formulation.
Statistical one-way ANOVA analysis (using GraphPad Prism® Version 5) of the potency
data obtained for the optimized formulation at different storage conditions indicated that
only at 6 months storage at accelerated storage condition of 40°C/75%RH, the E2 potency
was statistically significant (p<0.05) compared to the observed potency at day 0 (Figure
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VII.9). Although significant, the E2 potency values of the formulation were within the
specification limit of 90-110% throughout the study duration at all tested storage
conditions, and hence considered highly stable and desirable.
Table VII.7. Potency of E2 at different time points in the optimized in situ gel-forming
solution eye drops stored at different conditions.
E2 Potency (Mean % ± SD)
Storage Time

Storage Condition
RT

INT

ACC

Zero/Initial

100.3 ± 1.2

---

---

1-Month

99.4 ± 0.7

99.9 ± 1.1

100.0 ± 3.3

2-Month

99.1 ± 0.9

99.1 ± 2.4

97.8 ± 2.6

3-Month

99.0 ± 1.9

98.9 ± 1.6

98.4 ± 1.2

4-Month

99.7 ± 3.2

98.3 ± 1.9

97.9 ± 1.4

6-Month

99.3 ± 1.5

97.7 ± 1.5

*96.6 ± 1.2

*p<0.05(1-wayANOVA)
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Figure VII.8. Effect of storage conditions on the potency of E 2 in the optimized in situ
gel-forming solution eye drops at different time points
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Figure VII.9. E2 potency (Mean ± SD) in the optimized in situ gel-forming solution eye
drops stored at 40°C/75% RH at different time points.
The E2 degradation in the solution eye drops followed zero-order kinetics at all
tested storage conditions (Figure VII.10-VII.12). The degradation rate constant at realtime (RT) storage condition was 0.003%/day and the estimated shelf-life (t90) was 3323
days or 9.1 years (Table VII.8). The degradation rate constant at intermediate (INT)
storage condition was 0.015%/day and the estimated shelf-life (t90) was 668 days or 1.8
years (TableVII.8). The degradation was relatively faster at accelerated (ACT) storage
condition with rate constant of 0.02%/day and estimated shelf-life (t90) of 500 days or 1.4
years (TableVII.8). Such long shelf-life at ACC storage conditions indicates acceptable
stability of the formulation. ICH guidelines recommend a tentative shelf-life of 2 years at
room temperature if the product remains stable and drug potency varied within the
specification limits of 90-110% at accelerated storage condition for 6 months (ICH Q2
(R1), 1996; ICH Q1A (R2), 2003a). Accordingly, a tentative shelf-life of 2 years was
assigned for the optimized in situ gel-forming E2 solution eye drops for storage at room
temperature.
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Table VII.8. Summary of zero-order degradation rate constants of the optimized E 2 in
situ gel-forming solution upon storage at different conditions for 6 months
Storage Condition
RT

INT

ACC

Ko(%/day)

t90(days)

Ko(%/day)

t90(days)

Ko(%/day)

t90(days)

0.003

3323

0.015

668

0.020

500

RT

lower 95% CI

Upper 95% CI

110

y RT = -0.0032x + 99.726

E2 Potency (%)

R2 = 0.1943

100

90
0

30

60

90

120

150

180

210

Storage Time (month)

Figure VII.10. Zero-order degradation kinetics of E2 in the optimized in situ gel-forming
solution eye drops stored at 25°C/60% RH for 180 days
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Figure VII.11. Zero-order degradation kinetics of E2 in the optimized in situ gel-forming
solution eye drops stored at 30°C/65% RH for 180 days
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Figure VII.12. Zero-order degradation kinetics of E2 in the optimized in situ gel-forming
solution eye drops stored at 40°C/75% RH for 180 days
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Drug Release Characterization:
The cumulative E2 release profiles from the optimized in situ gel-forming solution
eye drops at different time points during storage at real-time (RT) and accelerated (ACC)
conditions are shown in Figure VII.13 and VII.14, respectively. The drug release was
found to be sustained with 80% of the drug released in 6-12 hr. Burst release of the drug
from in situ gel-forming solutions was also observed with 20% of the drug released (i.e.
t20%) in 0.4-0.5 hr.
E2 Dissolution-Time Profile
120
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4Mo-RT

6Mo-RT

Mean(%) E2 Released

100
80
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24
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Time (hr)

Figure VII.13. Dissolution Profiles of E2 in the optimized in situ gel-forming solution
eye drops at different time points during storage at 25°C/60% RH.
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Figure VII.14. Dissolution Profiles of E2 in the optimized in situ gel-forming solution
eye drops at different time points during storage at 40°C/75% RH

The model fitting parameters and drug release estimates (i.e., t 20% and t80%)
obtained upon treating the drug release data to Korsemeyer-Peppas Model are
summarized in Table VII.9. The release rate constant (K) was in the range of 27.428.4(%h-n) at real-time (RT); whereas for the accelerated storage (ACC) condition, it was
in the range of 27.4-31.8 (%h-n). The magnitude of the release exponent n was in the
range of 0.50-0.51 at real-time storage condition; whereas for the accelerated storage
(ACC) condition, it was in the range of 0.48-0.52. The cut-off value of n for a purely
Fickian diffusion mechanism in case of gel systems with aspect ratio of 3.6 (i.e., 2a =
21.34mm and l = 5.96mm) was 0.45 (Figure IV.17). The n values >0.45 suggest that a)
E2 release from the gels during storage was function of drug diffusion from the polymer
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gel matrix as well as polymer relaxation, and b) E2 release kinetics or mechanism of drug
release was not significantly influenced by the storage conditions.
As shown in Table VII.9, the time for 20% or 80% of the drug to be released
(t20%) or (t 80%) respectively, decreased with storage condition and storage time. At room
temperature, t80% decreased from 8.1 hr at day 0 to 7.9 hr at 6 months; whereas for the
accelerated storage condition, t 80% decreased from 8.1 hr at day 0 to 6.8 hr at 6 months.
Faster drug release at accelerated condition was due to concomitant decrease in the
strength of the gel-structure (i.e., G‘) at higher temperature (i.e., 0.94 Pa at day 0 vs. 0.66
Pa at day 180 at accelerated condition). Although, the drug release was little faster upon
storage at accelerated condition, the drug release parameter estimates are well within the
acceptable criteria (Table VII.2).

Table IV.9. Summary of model fitting parameters and drug release estimates of E 2 in the
optimized in situ gel-forming solution eye drops during storage.
Storage

Storage

Time

Condition

Zero
2-month
4-month
6-month

K

n

r2

t20

t80

(hr)

(hr)

25°C/60%RH 27.4±0.3 0.51±0.01 0.98 0.54±0.02 8.12±0.04
25°C/60%RH 27.4±0.6 0.51±0.01 0.99 0.54±0.03 8.15±0.05
40°C/75%RH 27.4±0.1 0.52±0.01 0.99 0.54±0.01 7.93±0.06
25°C/60%RH 27.7±0.2 0.51±0.01 0.98 0.53±0.01 8.08±0.02
40°C/75%RH 30.1±0.2 0.49±0.01 0.99 0.43±0.01 7.49±0.11
25°C/60%RH 28.4±0.1 0.50±0.01 0.99 0.51±0.02 7.85±0.04
40°C/75%RH 31.8±0.3 0.48±0.01 0.99 0.38±0.01 6.84±0.06

241

Table VII.10. Comparison of dissolution profiles of E 2 in situ gel-forming eye drops
during storage using similarity factor (f2).
Storage
Time
2-month

Similarity Factor (f2)

Difference Factor (f1)

25°C/60%RH 40°C/75%RH 25°C/60%RH 40°C/75%RH
(RT)
(ACC)
(RT)
(ACC)
93
91
1
2

4-month

94

74

1

6

6-month

82

62

3

11

The similarity factor (f2) was used to compare E2 dissolution profiles from the
optimized in situ gel-forming solution at day 0 and at different time points during storage
at 25°C/60% RH (RT) as well as 40°C/75%RH (ACC). The f2 results are summarized in
Table VII.10. The f2 values for E2 drug release upon storage at RT at 2, 4, and 6 months
was 93, 94, and 82, respectively. Similarly, the f2 values for E2 drug release upon storage
at accelerated condition at 2, 4, and 6 months was 91, 74, and 62, respectively. The f2
values in the range of 50-100 at each time point and storage condition suggest that the
drug release profiles are statistically similar (SUPAC-IR, 1995). However, the larger the
value of f2 or the closer the value of f2 is to 100, the smaller is the difference between the
two curves. Hence, it can be concluded that the differences in the drug release profiles
upon storage at 25°C/60% RH (RT) were smaller compared to storage at 40°C/75%RH
(ACC).
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VII.D. CONCLUSIONS
Forced degradation of the prototype E2 in situ gel-forming formulation indicated
estrone (E1) and estriol (E3) to be the major E2 degradation products. The stability
indicating HPLC-method was successfully developed and validated to accurately
measure E2 concentration in the presence of its impurities. The developed method was
found to be simple, precise and accurate and reproducible
Analysis of the optimized formulation during storage at 25°C/60%RH (RT),
30°C/65%RH (INT), and 40°C/75%RH (ACC) for six months indicated acceptable in
vitro product performance characteristics throughout the study duration.
The critical product characteristics such as pH, clarity and osmolality remained
stable within the specification limits at all tested conditions. The optimized formulation
was sterile and the antimicrobial efficacy was preserved during storage. Therefore, the
formulation is considered stable and highly desirable.
The formulation was found to be shear thinning as alone and viscoelastic in the
presence of simulated tear fluid at all temperatures and storage conditions. The
rheological parameter estimates (i.e., apparent viscosity/ gel strength) were within the
specification limit throughout storage. However, increase in temperature from room
temperature to intermediate or accelerated conditions resulted in statistically significant
decrease in the apparent viscosity and elastic modulus of the optimized formulation at 4
and 6 months of storage.
Effect of storage on drug degradation was found to be minimal as the potency
remained >97% throughout the stability study. As the degradation was <5%, 2 years
tentative shelf-life period was assigned to the product. Similarly, storage conditions did
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not show significant influence on the drug release estimates of the optimized in situ gelforming solution eye drops. Further, comparison of the E 2 release data using similarity
factor (f2) indicated the drug release profiles to be similar throughout the study duration.
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CHAPTER VIII

SUMMARY

Cataracts are very common, with the highest risk in aging women. Currently,
there are no therapies that can delay or prevent cataract development.

Studies on

estrogen in women and animal models indicate it has promise to protect the lens from
developing cataracts. The prospect of the lens being responsive to estrogens opened the
possibility that age-related cataracts can be delayed or prevented with estrogen
replacement therapy. Knowing estrogen directly influences the lens presented the option
of topical treatments, which may provide a means to minimize negative side effects of
systemically administered estrogen (i.e., risk of endometrial cancer). Hence, the focus of
this dissertation was to develop an ophthalmic estrogen therapy that can be instilled
directly to the eye with prolonged contact time and with minimal systemic absorption to
locally supplement estrogen levels that decline with age without the need for systemic
hormone therapy.

The project is the first to investigate the potential of a topical

ophthalmic estrogen delivery system to prevent or delay the onset of age-related
cataracts.
As described in Chapter III, SBE 7 was used as the aqueous solubility enhancing
agent of estradiol because of its well established safety and extended hydrophobic cavity.
In the presence of SBE 7, the aqueous solubility of E 2 was significantly enhanced due to
inclusion of E2 aromatic ring into the hydrophobic SBE 7 cavities. The inclusion complex
was thermodynamically stable, as E2 inclusion into the SBE 7 cavity displaced the
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enthalpy-rich water causing the release of energy that favored the formation of inclusion
complex. The stoichiometry of 1:1 between E2 and SBE 7 was observed in the complex.
Pre-formulation studies identified excipients that provided desirable characteristics to the
ophthalmic preparations, such as osmolality, clarity, sterility, etc. Deacetylated gellan
gum (Kelcogel® CG-LA) was used as a suitable vehicle for in situ gel-forming systems as
its solutions were visibly clear and remained liquid in vitro, but formed a gel on contact
with the mono (Na+, K+) and divalent cations (Ca 2+) in the tear fluid. The mechanism of
gelation involved reduction in electrostatic repulsions between the carboxyl groups of the
gellan gum chains in the presence of cations; which promoted a coil-to-helix transition
followed by helix aggregation to form a gel network. Rheological characterization
illustrate that the hydrogel formed was viscoelastic in nature with potential to increase
contact time in the eye and provide improved drug absorption and increased duration of
therapeutic effect. Mannitol was used as a tonicity adjusting agent in the formulation to
adjust its osmolality and make it isotonic with physiological fluids. Quaternary
ammonium preservative, benzalkonium chloride, was used in the formulation because of
its established efficacy against both gram positive and gram negative microorganisms and
extensive use in commercial ophthalmic preparations. But, in the presence of other
anionic excipients (i.e., gellan gum and SBE 7) in the formulation, its efficacy in
inhibiting the growth of microorganisms was lost due to low amounts of free preservative
available as a result of excipient-excipient columbic interactions.
In order to overcome the challenge of preservative inefficacy of the prototype in
situ gel-forming formulation, in Chapter IV, use of a non-ionic drug solubilizing agent
and new preservative system was described. Polysorbate 80 was used as a non-ionic
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solubilizing agent to increase the aqueous solubility of estradiol. A preservative system
composed of potassium sorbate (0.3%w/v) and disodium-EDTA (0.03%w/v) was used to
achieve USP anti-microbial efficacy. EDTA binds to the essential minerals in the
microbial cytoskeleton and disorganizes its assembly, thereby to enhance the
permeability of potassium sorbate and to provide a synergistic anti-microbial effect.
Using this new preservative mixture and non-ionic polysorbate 80, the excipientexcipient ionic interactions were minimized and the formulations demonstrated USP
antimicrobial efficacy. Gellan gum, being a polysaccharide, has shown potential to
support microbial growth in the formulation. Pre-optimization studies illustrate the need
for adjusting preservative concentrations with the gellan gum concentration in the
formulation. Also, with the preservatives being the salts of potassium and sodium, they
displayed the tendency to interact with anionic gellan gum polymer and, at higher
polymer concentrations (i.e., 0.5% w/v Kelcogel® CG-LA), resulted in formulations that
are too viscous to flow. Therefore, formulations containing lower concentrations between
0.1-0.3% w/v Kelcogel® CG-LA were used for further testing.
Analyses of statistically designed formulations illustrated the significant influence
of polymer and drug concentrations on the product performance characteristics of the in
situ gel E2 formulations. The drug release from in situ gel followed non-Fickian
mechanism, with which drug release is a function of its diffusion from the gel matrix as
well as polymer relaxation. The deviation from purely Fickian mechanism was attributed
to the reason that the formulations during gelation imbibe large amount of dissolution
media leading to a swollen state of the gel. Formulations containing 0.1-0.3%w/v
Kelcogel® CG-LA and 0.001-0.025%w/v E2 concentrations demonstrated acceptable
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characteristics of in situ gel-forming ophthalmic solutions and, hence, were used for
further in vivo evaluation of product safety and efficacy in animal models.
As described in Chapter V, estrogen delivered by ophthalmic route was able to
induce known estrogen responses in the eye. In pre-pubertal ERΔ3 mice, gross cataracts
were observed as early as 2 weeks post-treatment with ophthalmic in situ gel-forming E2
eye drops. No lens abnormalities were observed in mice treated with the vehicles, as
estrogen was required to interact with the estrogen receptors in the lens and other ocular
tissues and activate ERΔ3 repressor to result in cataract formation in this mouse model.
The onset and severity of gross cataracts were found to be function of polymer and
estradiol (E2) concentration in the ophthalmic eye drops, which suggests that increasing
estrogen levels to the eye for longer periods would enhance ERΔ3 repressor activity and
accelerate the lenticular changes observed with cataracts. At the same E 2 dose/mouse,
ophthalmic delivery of E2 using in situ gel-forming eye drops containing 0.3%w/v
polymer concentration resulted in an earlier cataract onset vs. eye drops containing 0.1%
polymer or systemic treatment. The better efficacy with the higher polymer content was a
result of better gelling behavior and longer contact time in the eye.
Similarly, at the same E2 dose/mouse (i.e., 40 μg/kg), ophthalmic treatment
resulted in a significant increase in expression of pax6, a gene known to influence
cataract development and which is increased in the ERΔ3 lens after short-term E2
exposure vs. vehicle, unlike the same systemic dose (sc). Also, the estrogen-induced
uterine stimulation due to systemic E 2 absorption was lower with ophthalmic eye drops
compared to systemic estrogen therapy at all tested E 2 doses in pre-pubertal
ovariectimized ERΔ3 female mice. At the lowest E 2 dose of 0.4 μg/kg in ERΔ3 mice, the
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ophthalmic eye drops containing 0.3%w/v polymer did not stimulate the uterus; but, were
not tested for cataract induction. Therefore, additional testing is needed to determine if
sufficient estrogen levels can be delivered to the eye to influence a known estrogen
response in the lens without evidence of systemic bioavailability. However, as the
ophthalmic E2 dose of 4 μg/kg did not stimulate uterus in rats and induced cataracts in
ERΔ3 mice, this dose may not result in systemic bioavailability in humans while still
protecting the lens.

These data suggest that the in situ gel-forming E2 eye drops

containing 0.3%w/v Kelcogel CG-LA is an optimum formulation for future testing in
pre-clinical models such as MNU-induced cataracts model in rats as a long-term
treatment for cataract prevention.
As described in Chapter VI, the optimized in situ gel-forming E2 eye drop
formulation was well tolerated and did not show any clinically relevant signs of irritation
or toxicity in the eyes or other ocular tissues in rabbits. Based on the Draize irritation
score in rabbits, the optimized formulation was classified as practically non-irritating to
the eyes. Upon ocular administration in rabbits, E 2 from the optimized in situ gel-forming
eye drop was able to rapidly permeate cornea and achieve maximum concentration in as
early as 15 minutes. E2 was preferentially absorbed into the aqueous humor of the eye
and resulted in the area under the curve (AUC) that was 250-fold higher than in the
systemic circulation (serum). E2 concentrations in the aqueous humor were sustained due
to sustained release nature of the drug from the in situ gel-matrix formed, and/or low E2
metabolism due to lack of sufficient levels of drug metabolizing enzymes relative to
systemic circulation.
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Serum levels in the rabbits treated with the ophthalmic drops were substantially
lower compared to animals receiving the same dose by IV injection; plus, these levels
also decline to baseline levels within the 2 hr test period due to viscoelastic nature of the
formed gel that reduced drug drainage through nasolacrimal duct and minimized systemic
drug absorption. The systemic bioavailability (BA) of E 2 upon topical administration of
the in situ gel-forming eye drops was found to be 20%. These data indicate that only low
levels are systemically delivered compared to the high levels that are present in the
aqueous humor. Due to the effective delivery of high doses to the aqueous humor using
the optimized in situ gel-forming eye drops, future studies using lower doses that do not
result in detectable serum levels and yet provide sufficient levels in the ocular tissues to
influence a known estrogen response will likely be sufficient to protect lens transparency.
As described in Chapter VII, the optimized formulation was stable and storage
conditions and duration had no significant influence on the product performance
characteristics. The critical product characteristics such as pH, clarity, and osmolality
remained stable within the specification limits at all tested conditions. The optimized
formulation was sterile and the antimicrobial efficacy was conserved during storage. As
the drug degradation was <5%, a tentative 2 year shelf-life period was assigned to the
product for storage at room temperature.
The results demonstrated in individual chapters illustrate that the optimized in situ
gel-forming E2 eye drop formulation was stable and non-irritating to the eyes. It delivers
sufficient estrogen to the lens and increases its contact time in the eye to induce known
estrogen responses, which could occur with little to no effects on other non-ocular,
estrogen-responsive tissues, such as the uterus. Although the optimized formulation was
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very effective at inducing cataracts in ERΔ3 model, this model cannot demonstrate the
protective influences of the ocular formulation on cataract development or progression.
Therefore, in future studies the formulation will be tested for cataract prevention in
animal models without the ER3 repressor and in which cataracts can be induced (such
as MNU induced cataracts model in rats). Once its efficacy in prevention is verified with
limited to no uterine stimulation to confirm the minimal systemic exposure, the
formulation can be tested in humans.
The work described within this dissertation is significant in that it facilitates
future testing in pre-clinical animal models and humans on the benefits of long-term
treatment of topical estrogen in delaying cataract development. As delaying cataract
development by one decade could reduce the number of cataract surgeries by almost half,
this topical ophthalmic therapy could provide a significant health benefit to the elderly
and, accordingly, reduce the substantial medical costs associated with these surgeries.
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